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ABSTRACT OF THE DISSERTATION
THE STUDY OF TISSUE-SPECIFIC DNA METHYLATION AS A METHOD FOR
THE EPIGENETIC DISCRIMINATION OF FORENSIC SAMPLES
by
Joana Alexandra Pereira Antunes
Florida International University, 2018
Miami, Florida
Professor Bruce McCord, Major Professor
In forensic sciences, the serological methods used to determine which body fluid
was collected from the crime scene are merely presumptive or labor intensive since they
rely on protein detection or on microscopic identification of cells. Given that certain
forensic cases may need the precise identification of a body fluid to determine criminal
contact, such is the example of a suspected sexual assault of a minor; certainty in the
body fluid of origin may depict a precise picture of the events. The identification of loci
that show differences in methylation according to the tissue of origin can aid forensic
analysts in determining the origin of a DNA sample. The process of DNA methylation
occurs naturally in the genome of living organisms and consists in the presence of a
methyl group on the carbon 5 of a cytosine, which is typically followed by a guanine
(CpG). Analyzing patterns of DNA methylation in body fluids collected from a crime
scene is preferential to the analysis of proteins or mRNA since the same extracted DNA
used for STR typing can be used for DNA methylation analysis. We have validated and
identified loci able to discriminate blood, saliva, semen and vaginal epithelia. In the
current study, we have also established the minimum amount of DNA able to provide
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reliable results using methodologies such as pyrosequencing and high-resolution melt
(HRM) analysis for the different markers identified. Lastly, we performed an alternative
bioinformatic analysis of data collected using an array that studied methylation in over
450,000 individual cytosines on the human genome. We were able to sort the locations
that showed potentially higher methylation differences between body fluids and
investigated over 100 of them using HRM analysis. The results of that study, allowed the
identification of three new loci able to distinguish blood and two new loci able to
distinguish saliva and vaginal epithelia, respectively.
The use of DNA methylation patterns to aid forensic investigations started with a
publication in 2010, therefore each small contribution such as this work may, similarly to
what occured in the biochemistry field, result in the discovery of a method able to put the
technology in the hands of forensic analysts.
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CHAPTER I - INTRODUCTION AND LITERATURE REVIEW
A. The Molecular Structure and Biochemistry of DNA
The molecular structure of deoxyribonucleic acid (DNA) was established in 1953 as a
result of several years of research. Maurice Wilkins and Rosalind Franklin were able to
capture high quality X-ray diffraction photographs of the molecular structure of DNA (1).
In 1952, Alexander Todd and colleagues (2) established the existence of 3’-5’
phosphodiester bonds in DNA which laid the ground work for the final structure of the
double helix explained by James D. Watson and Francis Crick in 1953 (3). The DNA
structure includes a double helix composed of two linear strands, similar in structure, that
bind to one another through hydrogen bonds. Each linear strand is composed of building
blocks named adenine (A), cytosine (C), guanine (G) and thymine (T) that compose the
interior part of the double helix. These nitrogen bases are linked to a sugar-phosphate
backbone that forms the linear structure. The two linear strands of DNA form the double
helix by complementary hydrogen bonds between the nucleotides or nitrogen bases
(Figure 1.1). Each base-pair on the double helix was named Watson-Crick base pairing.
The double helix coils around a central axis and the stacking of the bases on its interior
has the distance of 3.4 Å. Each base has a rotation of 36 degrees from the adjacent ones
and therefore each turn (360 degrees) is composed of 10 bases (4). The two DNA strands
within the double helix are also organized in an anti-parallel fashion. The connection
between adjacent nucleotides is made between the previous nucleotide and the 5’carbon
and the hydroxyl group on the 3’carbon of the deoxyribose to the next nucleotide.
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Figure 1.1 – The structure of the DNA double helix showing hydrogen bonds between
two antiparallel strands. The nucleotides on the same strand are linked together by
phosphodiester bonds through the 3’-OH of one group to the 5’-phosphate of the next.
Adapted from (4).
The formation of the double helix depends on different chemical forces that act on
the structure’s constituents. The covalent binding of atoms in the nucleotides’ structures
is the strongest chemical force present in the DNA structure. For that reason, the building
blocks are stable structures and rarely suffer modifications on their structure. Several
forces are responsible for the high stability of double-stranded DNA when compared to
single-stranded structure. Hydrogen bonds are formed between a hydrogen donor and an
acceptor. The hydrogen atom itself is shared between two electronegative atoms such as
nitrogen and oxygen, typically in complementary nucleotides of the double-strand
structure. In this fashion, adenine base pairs with thymine in a double hydrogen bond and
cytosine base-pairs with guanine with a triple hydrogen bond (5). When the two DNA
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strands exist apart from one another, the nucleotides are exposed to water forming
hydrogen bonds with the molecules of water. As the correct complementary nucleotide
gets closer, the hydrogen bonds that form between the complementary nucleotides
replace those formed with water molecules. Because the energy required to make the new
bonds and to disrupt those with water is similar, the total energy of the molecule and its
environment is constant and the First Law of Thermodynamics is observed (5). However,
if the nucleotides are not complementary, some of the hydrogen bonds cannot form which
makes the reaction greatly disfavored. Additionally, the formation of a non-polar moiety
within the double-strand contributes to hydrophobic interactions that force water to the
outside of the structure. These forces help explain why there is a release of energy in the
formation of the double strand, therefore increasing the entropy of the surroundings and
favoring the double-helix formation. Van der waals forces between adjacent nucleotide
bases in the double helix are also optimal which further contributes to the stability of this
structure when compared to single stranded DNA (4). However, some unfavorable
electrostatic interactions between the negative phosphate groups of the backbone also
exist. These unfavorable interactions occur mainly on adjacent phosphate groups present
when the double strand circles around the axis. These forces are reduced because of the
presence of positively charged ionic species like sodium and magnesium and the
dielectric constant of water that stabilizes the negative charge of phosphates.
Even before Watson and Crick proposed this model for the double-helix, there was
already the notion that DNA was responsible for storing genetic information able to code
for effector proteins that carry specific tasks within a cell (5).
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B. The Location of Genomic DNA and The Central Dogma
Deoxyribonucleic acid itself is not the effector biomolecule that allows all cellular
processes to exist. Genomic or nuclear DNA is located in the nucleus of a cell and
therefore cannot process cellular mechanisms that operate on the cytoplasm and other
organelles of the cell. Instead, DNA contains the information necessary to synthesize
proteins, which are the effector molecules within cells (5).
To explain how the information stored in the DNA can be transformed into effector
proteins, Francis Crick proposed the central dogma pathway in 1958 (6). According to
the central dogma model, genetic information stored in the DNA molecule is transcribed
to ribonucleic acid (RNA), which carries it to the cytoplasm. Once in the cytoplasm of
the cell, RNA is then translated to proteins. Specific characteristics make this model
unique (6, 7). The first characteristic is that the information stored in the DNA code can
be duplicated to form two identical copies of the same template of DNA. The duplication
of DNA happens before cell division in order for the new cell to obtain one DNA
molecule with the same genetic information as the template. The second characteristic of
the central dogma is that the flux of information happens in a single direction from DNA,
to RNA and then proteins. Third, the intermediate player – RNA – is transcribed from the
template DNA and travels to the cytoplasm transferring the information to be translated
into proteins.
The duplication (also known as replication) of DNA depends on the concerted
action of enzymes such as helicases, DNA polymerases and DNA ligases. The initial step
necessary to DNA replication is the unwinding of the double strand at specific regions
called origins of replication by the initiator proteins. Each human chromosome has an
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origin of replication for each 30-40 kilobases (kb). The DNA helicase then binds to the
single-stranded DNA (ssDNA) to further unwind it and allow the primase to synthesize
RNA primers necessary for DNA duplication (8). The primase is a specific RNA
polymerase that specifically synthesizes 5-10 RNA nucleotides complementary to the
ssDNA at the origin of replication. The primer:template junction acts as a substrate for
DNA polymerase and signals it to initiate copying the DNA molecule. The tertiary
structure of human DNA polymerase enzymes resembles a hand that grips the DNA
molecule. The catalysis occurs in the palm whereas the fingers and thumb provide the
stabilization residues necessary to the correct nucleotide to be added to the newly formed
strand(9). In the moiety of the DNA polymerase, the free 3’-hydroxyl (3’-OH) group of
the primer:template junction attacks the alpha-phosphoryl group available on the next
deoxynucleoside triphosphate (dNTP) brought close by the polymerase.
Also associated with the DNA polymerase are sliding clamps that maintain its association
with DNA even after the end of new strand by the polymerase. The sliding clamp allows
the action of other enzymes necessary to the correct duplication of DNA and provides
easier association of different DNA polymerases in case corrections are needed in the
new copy of DNA. The process continues through DNA unwinding by helicases ahead of
the association between the DNA polymerase that copies the leading strand with a direct
addition of nucleotides to the 3’ –end of the new strand and the template DNA, which
forms the replication fork (9). Since the replication can only occur by addition of
nucleotides on a free 3’-OH and each ssDNA runs anti-parallel to one another on the
double helix, only one template strand (called the leading strand) can be directly copied
as the replication fork forms. The complementary strand that runs in the opposite
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direction of the leading strand cannot be immediately copied and is therefore called the
lagging strand. Only when there is enough lagging strand template present on the
replication fork, can a second sliding clamp associate to the lagging strand, allowing the
primase to synthesize a new primer:template junction. The replication of the lagging
strand is therefore achieved by the synthesis of small DNA fragments, called Okazaki
fragments, instead of a single long strand (8). Each fragment is formed as a result of the
progression of the replication fork and recruitment of its own set of replication
machinery. At the same time that the DNA polymerase copies the lagging strand on the
second Okazaki fragment, it also uses its 5’-3’ exonuclease activity to remove the portion
of RNA primer from the first fragment. The existing nick between the two Okazaki
fragments is sealed by another enzyme present in the replication machinery called DNA
ligase. The process of copying one entire DNA molecule allows the duplication of
information prior to cell division and thus the propagation of the genetic code to the
subsequent generations.
The second process described by the central dogma is called transcription.
Transcription allows the code stored in the DNA to be transcribed to RNA. Because of
the similarity between the two molecules, the process of transcription presents some
common steps to replication. The main differences reside in the specific enzymes that
catalyze the reaction and in the product formed.
RNA polymerases are enzymes capable of reading deoxyribonucleotides from DNA and
convert them to ribonucleotides in the RNA. The pairing of complementary nucleotides is
similar to DNA, except to the adenine that is base-paired with uridine, since RNA does
not contain thymines. Another difference is that the RNA molecule exists as a single

6

strand, the only time it exists as double-paired is during transcription, when it is paired
with DNA.
The initiation of transcription happens when RNA polymerase binds to the DNA
at promoter regions. The DNA nucleotide that is first transcribed is called the
transcription start site (TSS) and is referred to as the ‘+1’ position. Nucleotides located
before the TSS are called upstream and their relative distance to the TSS is established by
negative numbers, for example, -10 corresponds to the nucleotide located 10 base-pairs
upstream of the TSS. Similarly, nucleotides located after the TSS are called downstream
and carry positive numbers (10). Before the initiation of transcription, proteins capable of
recruiting the transcription machinery, which includes the RNA polymerase, recognize
specific DNA sequences. Those DNA sequences, also called elements, are present near
the TSS in the core promoter regions or in other regulatory sequences further away
upstream or downstream of the TSS (10). Each core promoter region can be 40-60
nucleotides long and contain different combinations of the possible elements.
Transcription occurs from the 5’ to the 3’end similarly to replication and it does not
require primers. As elongation occurs, the polymerase encounters specific sequences that
signal the end of the gene thus promoting termination. Transcription of those specific
sequences triggers the transfer of polyadenylation enzymes to the newly formed RNA.
The RNA copied from a single strand DNA needs to undergo post-transcription
modifications such as addition of a poly-A tail, addition of a 5’-cap and splicing (11).
Polyadenylation enzymes catalyze the addition of about 200 adenines (poly-A tail) to the
3’-end of the newly formed RNA (pre-mRNA) and also allow the complete detachment
of RNA polymerase and the messenger RNA (mRNA) from the DNA molecule. The
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5’cap consists in the addition of a modified guanine to the 5’-end of the newly formed
RNA. The 5’ cap has functions in the transport of mRNA to cytoplasm as well as
important functions in translation to proteins and protection against exonucleases. Before
exiting to the cytoplasm, the pre-mRNA must also be spliced to remove any regions of
RNA transcribed from DNA but that do not code for proteins (11).
Within each DNA region that codes for proteins, downstream of the promoter, the DNA
sequence has coding regions or exons interspaced by non-coding regions called introns.
The pre-mRNA contains a transcription of both exons and introns, which need to be
removed. The spliceosome is composed of 150 proteins and 5 RNAs that catalyze
transesterification reactions responsible for RNA splicing - the removal of introns and
combination of exons to form a mature mRNA. The importance of this process is that it
allows the generation of several spliced mRNAs that code for different polypeptides from
one pre-mRNA molecule transcribed from the same DNA region (11). The process from
splicing the RNA and formation of a mature mRNA with different exons is called
alternative splicing and it accounts for the diversity of proteins that each gene can code.
In humans, 75% of genes undergo alternative splicing, explaining the enormous diversity
observed for the number of genes carried by each individual considering the size of the
genome. Since exons from different genes can combine to form new proteins, alternative
splicing is thought to have greatly contributed to evolution and to the immense increase
in cell functions from simpler organisms to the complex biology in humans (12).
The last process described in the central dogma is translation. The translation of
mRNA happens in the cell cytoplasm, therefore the mRNA must exit the nucleus through
a pore protein called nuclear pore complex. As it reaches the cytoplasm, translation can
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start at the 5’ end of a string of codons called open reading frame (ORF, (13)). In
eukaryotes, the first codon is called start codon and is the sequence of the ribonucleotides
5’-AUG-3’. Translation ends with one of three possible stop codons: 5’-UGA-3’, 5’UAA-3’ or 5’- UAG-3’. The translation process occurs by the ribosome being recruited
and assembled at each mRNA. The recruitment is initiated by the presence of the 5’cap
on the mRNA which promotes two subunits of the ribosome (60S and 40S) to assemble
at the 5-end of the mRNA. In the newly formed protein, the larger subunit is responsible
to form the peptide bonds between amino acids whereas the smaller subunit decodes the 3
nucleotide codons to recruit the corresponding amino acid. In fact, even before assembly,
the small subunit is already associated with a transfer RNA (tRNA) that codes for
methionine and recognizes the start codon (13). After assembly, the ribosome scans the
mRNA until it finds that start codon allowing the first methionine to initiate translation.
As translation progresses, the ribosome translocates to the next codon allowing several
ribosomes to simultaneously translate a single mRNA molecule. Each ribosome is
capable of associating simultaneously with 3 tRNAs that recognize 3 successive codons.
Thus, the ribosome is a specialized organelle that allows the concerted action of tRNAs,
which specifically recognize codons providing the respective amino acid for protein
synthesis. Upon encountering the stop codon, the ribosome disassembles, translation
ends and the polypeptide formed dissociates from both subunits (13).
The genetic code followed by each tRNA corresponds a codon and an amino acid. Each
tRNA possesses an anti-codon sequence which is complementary to the mRNA, and it
also carries the respective amino acid according to the genetic code. Since each codon
has 3 ribonuclotides, there are 64 possible codons. From those 64 codons, 3 are used as a
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stop signal and the remaining 61 codons are translated to 20 amino acids(14). As a result,
each amino acid is coded by more than one codon, which classifies the genetic code
degenerate. The degeneracy of the genetic code promotes correct translation even in the
presence of random single nucleotide errors that could accumulate during either
replication or transcription (15).

C. The Structure of the Eukaryotic Cell
The evolution of species throughout time depended on the selective advantage for
unicellular organisms to combine into multicellular colonies. With evolutionary time,
certain individuals in each colony were able to differentiate and have specific functions.
The colony was then able to form an independent tissue with complex signaling pathways
between all individual cells. Therefore, the single, common structure to all living
organisms is the cell. Cells can be prokaryotic or eukaryotic. The cells that compose the
tissues in the human body are eukaryotic and share common characteristics with other
organisms that are composed of the same type of cells (16).
In eukaryotic cells, the cellular membrane separates the cell from the outside
environment, keeping a balanced level of salts and an adequate pH to cell functions. The
membrane is composed of a bilayer of phospholipids associated with proteins. Some
proteins can function as pores or channels that allow specific passage of extracellular
components, such as nutrients, neurotransmitters, hormones and others. Inside the cell, a
fluidic structure called the cytoplasm maintains several organelles that carry out
pathways allowing for cell survival and response to external stimulus. Another structure
present inside the cells is the nucleus. A nuclear membrane separates the genetic
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information stored in the DNA from the cytoplasm where the organelles are located. The
compartmentalization of organelles is a characteristic of eukaryotic cells which provides
them with a higher complexity when compared to prokaryotic cells. Since each specific
compartment can have its own environment, the compartmentalization allows the
survival of organelle-specific enzymes which leads to more specialized organelles. At
any certain point in time, numerous pathways take place in an eukaryotic cell due to the
presence of proteins, ions, water, genetic material (DNA and RNA), organelles and
several biochemical compounds that are either the substrate or the product for such
pathways (16).
Genomic DNA is found in the nucleus of the cell condensed into chromosomes
and mitochondrial DNA is found in the mitochondria in the form of a circular molecule.
The genomic human DNA is extremely lengthy and therefore needs to be compacted into
chromosomes in order to fit inside the nucleus of the cell. Human chromosomes are
linear structures, contain telomeres which are located at the ends of the chromosome
arms; and a central region – centromere – connecting the arms. In the process of cell
division, the centromeres form a kinetochore which interacts with protein filaments that
help pull the two copies of each chromosome to opposite sides of the dividing cell (17).
The mitochondrial DNA is located in the mitochondria which is the main organelle
responsible for the synthesis of adenosine triphosphate (ATP) - the main energy currency
in the cell. The mitochondria are capable of oxidizing proteins, lipids and sugars to
convert them to carbon dioxide and water with ATP production. The mitochondria also
has its own RNA, ribosomes and a small number of proteins that allow for self-assembly.
Similar characteristics between contemporary mitochondria and bacteria, illustrates how
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evolution may have occurred. A bacterium capable of oxidizing nutrients fused with an
archaic eukaryotic cell providing it with an enhanced system of acquiring ATP from
more complex nutrients. The fusion of both cells proved to be advantageous and therefore
such symbiosis relationship was selected (17).

D. The Cell Cycle
In order to form an organism, the initial cell is composed by the fusion of male
and female gametes and must divide several times to form a population of cells. Once
that occurs, some cells gain specialized functions and then further divide to maintain a
constant replacement of cells that are either damaged or that have died resulting from loss
of functions (apoptosis). Both pathways – expansion of a population of cells to form and
organism, or cell division to maintain the organism – have similar characteristics. In both
cases the cell cycle is composed of a series of events that allow for the duplication of all
the constituents of a cell followed by the division of such cell giving origin to two
identical daughter cells (18). When a new organism is being formed, the initial cell is
undifferentiated and is commonly called a stem cell. Once it receives specific stimulus,
the stem cell can divide and one of the daughter cells undergoes a cycle of rapid
duplication and division to form a subpopulation of cells. Upon the cessation of cell
divisions, the subpopulation of cells differentiates to acquire the characteristics of the
tissue they form. In humans, the process from stem cell to differentiated cell occurs for
example in the zygote cell formed upon egg fertilization and also in adult tissues that are
constantly regenerated, such as skin. In both cases, the cell cycle is divided into
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interphase in which the cell grows and duplicates all of its contents, and a second phase
called M phase, where the cell divides into two identical daughter cells (18).
When differentiated cells divide, they do so in order to replace cells that die. In
such case, the number of chromosomes must be maintained and the division is called
mitosis. During the interphase, more specifically in the S phase, the chromosomes
duplicate by forming an identical copy of each other through DNA duplication. Before
and after the S phase, two gap phases G1 and G2 function as check points to both prepare
for the next phase and to confirm that the previous actions were completed successfully.
The M phase follows which is composed of a rearrangement of the chromosomes in the
center of the cell to prepare it for division (18). The kinetochores and associated
microtubules pull the chromosomes in separate directions and so when the cytoplasm of
the cell divides, each new daughter cell has a diploid number of chromosomes, similar to
the cell that gave them origin.
Somatic cells have ‘2n’ or diploid number of copies of chromosomes whereas
gametes have haploid or ‘n’ number of chromosomes. In humans the gametes are the
sperm cell and the egg and when they fuse, they form the zygote with a diploid number of
chromosomes. Both egg and sperm are formed from precursors of reproductive cells
which are diploid. When these cells divide, they do so by a process called meiosis. In
meiosis, after the initial duplication of chromosomes and cell components, there are two
consecutive rounds of cell divisions without further duplication of chromosomes. The
two cell divisions that occur after chromosome duplication leave each gamete with
haploid number of chromosomes, allowing them to combine to another gamete and form
a diploid cell (18).
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E. DNA organization in Nucleosomes and Chromosomes
Human chromosomes are linear structures composed of DNA wrapped around
proteins. The number of chromosomes is characteristic of each type of eukaryotic cell. In
humans, all cells except the reproductive cells, are diploid and contain two copies of each
of the 22 chromosomes plus a single copy of the sex chromosomes, X and Y for males
and two copies of X for females.
The chromosomes are visible under the microscope and their structure varies according to
each phase of the cell cycle. For example, chromosomes in the M phase are condensed
and present a typical ‘X’ shape with visible arms and the centromere (18, 19). During
interphase, the structure is less compact and it is called chromatin. The more compact
version of chromatin is called the 30-nm fiber whereas the less compact is called the 10nm fiber. Under the microscope, the 10-nm fiber has the appearance of beads on a string.
The chromatin fiber is composed of nucleosomes which are constituted by a core of
histone proteins and a DNA molecule that is wrapped around them. The shape of beads
on a string visible under the microscope is therefore the nucleosomes (beads) with a
string of approximately 20-60 base pairs (bp) of DNA (linker DNA) uniting them (19).
The histones are proteins that are specific to nucleosomes. Each nucleosome contains two
copies of H2A, H2B, H3 and H4 histones. Immediately after DNA replication, the
nucleosomes assemble thanks to the specific action of histone chaperones which are
negatively charged. The replicating DNA functions as a signal for the chaperones, which
are then directed to form complexes with the tetramers or dimers of the H2A, H2B, H3
and H4. To initiate the formation of the nucleosome, a tetramer of two copies of H3 and
H4 associates with DNA, promoting the recruitment of two H2A.H2B dimers. Each
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newly formed nucleosome contains histones from the parental cell that were released
upon relaxation of the chromatin fiber and new histones formed during the interphase.
Since some of the existing histones are recycled to the new cell, the chaperone needs only
to direct the assembly of the new ones. Additionally, the histones regenerated from the
mother cell carry with them important modifications that can be copied to the daughter
cells (19).
The DNA is wound 1.65 times around the core of histones for a total of 147 bp
per nucleosome. Further condensation of the structure is achieved when a fifth histone –
H1 – binds to the linker DNA, further condensing the chromatin fiber and originating the
30-nm fiber. The histones have amino-terminal tails that protrude from the nucleosome
core and that can have modifications such as presence of methyl or acetyl groups that
help recruit proteins and also stabilize the DNA. Depending on which modification is
present in the histone tails at each time, the proteins recruited can help further condensing
or relaxing the chromatin structure. A more relaxed structure is more suitable for DNA
replication or transcription (19).
Overall the human genome is composed of 3,200 Mb (Mega-bases) of DNA from
which only 48 Mb are genes that code for proteins. Introns, unstranslated regions (UTRs)
and pseudogenes compose about 1,152 Mb and another 2,000 Mb are intergenic DNA.
Regulatory regions such as those that code for miRNA allow the regulation of gene
expression (19). About 3% (or 90 Mb) of DNA is composed of microsatellites, which are
short-tandem repeated sequences of less than 13 nucleotides. The gene density defined as
the number of genes per Mb of DNA, and not the total number of genes or length of
DNA is what determines the level of complexity of a species. More complex species have
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their gene-coding regions interspaced with non-coding DNA such as repeated sequences,
intergenic sequences, introns, etc, thus having a lower gene density (19).

F. Epigenetics
Epigenetics is a term that was first defined by Doctor C.H. Waddington in 1942 to
explain the interactions between “genes and their products, which bring the phenotype
into being.” (20). Nowadays the term ‘epigenetics’ is used to coin all the genome
modifications that cause differential gene expression, independent from changes in the
DNA sequence (21). Some of the mechanisms included in epigenetics cause regulation of
gene expression through changes in the level of chromatin condensation, changes in the
mRNA resulting from transcription or changes in the DNA itself - DNA methylation.
Since the DNA contains the genetic information that codes for chromatin condensation
and mRNA synthesis, DNA methylation can be linked to modifications in the chromatin
and RNA therefore resulting in cell-specific gene expression (22).
The epigenetic mechanisms that allow changes in the degree of relaxation of
chromatin are commonly known as chromatin remodeling and can directly influence
DNA transcription. The nucleosomes are composed of 147 bp of DNA wrapped around
histones. If the wrapping is tight, the DNA is less likely to be available for transcription
(19). The tightening of the chromatin fiber can be promoted by the presence of different
modifications on the histone tails, which are mostly composed of residues of arginine and
lysine (5). The specific modifications on the histone tails occur post-translationally and
can be methylation, acetylation, phosphorylation, propionylation, butyrylation,
ubiquitylation, sumoylation and citrullination. Each set of modifications in the histone
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tails is known as ‘histone marks’ and a combination of several histone marks leading to a
gene regulation event is known as ‘histone code’ (23).
One of the most studied examples of histone modification is the methylation of lysine (K)
residues in tails of histone H3 that can either cause gene repression when tri-methylation
occurs on lysine 9 of histone 3 (H3K9me3) or gene activation for H3K4me3 (24).
Another type of histone modifications intimately related to gene expression consists on
the presence of histone variants. Some histones contain differences in few amino acid
residues when compared to the canonical histones. For example, in mammals there is a
known variant of the histone H2 called H2A.X. When H2A.X is phosphorylated, it marks
a double strand DNA break. Another variant known as H2A.Z, which is widely present at
transcription start sites, shows a negative correlation with the existence of DNA
methylation. Even though information regarding the mechanism of action of these
variants is limited, the existence of dedicated mechanisms responsible for the removal
and addition of these histone variants into the nucleosome further reinforces the
importance of these histones in gene expression (22).
Gene expression can also be regulated at posttranscriptional levels through RNA.
Two main mechanisms are known to date: one is related to the RNA secondary structure
and the other related to the binding of small regulatory RNAs to the mRNA.
Regulation through the RNA secondary structure occurs when a specific factor binds to
certain mRNA transcripts preventing them from unfolding thus preventing translation.
For example, in eukaryotes several proteins such as ferritin mediate the harmful
accumulation of iron. Ferritin is an iron-storage protein mainly found in the liver and
kidneys. The ferritin mRNA can only be translated when the 5’-end stem-loop is free
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from another protein called IRP. Since iron binds to IRP strongly, in high concentrations
of iron, the IRP preferentially binds to iron releasing the ferritin mRNA and promoting
translation for higher protein availability (5).
Another type of gene expression at the RNA level can occur when specific mRNA
transcripts are deleted. The deletion of mRNA after it has been transcribed occurs when
certain small RNA – called micro RNAs (miRNA) – are transcribed from specific genes.
After being synthesized the miRNAs bind specific proteins from the Argonaute family,
which have the capacity to degrade mRNA transcripts complementary to the miRNA
sequence. Since each miRNA sequence can be complementary to several mRNA
transcripts, several types of mRNAs can be degraded in this manner (5). Recent
discoveries show that this form of gene silencing mediated by miRNA can establish a
repressed chromatin state through back-signaling to DNA. Such chromatin state
represents a more stable gene silencing mechanisms since it can be propagated through
several cell divisions (22). Additionally, small nuclear RNAs can also operate through
transcriptional gene silencing (TGS, see Figure 1.2) pathways. It has been proposed that
in order to defend the organism from harmful DNA elements introduced by viruses, small
RNAs can interact with effectors of histone lysine methylation pathway to silence the
extraneous DNA (22).
The third type of epigenetic modification, the DNA methylation, has been widely
studied. In humans methylation occurs primarily in the 5’ carbon of cytosines followed
by guanines (CpGs) and because of the large effect of that methyl group in gene
expression, methylated cytosines have been referred by some as the 5th nucleotide (25). In
fact, DNA methylation plays important roles in several genetic processes such as
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repression of transposons and repetitive elements, genomic imprinting and Xchromosome inactivation, where one of the X chromosomes is silenced in every somatic
cell of female mammals (21, 26).

Figure 1.2 – Schematic representation showing all the genomic and epigenomic
factors and mechanisms involved in gene regulation. The center of the figure
represents 4 nucleosomes and the main mechanisms for epigenetic regulation
such as DNA methylation (red circle with Me), histone modifications (Mod),
histone variants (yellow nucleosome) and non-coding RNA (wavy blue lines).
The brown boxes display genomic functions that affect epigenome modifications
and help in its regulation. The main factors needed for genomic functions are
shown near the boxes. Adapted from (22)
The close physical relationship between DNA and histones in the nucleosomes
precludes possible correlations between the different states of chromatin and DNA
methylation. Ongoing research aims to further draw a mechanism of how such
interactions affect gene expression. In 2010 direct evidence was found that connect the
methylation status of CpGs to recruitment of proteins able to mediate modifications in the
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histone tails. One example is the specific recognition and binding of protein CXXC-type
zinc finger protein 1 to unmethylated CpGs which promotes the recruitment of enzymes
called histone lysine methyltransferases (KMTs). Methylation of histone tails on their
lysine residue by KMTs seems therefore to be influenced by unmethylated cytosines on
associated DNA regions (27).

G. DNA Methylation
The genetic diversity observed in humans is not only a result of DNA
polymorphisms in the DNA sequence that accumulate over generations, but also due to a
more transient modification – DNA methylation – that is altered during the life of one
individual and accounts for phenotypic changes (24). In the 1980s the link between DNA
methylation and gene expression was established. After blocking DNA methylation in
vitro using the drug 5-azacytidine, researchers were able to establish the link between
irregular DNA methylation and the onset of cancer. The connection between anomalous
DNA methylation and such a devastating disease such as cancer greatly increased
research interests towards studying DNA methylation and the enzymes responsible for
maintaining a stable methylome (22).
Typically, the cytosines that can undergo methylation are followed by a guanine
and therefore they are commonly referred as CpGs. The ‘p’ between the C and G
highlights the phosphate link between the two nucleotides on the same strand of DNA as
opposed to the complementary cytosine-guanine hydrogen bond in the Watson-Crick
base-pairing. Cytosines in other dinucleotides such as CpA, CpT or CpC can also
undergo methylation, however those forms are less common.
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The DNA methyltransferases (DNMTs) promote the catalysis of cytosine methylation
(28). Methylation in somatic cells of mammals is most predominantly seen in CpGs as a
result of an increased affinity (40-500 fold) of DNMTs to that dinucleotide, when
compared to the dinucleotides CpA, CpT or CpC (29). Non-CpG methylation is therefore
a rare event in somatic cells. A different scenario is present in pluripotent cells such as
stem cells where non-CpG methylation accounts for about 25% of all methylation seen in
those cells. Interestingly, the levels of non-CpG methylation for in vitro-induced
pluripotent cells are similar to those of embryonic stem cells, indicating that non-CpG
methylation levels are re-established when cells are in their undifferentiated state (28,
29). The exact molecular mechanisms that allow the non-CpG methylation to occur only
in pluripotent cells can be of great interest to understand how DNA methylation is
involved in establishing cell type identity and to help future determination of genomic
regions that are involved in cell differentiation.
The successful establishment of an embryo depends on how gene expression and
silencing is modulated between the two progenitor’s DNA. All stages from oocyte
development, maturation and after fertilization are marked with several epigenetic
modifications. Whole genome demethylation occurs in two specific events in the embryo
development – during germ cell migration and immediately after fertilization.
Demethylation of DNA in these stages is crucial to develop the new embryo’s epigenome
by first erasing the progenitor’s epigenome and thus establishing state of pluripotency
necessary for cell development (30). After embryonic implantation, a de novo
methylation is generally observed in the whole genome occurs and a new methylome is
established (31). In contrast, de novo methylation is not so prominent in specific tissues
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during differentiation, establishing a link between low level of new methylation in the
genome and cell differentiation. At the tissue level, de novo methylation is therefore rare
in normal development and cell differentiation but is widely seen in the development of
cell lines in vitro and in cancer (32). Research using pluripotent stem cells (ESC) have
observed that unlike somatic cells, ESC have the ability to de novo methylate exogenous
DNA introduced in the cells. At this stage of organism development, unique motifs in the
DNA sequence determine which regions are methylated. It has been observed that at the
time of implantation, some CpGs such as those of housekeeping genes, are protected
from de novo methylation. Most of those unmethylated CpGs are located near places
where the RNA polymerase binds (transcription start sites) marked with H3K4me3,
suggesting a role for RNA polymerase to bind the DNA and protect it from de novo
methylation (31).
Regarding the distribution of DNA methylation in adult human genomes (somatic
cells), it has been established that there is an equal distribution on gene bodies,
transposons and intergenic DNA (28). From all the CpGs in the human genome, those
that are unmethylated regardless of gene expression constitute only 1-2% of all CpGs and
they are located mostly in CpG islands (CpGi). CpGi are areas with higher-than-normal
density of CpGs and they are mostly located near or at gene promoters (33). The physical
proximity between CpGi and promoter regions agrees perfectly with the notion that
changes in DNA methylation can lead to changes in gene expression (28, 34). Moreover,
it has been proposed that when CpGi regions become methylated during development,
the gene associated is silenced permanently (32). Furthermore, Quante and Bird (2016)
(35) recently suggested a connection between DNA sequence and DNA methylation.
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Such connection was established due to the observation that sequence-specific proteins
such as those with CXXC domains, because they recognize unmethylated CpGs, they are
preferentially recruited to CpGi, which in turn preserves their unmethylated status. The
revolutionary view that sequence and epigenome are intertwined has been supported by
some studies, but has not been established yet (35).
Apart from CpGi, other genome regions have been shown to have specific methylation
patterns. Such regions are linked to tissue type and are therefore named tissue-specific
DNA methylation regions (tDMRs). Initially it was thought that tDMRs would be more
prevalent near gene promoters, in or around CpGi and thus research was focused on such
loci. However, in 2012 Fernandez and colleagues (36) looked at the methylation status of
1505 CpGs for 434 DNA samples donated by healthy individuals and determined that
transcription start sites, and not promoter regions of genes are the DNA regions more
predominantly linked to tDMRs. The discovery that transcription start sites coincide with
tDMRs was further corroborated by an array study that interrogated more than 450,000
individual CpGs reported by Slieker et al. (2013). In this study, Slieker and colleagues
confirmed that tDMRs are commonly associated with CpG-poor regions, not CpGi and
are intimately linked to alternative transcription sites (37).
Even though the specific mechanisms by which the distribution of DNA
methylation is established in the embryo and maintained throughout the organism’s life
are not known, most of the enzymatic pathways that catalyze methylation have been
studied and are related to different family members of the DNMTs. The de novo
methylation established in the embryo after fertilization occurs due to the action of
DNMT3A and DNMT3B which catalyze the addition of a methyl group to cytosines. The
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methyl group is donated by s-adenosyl-L-methionine which specifically functions as a
methyl donor (38). In more detail, DNMT3A seems to be highly expressed in germ cells
whereas expression of DNMT3B peaks in early development following fertilization (39).
Both DNMT3A and 3B contain a c-terminal catalytic domain and an N-terminal
regulatory domain. Next to the regulatory domain a conserved motif Pro-Trp-Trp-Pro
(PWWP) has been described, which appears to provide a link between the DNMTs to
histone tails that show particular types of modifications. For example, a point mutation
on the PWWP motif reduces the capacity of DNMT3B to recognize and bind the
H3K36m3- modified nucleosome, leading to a loss of methylation which in turn leads to
the pathological phenotype called Immunodefficiency Centromeric instability and Facial
anomalies syndrome (40). A third enzyme – DNMT3L – co-localizes with both
DNMT3A and 3B and works as an enhancer of the activity of DNMT3A and 3B. DNA
methyltransferase 3L does not possess a PWWP motif, and even though it has a catalytic
domain, it is unable to catalyze the methylation reaction on its own. Instead, two
monomers of DNMT3L and two monomers of DNMT3A form a tetramer complex that
catalyzes the methylation reaction. Because of the size of the catalytic tetramer,
periodicity of de novo methylation occurs on every 8-10 base pairs (41). In summary, the
factors determining which CpGs will be de novo methylated leading to a functional
methylome are the spacing necessary for the tetramer DNMT3L:3A to bind and the
histone modifications ability to bind the PWWP domains.
After the establishment of the methylome, maintaining the same patterns of DNA
methylation in healthy cells and tissues relies on the genome’s ability to methylate
specific CpGs after each cell division. Before cell division and after the DNA sequence is
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duplicated, it becomes necessary to copy the methylation pattern to the newly formed
strand. The enzyme responsible for the addition of methyl groups on specific cytosines of
the newly formed strand is called DNMT1. The specific mechanism depends on a 30-40
fold preference of DNMT1 to hemimethylated DNA. Hemimethylated DNA is DNA
where only one strand (the template strand) has a methyl group on the cytosine, whereas
the complementary strand (the newly synthesized strand) has an unmethylated cytosine.
The catalytic domain in DNMT1 is longer than that in the DNMT3 family and it also
contains a motif that binds to the replication machinery (specifically to PCNA). The
proper functioning of DNMT1 depends on an accessory called UHRF1 (ubiquitin-like,
containing PHD and RING finger domains 1). In more detail, the SRA domain within the
UHRF1 flips the DNA strand open and exposes the hemimethylated site, which in turn
allows the unmethylated cytosine to fit into the catalytic pocket of UHRF1 and therefore
be methylated (41). Somatic cells are rich in DNMT1 and poor in DNMT3A and 3B
which further establishes the importance of such methyltransferase in maintaining the
methylome in post-embryonic development. However, the division of roles in DNMTs is
not clear-cut. Some results have shown that DNMT3A and 3B can aid the maintenance of
methylation patterns in somatic cells (39). The experimental design showed that when
embryonic stem cells that lack DNMT3A and 3B expression are subject to successive in
vitro multiplication, a decrease in DNA methylation is observed with cell division. The
embryonic stem cells contain healthy levels of DNMT1, which should be sufficient to
maintain the DNA methylation pattern even if no DNMT3A or 3B are present to perform
de novo methylation. After these observations, it has been suggested that the presence of
DNMT3A and 3B is essential to aid DNMT1 in the maintenance of DNA methylation
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patterns (39). The interplay amongst DNMTs and other factors creates a pathway which
define and maintain stable DNA methylation patterns in somatic cells.
In mammalian development, the male genome is actively demethylated within
hours of implantation, whereas the female genome is only passively demethylated with
each successive cell division (30, 31). Demethylation is therefore another important
biochemical process necessary to maintain proper levels of methylation and to allow
successful development of embryos. Initially it was thought that demethylation occurred
uniquely in a passive manner when successive cell divisions occurred without being
accompanied by an adequate increase in DNMT activity. However, such passive loss of
methyl groups could not account for demethylation of the entire genome postfertilization, especially since at that stage of embryonic development there is no cell
division. For that reason, another mechanism was proposed and it was called active
demethylation (42). Nowadays, both mechanisms are generally accepted and research is
focused on determining at which stages of cell division or development one is prevalent
over the other.
Passive demethylation occurs when the DNMT1 fails to recognize, bind or
process a hemimethylated site and thus the newly formed strand is kept unmethylated.
When the next cell division occurs and if not corrected, the copy of that strand will
perpetuate the unmethylated state in that particular CpG. One example of how DNMT1
may not be able to bind DNA is if the binding site for DNMT1 on the DNA strand is
occupied by a transcription factor. Unmethylation of DNA in this fashion may be a
controlled event in the cell or tissue as a way to respond to specific gene expression due
to the encounter with a new environment (28).
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Active demethylation on the other hand depends on enzymatic reactions catalyzed
by TETs (ten-eleven translocation). The TET family of enzymes is composed of three
members thought to be involved in embryonic development, meiosis, stem-cell
reprograming, maintenance of imprinting as well as maintaining the correct DNA
methylation patterns which leads to proper gene expression (28, 43). Such enzymes
successfully oxidize 5-methylcytosines (5-mC) to 5-hydroxymethylcitosine (5-hmC), 5formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). Experimental data has not
established yet whether these oxidized forms of 5-mC are only intermediates on the
demethylation process or if they have an active role on the genome. However, if indeed
they are mere intermediates in an enzymatic reaction, then it would be extremely difficult
to find stable forms of such oxidized methylcytosines in vitro. However, there are
sufficient numbers of those methylcytosines to permit their quantification. Genome-wide
studies show a lower abundance of these oxidized derivatives (less than 30%) when
compared to 5-mC (above 80%), but they are nonetheless a quantifiable presence in the
human genome (25). The fact that stable oxidized forms of methylcytosine are easily
found and quantifiable on the human genome may indicate a biological role yet to be
discovered (42). Another indication that 5-hmC may indeed have some undiscovered role
in the genome comes from the fact that the 5-hmC is not the TET enzymes’ preferred
substrate. Moreover, complete demethylation via this pathway depends on Base Excision
Repair (BER) enzymes that can further treat the oxidized cytosine as a DNA lesion and
repair it to then become an unmethylated cytosine (Figure 1.3). Also the enzyme
thymine-DNA glycosylase which is an important part of BER-dependent demethylation,
is much more efficient at recognizing 5-fC and 5-caC when compared to 5-hmC. The
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combination of both factors - the low level of oxidation of 5-hmC to 5-fC and 5-caC by
TET and the low excision and repair activity of 5-hmC by the BER glycosylase - can lead
to an increase in the presence of 5-hmC in the genome. At this point the role of 5-hmC
remains elusive but its presence in both dividing and non-dividing cells suggests a
potential role in gene regulation (42).

Figure 1.3 – Schematic representation of the enzymes and the
chemical modifications they catalyze. Cytosine is modified to 5methylcytosine by DNMTs. The methylated cytosine can undergo
modification by one enzyme of the TET group which converts it to
5-hydroxymethylcytosine, which can be further oxidized to 5formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). The
conversion back to unmethylated cytosine can be catalyzed by
thymine-DNA glycosylase (TDG) – mediated base-excision repair
(BER) or by decarboxylases. Adapted from (25).
The initial studies that linked DNA methylation with gene expression observed
that tDMRs are unmethylated on their specific tissues and highly methylated in other
tissues leading to gene silencing. Comparisons between methylation in DNA and mRNA
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levels also showed that the expressed genes are unmethylated. One of the first
mechanisms proposed for gene silencing as a result of DNA methylation included the
inability of transcription factors to bind methylated DNA, thus preventing the
transcription of such gene (31). Alternatively, other proteins called methyl-CpG binding
proteins specifically bind methylated CpGs and are mediators in gene silencing (32).
Even though such mechanism may be present for some genes and may constitute the
main mechanism for transient gene expression, most transcription factors do not have
CpGs in their binding sites which indicates the existence of other mechanisms.
Research on gene expression has demonstrated that DNA methylation may affect
chromatin packaging. With most of the methylated CpGs located in the core center of the
nucleosome and not on the DNA in between nucleosomes, the chromatin adopts a
condensed state. Moreover, the recruitment of proteins capable of modeling chromatin
structure may depend on the presence of methyl groups in the DNA. Combined, these
mechanisms explain better the observed phenomena of some genes being transiently
silenced and others keeping their repressed state through the entire lifespan of the
organism. Certain parts of the genome can undergo changes in methylation status after
the embryonic stage of implantation. One of these changes involves the loss of the
pluripotent state of embryonic cells as they get differentiated in specific tissues. Another
major event is the inactivation of one of the X chromosomes in females. In both cases
modifications of the chromatin structure as well as changes in gene expression and
replication timing occur prior to de novo methylation of CpGs. The observation that
DNA methylation occurs after chromatin structure modification at certain genome
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locations suggests that DNA methylation locks the gene repression phenotype and is not
responsible for causing it (31).
During the lifetime of an organism, changes in DNA methylation occur resulting
from exposure to the environment and as a direct consequence of molecular ageing. The
epigenome of an organism is a dynamic system that allows the modulation of the
molecular environment due to factors present in the external environment. Several bodies
of research have focused on the impact of changes in the environment and its
consequences on DNA methylation or chromatin remodeling (44-46). Environment
constitutes everything surrounding an organism, including diet, smoking habits, physical
exercise, pollution, contact with known carcinogenics, etc. Some of those factors are
known to promote general health and increased life-span in humans (type of diet and
physical exercise), however it becomes difficult to pinpoint the exact molecular
mechanisms that affect an individual’s health. For example, the regulation of folate in
diet can alter the levels of s-adenosylmethionine, which is the main methyl donor for the
DNMTs, thus changing the levels of DNA methylation. Also, the hypomethylation of
genes related to inflammatory processes is delayed when moderate physical exercise is
adopted in the lifestyle of an individual (47). Additionally, ageing is a natural
phenomenon for all living organisms, and several studies have looked at DNA
methylation as a prediction of biological age with varying degrees of success (48-52).
However, biological age itself is dependent upon habits of each individual that range
from diet to physical exercise. At the molecular level, it is generally accepted that any
change in DNA methylation is transient until it gets locked-in by chromatin modifications
that can be transmitted to the next generation. Since in the gamete formation there are
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waves of demethylation and de novo methylation, most of such modifications are erased
from the genome (30).
Interestingly, recent studies looked at the epigenetic modifications of the
offspring of women that were pregnant during the Dutch Hunger Winter and a link was
found between changes in insulin resistant cells and epigenetic modifications. Even
though studies such as these are limited due to availability of cohorts, research in mouse
models has demonstrated a link between changes in DNA methylation and behavior
which can be perpetuated to later generations. For example, pregnant rats in the presence
of predators, display high levels of stress and show a decrease in grooming and nurturing
activities towards their pups. At the molecular level, it has been demonstrated that such
behavior causes an increase in DNA methylation at the glucocorticoid receptor gene
which is directed by a low level of serotonin in the pup’s hippocampus. The levels of
glucocorticoid receptors are maintained throughout the lifespan of the pups which will
result in the same lack of nurturing behaviors towards their offspring (53). In humans the
complexity of behaviors increases greatly since they depend not only on nurture but also
on acquired information during adult life, which may further influence the levels of
epigenetic modifications. The increased complexity observed in humans can create
difficulties in linking molecular phenomena with phenotypic or behavior.
With respect to the exposure to pollutants and other detrimental environmental
factors, changes in the epigenome will become stable with the persistence of the
environmental insult. As seen in the embryonic studies, some genome regions are greatly
protected from epigenetic changes thanks to the presence of condensed chromatin states
and the binding of proteins to the DNA. For that reason, tDMRs are expected to maintain
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a stable level of DNA methylation throughout the lifespan of an healthy individual (44,
45, 53).The cause-effect relationship of changes in global methylation as a result of the
exposure of environmental pollutants or a specific diet are difficult to prove. The
difficulty in proving such correlation is mostly because these changes are often subtle and
difficult to be directly observed by the appearance of an external phenotype in humans
(32).
As a consequence of the link between DNA methylation and disease, most
research is focused on the understanding of how changes in DNA methylation impact
disease. As mentioned before, one such diseases is cancer, which is also linked to age. In
fact, the mechanisms of age have been the topic of many research papers and it is
generally accepted that aging is characterized by an increase of damage to an organism,
whether because of a decrease in adaptability or as a result of accumulation of ‘mistakes’
in the genome. The accumulation of mutations can result from the presence of reactive
oxygen species or because of alteration of DNA repair mechanisns, such as is the case of
Werner or Cockayne syndromes where patients appear older than they truly are. Also, the
telomere shrinkage due to a decrease in the action of telomerase has been pointed to as an
additional cause of aging in humans. Even in the case of monozygotic twins, which share
the same DNA sequence, the process of aging is different, further emphasizing the role of
environmental factors in the process (47, 50, 54). Interestingly, aging seems to lead to a
global hypomethylation and localized hypermethylation in the human genome. The
regions hypomethylated are mostly those present within transposable repetitive elements,
such as Alu and LINE, and CpG-rich promoters of imprinted genes. The
hypermethylation seems to occur mostly in CpGi in promoter regions and in genes
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related to cell apoptosis and senescence. Additionally, the link between aging and
heterochromatin alterations has been known for over 20 years. However, the exact
mechanisms are still unknown. As more studies unveil the links between DNA
methylation, histone modification and heterochromatin stability, the picture will become
clearer on which molecular pathways contribute to aging. Nonetheless, an increasing
number of studies link altered levels of DNA methylation to age in humans, even
allowing the prediction of biological age (48, 55-57). However, in such studies the
accurate prediction of age is dependent on an initial identification of tissue of origin of
DNA, which indicates that DNA methylation differences between tissues are higher than
DNA methylation differences between the same tissue collected from individuals of
different age (47, 58).
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CHAPTER II - FORENSIC DNA ANALYSIS

A. History and Advancements in Technology
In 1985 a publication in the journal Nature denoted that the analysis of several
tandem repeats on the DNA sequence of humans “…are a powerful method for paternity
and maternity testing, can be used in forensic applications and might also be useful in
detecting inbreeding…”. In the same article, Dr. Alec Jeffreys called these sequences
“DNA fingerprints” (59). Following this discovery, ‘DNA fingerprinting’ was first used
in a murder case the U.K. by Sir Alec Jeffreys to help determine who committed the rape
and murder of two young girls. DNA was able to connect both crimes showing that the
body fluids found at the crime scene were from the same perpetrator. Dr. Jeffreys was the
pioneer of ‘DNA fingerprinting’ and its use spread to Europe and all over the world (60).
The DNA fragments, called fingerprints, are also known as RFLP (restriction fragment
length polymorphisms) and were obtained by incubation of DNA with restriction
enzymes that specifically cut the DNA in the same consensus sequences throughout the
DNA strand of interest. In the USA the enzyme most commonly used was HaeIII which
recognizes and cuts the sequence ‘GGCC’ (61). The RFLP method as used by Dr.
Jeffreys first extracts the DNA by lysing the cells and disrupting membranes and proteins
attached to the DNA. Next, the restriction enzymes are incubated with the extracted DNA
and the fragments they produce are separated by size through the use of an agarose gel. In
order to determine which fragments were present, the gel product was transferred to a
nylon membrane, the double stranded was then denatured by a strong alkaline solution
and the bands hybridized with DNA probes. The specific base pairing between the bands
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in the nylon membrane and the nucleotide sequence in the radiolabelled probes allowed
the detection of specific RFLP fragments. The membrane was placed next to X-ray film
and the location of the RFLP bands were photographed (62). In the original method, the
probes hybridized to several DNA bands creating a unique pattern that could be
compared with a control sample. However, since forensic samples often are composed of
mixtures, the bands would be the result of DNA from different contributors, which could
be difficult to analyze. The technology then evolved to use single-locus probes that
hybridize only to a single locus and give one band for homozygous or two bands for
heterozygous individuals (60). To analyze the presence of another RFLP, the process was
repeated by first removing the first single-locus probe by a alkaline solution washing, and
then hybridizing the membrane with new single-locus probe and a photograph taken. The
analysis of multiple RFLPs could take several weeks or even months to be completed.
Besides the low throughput, this method was also limited to samples with high yields of
DNA (>50 ng) and good quality and high molecular weight (>12 kb) DNA (63).
Kary Mullis had already invented the method referred to as polymerase chain
reaction (PCR) in 1986 (64). However it was not immediately used in forensics. PCR has
a great advantage since it mimics in vitro what occurs with DNA replication in vivo.
Briefly, the extracted DNA is incubated with a DNA polymerase, primers that flank the
region of interest to be copied, deoxyribonucleotides (dNTPs) and ions such as
magnesium which are necessary for enzymatic activity. The PCR product consists of
multiple copies of the region of interest, which is delimited by the primer sequences.
In 1990, some laboratories were using dot blot tests which work by hibridizing the
denatured PCR product with specific probes captured in a nylon membrane (65).
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Colorimetric detection allowed the appearance of blue dots for positive hybridization.
Even though there were issues with low power of discrimination of the method and the
possibility that the PCR products would re-anneal prior to hybridization with the probes,
the use of the method allowed the introduction of PCR-based technology in the court
system.
Once the sequence of the regions used in RFLP were further explored, several
attempts tried to perform PCR to amplify each of the RFLPs. In 1994, the D1S80 kit
allowed the amplification by PCR of the locus D1S80 which spanned 400-800 bp,
depending on the number of repeats present in the individual DNA sample (66). The PCR
products were analyzed by a vertical polyacrylamide gel followed by silver stain
detection. However, the relatively large length of fragments, made it still difficult to type
samples with degraded DNA. The main limitations of the methods at that point were
either the need to use long sequences of DNA making it problematic to analyze degraded
samples and presenting a low power of discrimination. Most importantly, none of the
methods studied were easily automatable or allowed a high throughput analysis.
Even though short-tandem repeats (STRs) were known since the late 1980’s, in
1995 the United Kingdom Forensic Science service launched the use of 6 STRs for
suspect match in forensic analysis (60). STRs are regions in the genome that show
smaller repeat units (2 to 7 bp), therefore called ‘microsatellites’ when compared to the 9100 bp found in the minisatellites typed with RFLP. In 1997, the FBI laboratory selected
the 13 USA core STRs as the necessary loci to be typed for DNA forensic analysis and
stored in a national database. Even though the small size of STRs compared to RFLP
allowed the use of degraded DNA, the analysis step still relied on silver staining of
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polyacrylamide gels thus not allowing high throughput. Another issue was that the same
DNA sample would have to be divided into 13 separate PCR reactions for each one of the
13 loci and their analysis was done separately on in groups of two or three. To overcome
such difficulty, a multiplex PCR reaction was developed allowing the amplification of
several STRs. Presently the multiplex amplification and analysis of 15 STRs allow a
power of discrimination of 1 in a trillion or greater (Table 1.1(67)).

Table 1.1 Summary of characteristics comparing RFLP and methods based on PCR, such
as STR typing. Adapted from (67)
Characteristic
RFLP Methods
PCR Methods
Time required to obtain
6-8 weeks with radioactive
1-2 days
results
probes; ∼ 1 week with
chemiluminiscent probes
Amount of DNA needed

50-500 ng

0.1-1 ng

Condition of DNA
needed

High-molecular-weight,
intact DNA

May be highly degraded

Capable of handling
sample mixtures

Yes (single-locus probes)

Yes

Allele identification

Binning required since a
distribution of sizes are
observed

Discrete alleles obtained

Form used in analysis

DNA must be double
stranded for restriction
enzymes to work

DNA can be either single
stranded or double
stranded

Power of discrimination

∼ 1 in 1 billion with 6
loci

∼ 1 in 1 billion with 8 to
13 loci (requires more
loci)

Automatable and capable
of high-volume sample
processing

No

Yes
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B. Methods used in Forensic Laboratories for DNA analysis
The forensic analyst performs analysis of available evidence left behind at crime
scenes, in order to establish what cannot be directly observed. The analysis of such
evidence may allow detectives to establish a timeline for the series of events that lead to
the crime. Biological fluids, fingerprints, documents, electronic disks, letters, magazines,
lost phone calls or text messages, are all examples of evidence that can be collected
during an investigation. Regardless of their origin, all evidence must be handled
according to established guidelines. Rules including chain of custody assure that the
origin of such evidence is not questioned in court and also that its integrity has been
preserved as much as possible. Similarly, all the methodology for handling, storing and
analyzing evidence has been established in the form of validated protocols that forensic
laboratories strictly follow.

B.1. Sample Collection
Several types of evidence can be collected as samples. For example, for DNA
analysis even as little as 0.1 ng of DNA can in certain circumstances, provide important
information (Table 1.1) for investigations. Because of the high sensitivity achieved
nowadays, even touching surfaces can leave behind enough DNA to form a full or partial
profile of an individual. Examples of samples that provide enough DNA to construct a
profile are urine in snow, tears on a tissue and even fragments of contact lenses found in a
vacuum cleaner bag (68).
The increase in sensitivity of methods for DNA analysis means that there is a higher
probability that instruments can detect the contamination of evidence as a result of
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improper collection and handling. To prevent such contamination, DNA evidence must
be collected and preserved properly from the point of origin. The first responders to a
crime scene may be law enforcement personnel; therefore training is important so that
they follow strict rules while at the scene. People collecting the evidence should wear
gloves and utilize equipment and tools that prevent the contamination of evidence with
the collector’s DNA. All evidence must be packaged in sterile bags, boxes or other
appropriate materials. DNA evidence must be stored in paper bags since the moisture that
gets trapped inside plastic bags can cause degradation of samples, if stored for long
periods of time. All samples collected must be sealed inside the package used to transport
them, dated and signed to maintain chain of custody (69).
A different type of sample is collected for DNA analysis - reference samples.
DNA reference samples are collected from suspects, potential innocent donors to serve as
a comparison to the DNA found at a crime scene. Reference samples can then be
collected from convicted felons or arrestees to be kept in a national database or can also
be collected from family members/ housemates of the victim and law enforcement
personnel to exclude any potential contribution of their DNA to the samples collected at
the crime scene (elimination standards). Typically the reference samples are collected by
a specialized investigator via blood drawn or a buccal swab which consists of a sterile
cotton swab rubbed against the inside of one’s cheek. Since they are collected directly
from the source, and not from different physical materials found at crime scenes, the
DNA content is higher and the likelihood of degradation is lower since their integrity is
protected while they are transported to a laboratory (70).
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For all samples collected, it is important that they are fully dried and maintained
in a refrigerated environment, diminishing the action of bacterial species, hydrolysis by
humidity and the action of digesting enzymes such as DNases. When arriving at the
laboratory, samples can be kept refrigerated, frozen or at room temperature until they get
processed and analyzed (68).

B.2. DNA Extraction
Body fluids are the most common source of DNA from crime scenes. Body fluid
samples arriving at a forensic DNA laboratory may have been deposited in different
physical matrices. For example, a bloodstain collected from a crime scene may have been
deposited in bed sheets or other type of fabric, it may have been left behind in a paper
towel or it may be in a floor tile. Regardless of what material the biological sample has
been deposited on, there are fundamental steps that are required for DNA extraction. As
mentioned before, genomic DNA is inside the nucleus of the cell in a compacted form
associated with proteins such as histones. The first step of any DNA extraction procedure
is to disrupt the cell membrane so that the cell contents are free in solution. The lysis
solution contains a buffer that maintains a proper pH for the proteinase K activity, which
breaks down the proteins associated with DNA. Commonly, lysis buffers also contain
detergents such as sodium dodecyl sulfate to aid the breakage of the lipidic cell
membrane. The result of this step is a solution containing a mixture of all cell
components such as proteins, DNA and cytoplasm and their constituents (71).
The second step consists on the DNA purification or extraction, which renders the
isolation of DNA from the proteins, lipids, ions and organelles in the lysis mixture.
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Finally, the DNA is purified, consisting of a liquid form that can stored at -20 ºC or -80
ºC depending on the expected length of storage. The frozen extracted DNA can last for
years and because it is kept in small tubes (of about 1.5 mL of capacity or lower), the
storage space necessary for each sample is small compared to the space necessary to store
the initial evidence (72).
The purification step can be performed by several different methods. The methods
presented here are the ones that were used for the project described in this dissertation.
One of the methods used was the Phenol-Chloroform extraction. The method is
also called organic extraction because it uses the properties of organic-aqueous mixture to
separate DNA from other cell components. The phenol-chloroform extraction is one of
the most popular DNA extraction methods and it has been used in forensic sciences since
the beginning of DNA analysis (73). A phenol-chloroform-isoamyl alcohol mixture
(25:24:1 v/v) is added to the aqueous medium containing the lysis product and following
centrifugation, the DNA moves to the aqueous phase, whereas other cell components
move to the organic phase. The aqueous phase is then removed from the top of the tube
and purified with ethanol precipitation or filters. The use of hazardous reagents and the
fact that PCR-inhibiting phenol residues can potentially remain on the extracted DNA
constitute two important limitations of this method (74, 75).
The other method used is called purification by affinity or solid-phase extraction.
The novelty of these methods when compared to the phenol-chloroform extraction is the
fact that the separation of DNA from the cell debris is performed through the use of
affinity substrates in solid form that specifically bind to the DNA. The binding does not
depend on solubility of DNA in the aqueous phase, but instead it depends on the negative
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charge of DNA when bound to a silica-based column. The binding of DNA to the silica
column depends on several conditions. First the presence of chaotropic salts such as
guianidinium chloride at pH 6 in the lysis buffer causes protein denaturation and a
disruption of stabilizing forces on the DNA molecule, such as hydrogen bonds and van
der waals forces (76). Second, the pH of 7.5 added to the lysis solution, increases the
adsorption between the silica membrane and the DNA (72). The increase of entropy
observed by the removal of solvated water on the DNA molecule and also the increase of
hydrophobic forces between DNA and silica, allow the specific binding of DNA, whereas
the other debris in solution are eluted through the membrane (77, 78). After several
washing steps, an alkaline buffer is added to the column and the DNA is eluted. Certain
commercial kits contain silica coated magnetic beads instead of a fixed column which
allows the automation of the extraction procedure increasing sample throughput.

B.3 DNA Quantitation
Determining the amount of DNA that is present in the extracted solution is
important to obtain optimized results for analysis. If too much DNA is added to the PCR
reaction, the reaction may not be successful or peak overloads will occur when the
samples are analyzed by capillary electrophoresis. Amounts between 0.5 to 2 ng of
human DNA added to the PCR reaction usually lead to good results in electrophoresis if
the DNA is not badly degraded (79).
There are several things to take into consideration when selecting a quantification
method. First, samples collected in crime scenes may contain a mixture of DNA from
several species, for example, the presence of DNA from pets or bacteria deposited in the
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surface prior to the crime. Also, DNA from certain body fluids like saliva and vaginal
fluid, contain bacterial and yeast DNA as a consequence of the commensal microbiota
population that inhabit the mouth and female reproductive tract. The DNA from blood
collected as a reference sample, on the other hand, should not contain non-human DNA.
Since forensic laboratories work with both crime scene samples and reference samples, it
is simpler to use a single quantitation method that is human specific. For that purpose,
several commercial kits have been developed and are currently used in forensic
laboratories in order to quantify human DNA (80-82).
Another consideration to take is the quality of DNA from crime scenes. If the
DNA was exposed to the elements for too long it may be fragmented. A quantification
method will perform better if it can provide the analyst with an idea of DNA quality and
not just quantity (83). Because of the specific limitations of forensic sciences and the
methods used, quantification kits have been optimized in order to standardize the
methodology between laboratories. The optimization of such kits together with the
amplification kits for PCR allows a forensic laboratory to validate protocols for
processing DNA in order to obtain a strong enough signal on the capillary electrophoresis
(79).
Typically the quantification kits in forensic laboratories work with a real-time PCR
instrument where the samples are ran as unknowns (unknown concentration) and
standard solutions with known concentration of human DNA are ran as standards to
calibrate the reaction (84). The number of PCR cycles after which the fluorescence
increases exponentially is called cycle threshold (CT). Standards with higher
concentration of DNA will have a lower CT since fewer cycles are necessary to observe
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fluorescence from the PCR products. A graph that plots the CT versus the log of the
concentration of the standards is determined and by linear regression, the concentration
of the samples is established (Figure 2.1, (79)).

Figure 2.1 – Schematic representation of the calculations
performed for DNA quantification using methods based on
real-time PCR. The increase of fluorescence as a result of
increasing copies of DNA are displayed in a graph of
normalized fluorescence versus cycle number (CT). On a
second graph the CT is plotted against the Log of the
concentration of DNA for the standard solutions (with
known DNA concentration). The concentration of samples
can be extrapolated from the linear regression line and the
efficiency is also calculated. Adapted from (79).

Using real-time PCR for quantification relies on the assumption that the reaction
conditions are similar for the standard solutions of DNA and for the DNA extracted from
the crime scene samples, however, that may not always be the case. For example, if the
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primers anneal to a region of DNA to produce a lengthy PCR product (>300 bp),
degraded DNA may not have fragments of that size, which would cause the amount of
DNA in the unknown samples to be underestimated due to degradation. Most kits
overcome this limitation by including primers that produce amplicons of different sizes,
thus providing the analyst with information about DNA quality (80, 85).
Another difference between samples and standards is that samples may include a mixture
of DNA from several individuals, for example in sexual assault cases a mixture of male
and female DNA. To overcome some of these issues, commercial kits were developed in
order to quantify autosomal and Y-chromosome DNA. For example, Quantifiler Trio (85)
(Thermofisher Scientific, USA) uses 3 sets of primers; one that amplify longer DNA
sequences (LA, Large Autosomal, 214 bp); another set of primers that produce smaller
amplicons (SA, Small Autosomal, 80 bp) and a third set of primers that amplifies 75 bp
region on the Y-chromosome. All three primers amplify several regions on the autosomal
or Y-chromosomes so that higher detection is achieved for samples with small amount of
DNA. In order to detect the amount and type of PCR product (or amplicon) formed
during the PCR, fluorescent probes are added to the PCR mixture together with the
primers. The probes are called TaqMan, which consist in small oligonucleotides that are
complementary to the target region located between where each forward and reverse
primer anneal (Figure 2.2). The probes contain a fluorescent dye on the 5’-end and a
quencher on the 3’-end. When intact, the quencher is close enough to avoid any
fluorescence to be emitted by the probe. With the progression of the PCR reaction, the
polymerase which has a 5’-3’ strand displacement ability, is able to perform similarly to
what is observed in vivo with Okazaki fragments, destroying the probe with the results
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that fluorescence is no longer quenched. The increase in the number of amplicons results
in an increase of fluorescence detected by the real-time instrument.

Figure 2.2 – Schematic representation of TaqMan probes and
their mode of function. Adapted from (79).
Another commercial kit used in forensic laboratories is the Plexor HY (Promega, USA)
that contains one set of primers for several copies of a 99 bp autosomal region on
chromosome 17 and another set of primers for multiple copies of a 133 bp on the Ychromosome (82). The fluorescence detection chemistry is different from the TaqMan
since there is no use of a probe to produce and quench the fluorescence (Figure 2.3).
Instead, the primers are designed to have a modified nucleotide (iso-dC) at the 5’-end that
is labeled with a fluorophore. As the amplification progresses, the polymerase will add an
iso-dG which is the only nucleotide capable of making hydrogen bonds with the iso-dC
on the template strand.
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Figure 2.3 – Schematic representation of how
Plexor chemistry fluorescently labels each
amplicon produced from primers tagged with the
same fluorophore. Adapted from (82)

The iso-dG contains a quencher dye thus a decrease in fluorescence is observed with the
increase of number of amplicons in the PCR reaction. The unique chemistry of Plexor
also allows the analysis of melt curves which are able to determine if there is an
inhibition of the PCR reaction (86) or the formation of unspecific products, which will
have a different melt curve compared to the target amplicon.
A third factor that can be different between DNA extracted from crime scene
samples and standard DNA is the presence of inhibitors that are co-extracted with the
DNA. While it is more common to find co-extracted inhibitors when the phenolchloroform is the method of extraction (phenol itself is a PCR inhibitor), silica-based
procedures can result in inhibition for certain type of inhibitors especially if present in
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high quantities (87). To tackle this issue, an internal control is added to the PCR mixture
together with the samples. If an inhibitor is present, the amplification of the internal
control is also impaired and the analyst is able to determine the best option of PCR
additives before performing the amplification that will be used for STR analysis (88).
Even though the use of commercial kits is highly advantageous in forensic
laboratories, in the scope of this project, using commercial kits for quantification of DNA
would be prohibitively expensive. For that reason, two main protocols were used to
quantify DNA. Both protocols use a standard curve that matches fluorescence units to
concentration. The Alu Quantification protocol uses amplification by a polymerase in the
presence of an intercalating dye such as SybrGreen (89), whereas the PicoGreen method
uses an intercalating dye to quantify the presence of DNA without any amplification
performed(90, 91). The AluQuant method is a primate-specific method since the primers
used only anneal to regions in the primate DNA. The primers selected amplify numerous
Alu repeats that are widely present in the human genome. The fluorescence increases as
the amplification progresses due to the capacity of the intercalating dye SybrGreen to
fluoresce intensely when intercalated in the double stranded DNA. The background
signal of SybrGreen fluorescing because of thr intercalation in the template doublestranded DNA is normalized by the instrument that uses a low gain of signal settings
based on the fluorescence read at the beginning of the run. As the amplification continues
there is an increase in DNA concentration in the reactions because of the accumulation of
amplicons. The standards can then be plotted similarly to what is observed in Figure 2.1
and the concentration of the DNA in the samples is determined (92). The AluQuant
method provides reliable quantification and its use is adequate to the research done in this
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project because all the samples used were collected from volunteers and not from crime
scenes. Considering the origin of samples, we do not expect DNA degradation or
contamination by inhibitors present in the initial sample. Regarding potential inhibitors
such as phenol carried over from extraction, the analysis of the melt curve as well as the
steepness of the curve allows DNA analysts to determine if significant inhibition is
present (93).
The PicoGreen method measures fluorescence of all DNA present in the samples,
regardless of its origin. Because it does not rely on primers or amplification, the
fluorescence observed is merely the result of how much fluorescence is emitted by
picogreen (an intercalating dye), which is proportional to the amount of genomic DNA
present in the sample (90, 91). For samples such as blood collected in sterile conditions,
this method represents a fast, reliable and cheap option to quantify genomic DNA.
Similarly to other quantification methods, the fluorescence measured in the samples with
unknown concentration of DNA is compared to the fluorescence of a standard curve and
the concentration is calculated by extrapolation.

B.4 Polymerase Chain Reaction (PCR)
Polymerase Chain Reaction somewhat mimics what happens in vivo during DNA
replication. A designated set of primers added in solution establishes the DNA sequence
to copy. The other components necessary for PCR are the extracted DNA template, the
DNA polymerase, dNTPs, magnesium and a buffer capable of keeping a stable pH for a
wide range of temperatures. Some commercial kits used in forensic laboratories also
include additives that minimize the effects of inhibition present in the samples.
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One of the first thermo-resistant DNA polymerase used in PCR was extracted from the
bacterial species Thermus aquaticus (Taq) which inhabits in hot springs. The Taq
resistance to high temperatures is important because in PCR, the DNA is firstly melted
with an increase in temperature which would degrade most DNA polymerases (94).
Nowadays the polymerases used for PCR are still called Taq polymerases, even though
most of them are genetically modified enzymes descendent from Taq. Another important
characteristic of Taq polymerases used in forensic sciences is the fact that they require an
activation step, usually performed at the beginning of the PCR reaction. The need for an
activation step prevents unspecific amplification by the polymerase at room temperature.
Enzymes that require the initial activation step are called Hot Start polymerases (95).
Despite of the differences in polymerases developed due to biotechnological
advances, all polymerases need magnesium to properly amplify DNA, therefore an
optimal concentration of magnesium is necessary in PCR (96). The primers commonly
used are small oligonucleotide sequences (18-32 bp) that are complementary to the
flanking regions of the DNA sequence to be copied. For each sequence to copy two
primers are necessary – a forward and a reverse primer – both flanking the beginning and
end of the region to be amplified. Typically the primers should have a GC (guaninecytosine) content around 50% and a melting temperature of around 60 ºC (95). The
melting temperature (TM) of a DNA template or of a primer:template region is the
temperature necessary to provide to the system in order to cause the separation of half of
the primer from the template DNA, respectively. The melting temperature depends on the
GC content and the length of the primer. Primers offer the 3’-OH necessary for
polymerase recognition of a substrate and to perform the extension of the strand copying
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the template by addition of dNTPs to the nascent strand. For STR analysis, the primers
anneal either to microsatellite regions of the genomic DNA and some to specific regions
of the Y or X chromosome.
The PCR reaction is carried on through several steps, namely denaturation,
annealing and extension. Each step has a designed temperature and duration, which are
precisely achieved by instruments called thermocyclers. The design of thermocyclers
allows each PCR tube to be surrounded by metal that quickly transitions its temperature
at a rate of several degrees Celsius per second. The tubes are composed of thin plastic
that allows an improved conductance of hear to the entire volume of the PCR solution.
During denaturation, the solution is heated to 95 ºC or above to ensure that the double
stranded DNA is melted to single stranded DNA. This melting of DNA mimics in vitro
the unwinding of DNA by the replication machinery that occurs in vivo. The next step,
called annealing, happens at an optimal temperature determined by the primer sequence
and length. Typically, the annealing temperature can be set on the PCR instrument as 5
ºC below the TM of the primers. At this temperature the primers anneal to the template
DNA thus creating the template:primer substrate for DNA polymerase. The instrument
will then raise the temperature to 72 ºC which is the optimal temperature for Taq
polymerase to extend the primers and form a new copy of the template. The cycle of
temperatures is repeated several times until several copies of the same sequence have
been made (95). Each double stranded PCR product will denature in the next cycle and
serve as a template for the polymerase. For that reason, in a reaction that is occurring in
optimal conditions, the number of PCR products increases exponentially with the number
of cycles. For the first cycles, the DNA serving as template is the genomic DNA added to
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the mixture. With the increase in PCR products, the template DNA soon becomes the
PCR products themselves. The fact that PCR products from the initial cycles become a
template is an important issue in the use of PCR in forensic laboratories since any
amplification errors made in the first few cycles are perpetuated until the end of the PCR
(97).
In forensic laboratories several DNA regions are amplified in one reaction, which
is called multiplex PCR. The simultaneous amplification of multiple DNA regions is
possible through the use of primers which have a similar TM and are designed to not
anneal to each other. Since the primers are labeled with fluorophores, the PCR products
corresponding to each set of primers can be distinguished from each other after PCR and
during analysis. Besides the use of multiplex PCR, another feature of PCR in forensic
laboratories is that it uses low amounts of DNA. When a low amount of template is added
to the PCR, it is possible that not all primers will be able to anneal to it with the same
efficiency. Therefore some products may be more predominant at the end of the reaction,
causing an artifact known as allele dropout. If the template added to the PCR is degraded,
meaning the genomic DNA is fragmented due to the action of extreme heat or other
environmental factors, the polymerase may not have an intact template to copy from. The
bigger the region to copy, the more likely amplification can be interrupted because of
fragmentation at that locus. The potential lack of amplification of larger amplicons as a
result of DNA fragmentation can cause an imbalance of STRs in the final PCR product if
the small STRs are properly amplified (95). The presence of inhibitors that are coextracted with DNA, if in high enough concentration, may decrease the PCR efficiency.
The only way to detect inhibition is during quantitation with the use of an internal
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control. Some forensic commercial kits contain additives such as bovine serum albumin
(BSA) that helps to diminish the effects of inhibition (95).
The commercial kits developed for STR amplification were designed to take these
limitations into consideration and therefore they require a certain amount of DNA to be
used as quantified by specified methods. Before being commercialized most of those kits
were tested by multiple laboratories to better predict the type of products they will
produce, thus diminishing the risk of unspecific or unexpected results. However, since
each DNA sample is unique because of its unique origin of crime scene, commercial kits
continue to be developed in research every day.

B.5 Capillary Electrophoresis
The analysis of PCR products in forensic sciences depends on its separation by
size. Electrophoresis is the method of choice since it allows the migration of PCR
products based on size. The DNA is negatively charged due to its phosphate backbone
and thus when an electric field is applied, it moves towards the positively charged pole.
In gel electrophoresis, smaller DNA products will travel faster due to lower interaction
with the gel, whereas bigger fragments travel slower and appear as bands closer to where
the sample was loaded (98).
Both agarose and polyacrylamide gels can separate DNA by electrophoresis with
different resolutions. Agarose gels cannot distinguish between PCR products of very
similar sizes, whereas polyacrylamide allows separation of products with 1 bp difference.
The resolution can be improved if the DNA is in its single strand form. Denaturing DNA
to its single strand form can be achieved by addition of formamide or by loading it in a
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denaturing gel. Denaturing gels have saturating concentrations of urea. Both urea and
formamide form hydrogen bonds with DNA, preventing the complementary bases to
anneal to each other (99).
The use of electrophoresis gels require time since each gel needs to be assembled,
manually loaded with the samples and can only be used once. The low throughput of
electrophoresis gels greatly impairs the usability of DNA in forensic sciences since a
single crime scene may have hundreds of DNA samples retrieved as evidence.
Additionally, gel electrophoresis may require a higher quantity of PCR product since the
bands are visualized by naked eye and the loading of samples is limited to how little an
analyst can pipette (99).
The use of capillary electrophoresis tackles the low throughput limitation since the PCR
products are ran through a capillary that can be reused many times and the instrument can
load each PCR product automatically, which allows for less sample usage. The capillary
contains a polymer that acts similarly to an electrophoresis gel, separating the PCR
products by size. The two ends of the capillary are immersed in buffers which have
opposite electrical charges thus creating a current within the tube. Because the capillary is
very thin, the heat caused by the increase of voltage is easily dissipated (100, 101). The
PCR products pass through a detection window in the capillary which is placed near a
laser. The passage of the fluorophores from the PCR products (from the labeled primers)
through the window of the capillary, the laser excites them and a detector registers the
fluorescence and time of passage. The detector is connected to a computer that has
installed software capable of analyzing the data. A size standard ran at the same time as
the PCR products allows the software to match time of passage through the detection
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window with a size in base pairs. The software will then display each PCR product
detected to a peak in a electropherogram. An electropherogram is a graph that displays
peak height and width, which is proportional to the amount of PCR product, versus
amplicon size. The units of an electropherogram are RFU (relative fluorescence units) vs
size in base pairs (101).
Each PCR product is composed of multiple fluorescent products that originated in
each of the primer pairs extended during the multiplex PCR. The capillary
electrophoresis instrument can read several fluorescent products at the same time. Peaks
with different fluorescence but same size will be displayed on the electropherogram as
overlapping peaks. The software analysis includes the separation of peaks by fluorescent
colors and the calling of peaks depending on sizes. Presently forensic laboratories use
capillary electrophoresis instruments capable of independently running and reading
several capillaries at the same time, greatly increasing the throughput of analysis (102).
Several commercial kits for multiplex PCR have been validated to use in forensic
sciences (103). To allow analysis of PCR products, those kits were designed to have the
STRs being amplified in a range of sizes per fluorophore color. Figure 2.4 displays all the
possible repeat numbers for alleles of each STR. For example, the blue panel corresponds
to a fluorophore that emits in the blue wavelength and because of the differences in each
PCR product size, 4 STRs can be detected without overlapping peaks. There are
approximately 12 possible alleles for D8S1179 according to population studies done in
humans (104). Any of those 12 possible alleles are smaller in length (base pairs) than any
of the 24 possible alleles of the D21S11, thus they appear first on the electropherogram.
Since both D8S1179 and D3S1358 overlap in size, they were designed to amplify with a
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different fluorophore colors so the software was able to separate them. In summary, the
analysis software indicates the number of repeats for each STR by analyzing the base pair
sizes for each PCR product and each color.

Figure 2.4 – Schematic representation of all possible alleles for 16 STRs plus
the sex marker amelogenin. The STRs are displayed in electropherograms
separated by fluorophore colors and sizes in base pairs. Adapted from (103)
An allele corresponds to the same region of DNA located in homologous chromosomes,
one donated from the mother and one from the father. Therefore a DNA sample that
originates in a single individual will have 1 or 2 alleles per STR locus, depending if the
person is heterozygous or homozygous for that particular locus. A person is said to be
heterozygous for an allele if the chromosome donated from the mother has different
number of repeats than the chromosome donated from the father in that specific STR.
For heterozygous individuals, the software will display 2 peaks with 2 different sizes
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within the region of that specific STR. After the analysis of each STR, the software
produces a list of all number of repeats for all STRs, which constitutes the DNA profile
of that person (105). If all the steps in the STR analysis, from multiplex PCR
amplification to analysis with capillary electrophoresis are calibrated properly, two
heterozygous peaks in an electropherogram must have similar peak heights. The presence
of a third peak or unbalanced heterozygous peaks on a known sample indicates issues
with amplification, analysis or with the sample itself (106). If the sample is a known
control DNA that was commercially bought, its molecular weight and quality should be
high so that no fragmentation is expected and the issue is most likely in the multiplex
PCR or electrophoresis analysis. If the DNA is from a crime scene, the third peak or two
imbalanced peaks may mean that a second contributor is present in the sample. For that
reason, control DNA samples are run at the same time as the evidence samples and the
commercial products available for amplification and capillary electrophoresis are
carefully tested and pass rigorous quality control tests (107, 108). When the analyst trusts
the commercial products they are using, the appearance of artifacts give them the
confidence that what is seen in the electropherogram is most likely due to the quality of
DNA or the presence of a second donor, which allows the analyst to employ standard
operation protocols to re-analyze the sample according to the perceived issue observed in
the results.
Since the entire process from sample injection in the capillary to data collection by the
software has been automated, the analyst is left with more time to analyze at the
electropherograms and interpret the results to tackle potential issues with the samples.
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There have been many advances in the technology for DNA analysis in the
forensic sciences since its first use in 1985 by Sir Alec Jeffreys. Most importantly the
quantity of DNA necessary to produce a profile has been greatly reduced. In addition,
automation has greatly increased the number of profiles that can be obtained in a short
period of time. It is quite remarkable how much improvement has occured within the life
span of one generation. One of the most positive characteristics of DNA analysis for
forensic purposes is the constant push of limits in the current technologies.

B.6 Methods for Body Fluid Identification
Samples collected from crime scenes can be of various origins. It is important to
determine the exact location of a body fluid in a piece of evidence. Identifying the
presence of a body fluid aids the analyst to determine where to extract sample for DNA
analysis and determining the type of body fluid can help investigators determine the
relevance of such evidence. A number of serological tests have been developed to
determine the presence and origin of biological fluids from crime scenes samples (108).
The Scientific Working Group on DNA Analysis Methods (SWGDAM) classifies the
tests based on their ability to determine the presence or identify the type of body fluid.
The SWGDAM has a Quality Assurance Committee that drafts revisions to the original
FBI’s Quality Assurance Standards that each forensic laboratory must meet to be part of
the national DNA index system. The committee meets twice a year and provides
recommendations to the FBI to update the quality standards as necessary. Furthermore,
the committee publishes online the new recommendations thus their website (109) is the
most up to date resource to determine what new standards will most likely be adopted in
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forensic laboratories in a near future. According to SWGDAM, serological tests can be
visual which allow the analyst to determine possible areas of where the biological fluids
have been deposited, including the use of alternate light sources. Chemical tests use
properties of the body fluid to change the color, fluorescence, solubility or other
properties of a chemical used to react with the fluid. Histological tests are those that use a
microscope to identify specific elements on the body fluid and immunological tests are
the ones that make use of an antigen-antibody reaction to determine the presence of
specific proteins in the fluid (107).
Alternative light source tests use light in different wavelengths such as the
ultraviolet or infrared ranges which cause certain body fluids to glow or darken (for
example, blood). Alternative light sources are mainly used to detect the presence of body
fluid stains in large pieces of evidence and is not able to identify the body fluid present
(110).
Two types of tests exist to determine which body fluid is present in a piece of
evidence - presumptive and confirmatory tests. Presumptive tests can simply be used to
tentatively determine a specific body fluid. They can be applied in large areas but they
have limited specificity, meaning, other substances may react with the same test.
Presumptive tests to determine the presence of blood generally rely on the detection of
hemoglobin which is present in the red blood cells which are the most abundant cell types
in blood. The Kastle Meyer test relies on the oxidation of phenolphthalein in the presence
of hydrogen peroxide catalyzed by the hemoglobin present in blood, which causes the
solution to turn pink (110). Another presumptive test is the use of Luminol which
fluoresces in the presence of blood (68). Luminol consists in a mixture of 3-amino-
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phthalhydrazide, sodium carbonate and sodium perborate, added immediately before the
solution is used (111). The reaction occurs due to the presence of Iron on the hemoglobin
and the solution can be sprayed in large areas. The UV light will then make the
fluorescence visible and able to be photographed in a dark room. Luminol does not cause
any inhibition of PCR therefore samples in contact with it can still be used for DNA
typing.
Presumptive tests to determine the presence of saliva can be quite useful since unlike
blood, saliva has no color and its presence may not be as easily detected. The
presumptive test for saliva is called Phadebas and it relies in the detection of a salivary
enzyme called alpha-amylase. Since this enzyme is also found in fungi, bacteria and
saliva from other animals, this test is not specific to human saliva. Moreover, close
variants of the saliva alpha amylase are also present in the pancreas and thus it can be
secreted in other body fluids like urine (110, 112).
The presence of semen and seminal secretions is also difficult to determine
without the help of presumptive tests. The tests used can detect proteins that are specific
to semen such as acid phosphatase which is an enzyme 400 times more abundant in
seminal fluid than in other body fluids (68). A dark purple color is observed when acid
phosphatase is exposed to sodium alpha naphtylphosphate and Fast Blue B. The prostate
specific antigen (PSA) test detects p30 which is a protein present mostly in semen but has
also been observed in lower concentrations in other body fluids namely breast milk.
Semen from azoospermic males are positive for p30 which makes this test useful to
determine the presence of semen even if no sperm cells are present (113).
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Confirmatory tests on the other hand, are designed to conclusively identify a body
fluid and to not cross-react with other body fluids. They can be more expensive and their
use be limited to smaller areas. Typically the portion of evidence used for confirmatory
tests cannot be used for DNA analysis, which further limits the applicability of these tests
especially when limited amounts of evidence are available.
Confirmatory tests to determine the presence of blood include the Takayama test
where the formation of crystals occur when a solution of dextrose, sodium hydroxide and
pyridine reacts with blood. The crystals are visible under a microscope and they exhibit a
salmon-pink color (111). Despite of its broad use, this test is not human-specific therefore
it has limited use in aiding the forensic analyst to determine whether to consider the stain
a viable evidence to collect DNA from (114). The ABA card HemaTrace strip kits have
an antibody against human hemoglobin which is mobile upon agglutination with
hemoglobin in blood. The result of the test is visible as bands on a test window. Cases of
false positives have been reported when samples of saliva where identified as blood using
this test (115), which makes its reliability limited. The RSID™-Blood test is a
commercially available test that detects human GlycophorinA but not hemoglobin.
Glycophorin A is a protein present in the cell membrane of erythrocytes (116). The
capacity of RSID™-Blood to detect other protein different than hemoglobin makes it not
susceptible to the high dose hook effect present in some tests that detect hemoglobin. The
high dose hook effect occurs when a test shows negative results because too much
hemoglobin is present because of too much sample being loaded into the test (117).
RSID™-Blood is commercialized as being blood-specific and not showing crossreactivity with other body fluids. Recently RSID™-Blood was reported to display some
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limitations such as not being able to detect blood after it has been cleaned with detergents
that possess active oxygen agents. The test also showed false positive results with saliva
samples collected from 15 individuals (115) and also presents low sensitivity when
compared to presumptive tests such as luminol and others (118). In summary,
confirmatory tests for blood available for forensic laboratories either render the sample
useless for STR analysis and show high dose hook effect, or have lower sensitivity like
the RSID™ and provide false negative in the presence of blood that has been cleaned or
in contact with active oxygen detergents.
In 2009 Virkler & Lednev (119) reported the absence of confirmatory tests to
determine the presence of saliva but mentioned RSID-Saliva as an emerging method.
Instead of detecting alpha-amylase based on its activity, the RSID™-Saliva uses two
monoclonal antibodies that specifically detect the presence of the enzyme. As a result, the
test is more sensitive and does not rely on enzyme activity, which can be impaired by pH,
temperature and other environmental factors. The test design consists of a lateral flow
strip test that contains the two monoclonal antibodies which migrate in the presence of
alpha-amylase. Validation experiments determined that the limit of detection for the test
is 0.05 µL of saliva. The same report published by the company that commercializes
RSID™ established that the test shows negative results when tested with a mix of urine,
blood or semen at different ratios but it shows faint positive results when tested with
breast milk. The test showed stability since it was able to detect saliva after being
exposed to 37 ºC for 11 minutes and 56 ºC for 30 minutes, it also showed primatespecificity since it only reacted positive to gorilla saliva and also proved able to detect
saliva in several forensically relevant items such as aluminium cans, plastic cups, etc
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Another commercial test that detects the enzyme alpha- amylase is the SALIgAE®
which produces results in the form of a colorimetric solution. According to the
information available on the tests’ website, the SALIgAE® requires 10 µL of saliva and
storage conditions should be around 2-8 ºC. No scientific literature has been cited by the
company indicating which validation tests were performed by them (120). However,
Meyers et al. (2008) determined that the SALIgAE® shows a lower sensitivity to saliva
since it is only able to detect it in dilutions of 1:10, whereas the Phadebas can detect
dilutions of 1:200 (121). Moreover, in the same study, the SALIgAE® showed positive
results for saliva swabs of guinea pig and weak positive results for saliva stains in
aluminum cans and other mock crime scene evidence. Another study aimed to compare
the RSID™-Saliva and SALIgAE® and it determined much lower sensitivities for both
(122). The RSID™-Saliva showed a sensitivity of 0.01 µL of saliva (122) in the report by
Pang and colleagues (2008), which is 5 times lower than the reported on the validation
studies (123). Overall, Pang et al. (2008) reported that the RSID™-Saliva shows superior
capacity to determine the presence of saliva whereas the SALIgAE® did not perform so
well. On the same report, both tests show false positives when tested with rat saliva,
human pancreatic alpha-amylase, stains of breast milk, liquid samples of urine (but not
stains of dried urine) and fecal swabs. It is important to mention that oftentimes
validation reports show different results for the same type of samples which may be due
to different preparation of samples. For example, on the report by Meyers et al. (2008),
the dilutions of saliva used to perform the sensitivity tests were dried in cotton fabric
prior to testing. It is not clear whether the samples were extracted from the cotton
material which would indicate further dilution. The limitations of both methods must be
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taken into consideration when considering their classification as confirmatory tests and
when reporting results used in the court of law.
The most widely test for the confirmation of semen is the microscopic observation
of sperm cells after Christmas tree staining. The staining makes the head of the sperm
cells red and the tails green allowing an easier observation (119). The two main issues
that arise with this method is that the semen of azoospermic males do not contain sperm
cells and the fact that microscopic analysis is time consuming. In order to detect the
presence of semen even from azoospermic males and to do so in less time, the company
Independent Forensics developed the RSID™-Semen strip test. Instead of identifying the
protein p30 or sperm cells, the test has two monoclonal antibodies specific for
semenogelin, which is a protein produced by the seminal vesicules. The validation report
published by the company determines the strip test to be sensitive to 2.5 nL of semen but
also gave false positives due to high dose hook effect when 3 µL of semen are added to
the sample chamber. The RSID™-Semen showed specificity for human semenogelin and
in the same report the test was able to detect semen in several mock crime scene samples
where stains of semen were deposited in different materials and fabrics. Besides the high
dose hook effect, mixtures of semen and some body fluids give false negative results and
also the RSID™-Semen seems to show poor results in post-coital samples and diluted
samples (124). Since it is impossible to know if evidence collected from a crime scene
consists of a mixture of body fluids or how much semen is present, the RSID™-Semen
test presents severe limitations for use in forensic evidence.
Even though vaginal secretions, urine and sweat constitute important evidence
and are commonly found at crime scenes, there are no established presumptive or
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confirmatory tests for the detection of vaginal secretion, urine and sweat. Some serology
tests are available but are not widely used in forensic laboratories.
The acid-Schiff reagent selectively stains glycogenated epithelial cells present in
vaginal secretions. However, the level of glycogenation depends on the menstrual cycle
and age of the donor. False positives from samples collected from the mouth or urethra
of males have been well documented for this test (119). In addition, the test is time- and
sample-consuming; therefore its use is very limited. One other test such as the detection
of isoenzymes 4 and 5 of lactate dehydrogenase which is merely presumptive since it is
not specific for vaginal secretions. The limitations of these tests leave this forensicallyimportant body fluid unable to be identified (125).
To presumptively determine the presence of urine, some colorimetric tests have
been used. The detection of urea, creatinine, uric acid or urease can be of value to
determine the presence of urine, however all the different tests used present limitations
and false positives with other body fluids. RSID™-Urine was developed to detect TammHorsfall glycoprotein, however the presence of vaginal fluid or blood can impair the
applicability of the test (119, 125).
Sweat existing in clothing and other items recovered from crime scenes can
contain enough DNA to provide a full profile. Regarding the serological identification of
sweat, the use of ELISA to specifically identify the protein G-81 has been reported with
successful results, however its use has not been widely implemented (119, 125). Another
method consists in the use of electron microscopy in combination with energy dispersing
X-ray analyzer that allows determining the chemical composition of very small stains.
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However the use of this technique is restricted to compare the evidence stain with another
stain of known origin, therefore its use for body fluid determination is very limited (119).

B.7 Description of the problem
The current confirmatory serology tests used in forensic sciences are used to
detect proteins and present several limitations. Proteins are the effector cells in the
tissues, and therefore in theory it is expected that their presence and relative abundance
can establish which body fluid is present. Proteins can be carriers or catalysts of
biochemical reactions and a test can use the proteins’ substrate as an indicator of an
active enzyme. However, for such detection to be possible, the protein must maintain
activity otherwise it will consist of a disorganized active center that does not recognize its
substrate. Extreme temperatures, changes in pH and moisture can easily denature a
protein, rendering its activity non-existent and therefore its detection impossible for body
fluid identification. Moreover, some enzymes lose its catalytic capacity due to the
presence of inhibitors present at the crime scene and collected with the body fluid stain.
These aspects are extremely important since the samples that arrive at a forensic
laboratory have not been in environments with controlled temperature, pH or clean from
other contaminants. Most of the confirmatory methods mentioned above have been
validated in mock crime scene samples, most consisting of samples placed in different
materials. Some have been exposed to long term storage or high temperatures but such
studies are limited.
Forensic serologists have studied the proteins that are specific to a tissue and
developed presumptive methods to identify tissues based on the presence or quantity of a
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single protein (110). According to the central dogma, proteins are translated from mRNA
transcripts. Therefore, measuring specific mRNA transcripts instead of proteins may
provide a method with higher sensitivity since unlike proteins, levels of mRNA can be
directly assessed without the need for catalytic activity. The transcriptome of a tissue is
defined as the pattern of gene expression for the cells that compose such tissue. Forensic
research has aimed to determine the transcriptome of body fluids commonly found at
crime scenes and identify which mRNA transcripts are specific for which tissues (126).
What is attractive about measuring levels of mRNA compared to proteins is the
possibility to use automated methods similar to those used for DNA.
To measure the levels of one specific mRNA transcript, first the total RNA of a tissue
must be extracted and quantified. The extracted RNA is then incubated with DNase I,
which will degrade any DNA co-extracted with RNA so it would not interfere with the
reverse transcriptase reaction. Using random primers that anneal in the poly-A tail of
mRNA or in other locations, a reverse transcriptase reaction is performed. The reverse
transcriptase reaction is similar to PCR but uses enzymes called reverse transcriptase,
which are capable of reading RNA, and synthesizing DNA (called cDNA), which is
complementary to the RNA. Following this reaction, a quantitative PCR or end-point
PCR will amplify the selected regions that correspond to the mRNA transcripts of interest
for the target tissue (127). Additionally, a housekeeping gene is also amplified to allow
the normalization of mRNA transcripts quantified. The amount of mRNA produced in a
cell or tissue may be momentarily increased as a result of the cell cycle or other factors
inherent to the status of the tissue (10). For that reason, the concentration of the specific
mRNA transcript is always normalized with the concentration of a housekeeping gene

67

(128). The transcripts of a housekeeping gene are considered stable because of a constant
need of such genes by the cells. Lack of normalization between the mRNA transcript of
interest and the transcripts of housekeeping genes would lead to several errors while
assessing the concentration or presence of a specific mRNA transcript since some are
only expressed at specific points of the cell cycle, and when analyzing a tissue, several
cells in different points of cell cycle are present.
For a quantitative PCR approach, the quantity of each transcript after normalization with
the housekeeping gene is determined through comparison of fluorescence of unknown
samples to those of standard solutions that have known concentrations (128). If end-point
PCR is used, the amplicons may be analyzed by capillary electrophoresis (CE) similarly
to what is done for STRs. Additionally, the use of high resolution melt analysis has also
been tested for analysis of mRNA transcripts in forensic samples (129). Multiplexing
several primers is also a possibility for this approach as long as they can be distinguished
by the real-time instrument or by the CE application (130, 131).
One of the first reports to quantify mRNA for body fluid characterization in
forensics was published in 1999 by Bauer et al. (132). In that report, the authors aimed to
determine the presence of epithelial cells in menstrual blood in stains stored for 6 months.
The positive results achieved initiated a body of research in stability and usefulness of
mRNA transcripts for the identification of body fluids. Juusola and Ballantyne (126, 130,
133) were very active in the identification and in performing multiplex reactions of
several mRNA transcripts specific for different tissues. Initially the analysis of transcripts
was merely to determine its presence in only the target body fluid and it was achieved by
gel electrophoresis (126), later with capillary electrophoresis (130) and in the last report
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by the two authors the use of a real-time instrument with TaqMan® technology (Figure
2.2). In real-time PCR, the determination of CT values for all transcripts in all tissues of
forensic interest allows the establishment of a reference table that would permit forensic
analysts to identify the tissue of interest. The number of fluorophores available and the
possibility that a mixture of body fluids and not a single source sample is present may
limit the analysis of mRNA transcripts by this method. Additionally, individual variation
in the mRNA expression of certain genes may also lead to false negatives (133).
Other reports (134) have used a multiplex approach similar to that of Juusola and
Ballantyne (2007) using different mRNA transcripts with varying specificities for the
target body fluid. With the aim of identifying the transcriptome of forensically-relevant
tissues, in 2013, Park and colleagues (135) performed a whole-genome microarray for
blood, saliva, semen and vaginal secretion in order to detect which mRNA transcripts
were present in higher quantities in which body fluids. In total, they were able to select
137 candidate genes from which a second selection of 41 was made. Some of the body
fluid-specific mRNA transcripts already reported by other groups also showed as
candidate genes for those body fluids in the microarray, further confirming the previous
work by others.
The main concerns with the use of RNA is the low stability of the molecule over
time and when exposed to the elements, variation in its abundance on the tissue of origin
and the need to use extra portions of evidence to extract RNA for body fluid
identification (136). Most of the forensic research using mRNA transcripts have done
some level of stability studies and developed mock crime scene samples to determine the
ability to detect mRNA in challenging samples. Despite the overall results being positive,
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environments with high humidity can cause issues in the detection of mRNA and more
studies are needed until this approach is robust enough for body fluid identification.
Regarding the use of extra evidence to perform RNA extraction, even though the
simultaneous extraction of DNA and RNA from the same piece of evidence is possible
(137, 138), handling RNA in a laboratory must be accompanied with extra care because
of the ubiquitous presence of RNases (including in human skin). For example, all water
used, including that used to dilute buffers and other solutions must be treated with diethyl
pyrocarbonate (DEPC), which includes long incubations so that the DEPC may combine
with all RNases and a final autoclave step to remove the DEPC from the water(128). The
limitation in the use of mRNA can also result from where the sample itself was collected,
since the presence of RNases is ubiquitous in the human body (139).
Other issues related to the use of mRNA for body fluid identification include the
use of DNase I to remove any DNA contaminating the extracted RNA (133, 140). The
accidental release of this enzyme in a forensic laboratory could signify the impairment of
DNA typing methods for several samples, even for samples processed several weeks after
the release happens. To tackle some of the stability issues inherent to mRNA transcripts,
some research has suggested the use of microRNA (112, 141). Because they are smaller,
microRNA molecules present higher stability when compared to mRNA (142, 143),
however the issues with DNase I and the ubiquitous presence of RNases are still a
concern even for these smaller RNA molecules.
Using the central dogma as a reference, it makes sense to look at DNA instead of
RNA or proteins to the identification of body fluids. DNA presents higher stability, it is
the source of the code for all genes and for differential gene expression in tissues.
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Moreover, the extraction, use and storage of DNA in forensic laboratories has been
already validated for several years (68, 72).
The reliability of a confirmatory test for body fluid identification for forensic
purposes depends on its capacity to accurately determine which body fluid is present
regardless of its concentration, its purity and whether its mixed or not with other body
fluids. The accurate determination of which body fluid is in the origin of a DNA samples
can be extremely important to solve some crimes, namely those that rely on
determination of the suspect’s involvement in the crime. If a serology test shows false
positives or false negatives in one of the validation studies performed, it creates
reasonable doubt for any piece of evidence analyzed with such test. Adding to this, the
amount of evidence recovered from the crime scene may already be very limited,
therefore any portion of it being used for a test known to show false results may be
considered a waste of sample. For this reason there is the need to establish a body fluid
determination test that can achieve similar degree of certainty as those methods currently
observed in DNA typing technologies. Due to the fact that all forensic laboratories are
well equipped to collect, extract, store and analyze DNA, it seems logical to choose DNA
as the biomolecule for body fluid discrimination in forensics.
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CHAPTER III – FORENSIC EPIGENETICS

A. DNA Methylation Analysis for Forensic Applications
Since the mid-1990’s that DNA has been used to match a suspect to a crime scene
(60). The optimization of methods and techniques from collection to analysis hasn’t
stopped since then. Most forensic laboratories are equipped with and have a set of
validated standard operation procedures to collect and store DNA. On the biochemical
research side, more information is known about DNA methylation presently than it was
10 years ago and several commercial kits have been launched to analyze DNA
methylation of loci known to be implicated in pathologies. DNA samples are already
commonly retrieved from crime scenes and stored after DNA typing. Oftentimes in the
investigation, the need to determine body fluid type emerges after DNA typing. The use
of DNA methylation methods in forensic laboratories would for example allow the
forensic analyst to simply retrieve a stored DNA sample rather than going back to the
evidence collected at the crime scene (shirt, sheet, etc) in order to analyze another
biomolecule (RNA or protein), thus saving precious evidence and time.

B. Methods to Analyze DNA Methylation Patterns
To determine which CpGs of a specific DNA region are methylated or
unmethylated several methods can be employed depending on several parameters such as
total amount of DNA template available, initial quality of the DNA template available,
etc (144). Most of the methods currently available for analysis of DNA methylation
patterns have been developed for health sciences such as for the study of gene expression

72

in cancer patients. Researchers in health sciences can depend on high amounts of intact
DNA since most samples are biopsies from patients. For that reason, some of those
methods present limitations regarding their potential use in forensic sciences and will
must be adapted or improved to achieve higher sensitivity. For example, since DNA
typing methods can match samples with as little as 100 pg of DNA, a method for body
fluid identification should aim to reach that sensitivity. Another example are the high
throughput and robustness of the body fluid identification method should be equivalent to
DNA typing methods so they can both be used with samples from crime scenes.
DNA typing methods have been validated according to the SWGDAM guidelines
(109). Even though the guidelines were designed specifically for DNA typing and
address some things specific for that analysis, any validation methods covered in the
SWGDAM will apply to body fluid identification using DNA methylation.
Different types of methods have been presented to study the DNA methylation pattern of
body fluids. Such methods start by using either restriction enzymes that recognize and
cleave the DNA in presence of methylated cytosines or methods that rely in the bisulfite
conversion of DNA which distinguishes unmethylated cytosines by chemically
converting them to uracil while leaving the methylated cytosines untouched. The analysis
downstream depends on which method was used but should also consider factors such as
throughput, automation, robustness and sensitivity.

B.1 Restriction Enzymes
Restriction enzymes are proteins capable of cutting DNA near or at specific
recognition sequences. There are over 50 restriction enzymes that recognize DNA at a
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CpG site. The cleavage of DNA will be dependent upon the recognition of unmethylated
cytosines in the dinucleotide CpG (145). Initially the loci of interest were studied and a
determination to which restriction enzyme would cut the DNA near the CpG of interest
was assessed. In the case of body fluid identification, the CpG of interest may be one that
is methylated in one body fluid (the target body fluid) and unmethyated in all others.
Alternatively, the target body fluid may have an unmethylated CpG whereas all other
body fluids present methylation at that specific dinucleotide. After the appropriate
restriction enzyme is selected, primers are designed to flank the region where the enzyme
cuts the DNA. The restriction enzyme HhaI has been commonly used in forensic studies
for the use of DNA methylation analysis in body fluid identification (146, 147). HhaI
recognizes and cleaves within the sequence GCGâC, where the arrow pointing down
represents where the sequence is cleaved if the cytosines are unmethylated (147, 148).
For a body fluid with methylated cytosines in the recognition sequence, there will be no
cut in the DNA and therefore both forward and reverse primers will be able to anneal and
amplify the region through PCR. If the cytosines are unmethylated the DNA is cleaved
and two fragments are formed preventing the amplification. The analysis downstream can
be done by capillary electrophoresis where a peak corresponding to the size of amplicon
is visible if the CpGs are methylated. Similarly to STRs, a multiplex PCR reaction can be
designed if all the loci contain the recognition sequence and by labeling each primer with
different fluorophores. However, the absence of a peak may indicate unmethylated CpGs
or incomplete cleavage by the restriction enzymes (146, 147). The fact that incomplete
digestion can lead to false results severely limits this methodology. Incomplete digestion
can occur when the temperature or time of incubation is not ideal; or due to an
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inssuficient concentration of enzyme relative to the quantity of DNA present. One
possible method to control for temperature and time of incubation would be to run known
controls at the same time as the forensic samples. However, if the incomplete digestion
occurred as a result of the inaccurate quantification of DNA or because of the presence of
other contaminants co-extracted with DNA, the use of a control DNA would not
necessarily indicate incomplete digestion. Another major drawback for the use of
restriction enzymes in forensic identification of body fluids is the necessity to identify
restriction enzymes able to recognize sequences at or near the loci of interest (149).

B.2 Bisulfite Modification
In forensic sciences, a more robust method is to use bisulfite modification to
maintain the patterns of DNA methylation (149). The deamination of cytosines to uracil
in the presence of sodium bisulfite was first described in 1970. The chemical reaction
consists on a deamination promoted by sodium bisulfite, in a slightly acidic (pH 5-6)
media heated to 66 ºC. The sulfite group is then removed by a reaction of desulphonation
at pH 10 resulting in uracil. No other nucleotides besides unmethylated cytosines are
affected by the sodium bisulfite. The presence of the methyl group on the 5’- carbon of
the methylated cytosines inhibits the capacity of a nucleophilic attack at the double bond
shared between carbons 5 and 6 in the cytosine ring (150, 151). DNA polymerase
recognizes the uracils resulting from this reaction by adding an adenine in the newly
forming strand. Bisulfite conversion can cause fragmentation of DNA which may be of
concern for forensic sciences. For that reason, it is advisable to amplify relatively short
loci as larger fragments of DNA may cease to be intact following conversion.
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After bisulfite conversion, the DNA is amplified by PCR and can be analyzed by a
veriety of methods capable of determining the status of individual CpGs or the relative
abundance of methylated versus unmethylated CpGs. The methods utilized in this
dissertation include pyrosequencing, high-resolution melt (HRM) analysis and SNaPshot.

B.3 Pyrosequencing
The quantification of methylation for each individual CpG in a targeted DNA
sequence can be performed using pyrosequencing, which was firstly described as an
alternative to Sanger sequencing. In 1986 Pål Nyrén developed a way to follow in real
time the release of the pyrophosphate by DNA polymerase during the incorporation of
nucleotides (152). Briefly, pyrosequencing uses a cascade of enzymatic reactions
following addition of a base by DNA polymerase to produce light emission that is
detected by a camera and displayed in a graph called a pyrogram. Prior to
pyrosequencing, a PCR is setup with primers that amplify a larger DNA region than the
one to be sequenced. The region to be sequenced is called target region and is located
within the amplicon of the PCR reaction. One of the PCR primers contains a biotin
molecule at their 5’-end. As amplification progresses the PCR product will consist of
double stranded molecules with one biotin-labeled strand. The amplicons are mixed with
streptavidin-coated beads and captured by vacuum on filter probes. The captured DNA is
then washed in successive solutions, including a denaturing one that separates the double
strand DNA, releasing the non-labeled strand and retaining the biotin-labeled one. The
beads with the single stranded DNA are then released in a solution containing a third
primer, called sequencing primer. After the sequencing primer anneals to the single-
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stranded DNA, the mixture is added to the pyrosequencing instrument and sequencing
begins (153). The instrument is composed of a cartridge that contains all 4 nucleotides, an
enzyme mixture and substrate mixture in separate wells and a place for a sequencing
plate. Due to increase in pressure, the contents of each well in the cartridge can be
individually dispensed on the plate. At first the enzyme mixture and the substrate mixture
are dispensed in all wells of the plate. The nucleotides are then added one at a time,
according to a specified order, to each well. If the added nucleotide is complementary to
the DNA strand being sequenced, the DNA polymerase will add the nucleotide and
release pyrophosphate, which is similar to what happens on any reaction catalyzed by
DNA polymerase. Next, adenosine 5’-phosphosulfate in the presence of the released
pyrophosphate is converted to ATP by the enzyme sulfurylase. Luciferase can then
catalyze the oxidation of luciferin to oxyluciferin due to the presence of ATP in solution,
emitting light. The amount of light generated is proportional to the amount of ATP and it
is detected by charge coupled device (CDD) and displayed as a peak on a pyrogram
(153). Before the next nucleotide is added to the mixture, apyrase degrades any ATP and
nucleotides that were not used. The peaks in the pyrogram have a height proportional to
the number of each nucleotide added. For example, on the sequence ‘GCAGGCCT’, the
pyrogram would be similar to what is shown on Figure 3.1.
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Figure 3.1 – Pyrogram depicting the relative
peak height for all the nucleotides dispensed
when
sequencing
the
fragment
‘GCAGGCCT’. The pyrogram only shows
peaks when the dispensed nucleotide is in the
sequence. The relative peak heights for a
position with two repeated nucleotides (‘GG’
and ‘CC’) are double the height of peaks in
positions that contain only single nucleotides.
Adapted from (154).

When performing analysis for DNA methylation, for each CpG the instrument will
dispense a T and a C and measure the light emitted after each dispensation. Since the
light is proportional to the amount of each nucleotide, quantification is possible. On the
Qiagen Pyrosequencing® method multiple assays with different PCR products and
sequencing primers can be ran in the same plate. The PyroMark® software used to design
each run allows the customization of each individual plate by a drag-and-drop method of
assays in the plate layout (155). The user needs to input the sequence to analyze and the
software will create the dispensation order. If the user also inputs the ‘sequence to
analyze prior to bisulfite conversion’, which corresponds to the genomic DNA sequence,
the software highlights possible locations for bisulfite controls in red.
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The peak height will provide information about the relative amount of cytosines
and thymines for each CpG. Since bisulfite reaction does not modify methylated
cytosines, a high peak when a cytosine is dispensed corresponds to a high methylation
percentage. On the example shown on Figure 3.2, the first CpG shows 2% of methylation
because the peak height for ‘C’ is 2% of the total peak height for a single nucleotide. The
PyroMark® software determines the peak height for all individual base pairs, such as the
first ‘G’ shown in the pyrogram (Figure 3.2, position 4). On the variable positions (CpGs)
the sum of peaks of ‘C’ and ‘T’ should be equivalent to the height determined by the
remaining sequence.

Figure 3.2 –Pyrogram showing the percent methylation in 5 CpGs (highlighted in blue).
The peaks corresponding to ‘C’ are very low when compared to ‘T’, which makes the
methylation level to be below 10% for all peaks. The pyrogram shows relative light units
on the y-axis and position on the target sequence on the x-axis. The ‘E’ and ‘S’ on the
beginning of the x-axis correspond to the dispensation of enzyme and substrate mixtures,
respectively. The ‘C’ highlighted in red shows the bisulfite control. On top of the
pyrogram is shown the sequence to analyze, where ‘Y’ corresponds to a CpG

The percent methylation is then calculated from the relative peak height of ‘C’ versus the
expected peak height for a single nucleotide. To confirm that the correct PCR product is
being sequenced instead of a random sequence that annealed to the sequencing primer,
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the instrument dispenses negative controls, that is, nucleotides that are not
complementary to the strand being sequenced and these should not display any peak
when dispensed. One example of a negative control is the first ‘G’ dispensed after the
substrate (S) on Figure 3.2. The sequence to analyze (Figure 3.2, on top labeled as ‘A2’)
starts with a CpG (labeled as ‘Y’ on the sequence to analyze) and thus either a ‘C’ or a
‘T’ should be dispensed, however the instrument dispensed a ‘G’ to confirm that the
sequencing primer annealed where expected. Comparing the sequence to analyze and the
nucleotides dispensed on the x-axis will provide information on which ones are negative
controls.
The bisulfite control is shown in the image as a dispensed ‘C’ on position 11. The
PyroMark® software assumes that all ‘Cs’ not followed by ‘Gs’ on the genomic DNA
sequence are unmethylated and thus will be converted to ‘Ts’. As we can see on the
sequence to analyze on Figure 3.2, after position 11 there is a string of 2 ‘Ts’, which
result from bisulfite modification of unmethylated ‘Cs’. If bisulfite modification had not
been completely successful, at least one of those ‘Ts’ would still be a ‘C’ and thus a peak
would show on the pyrogram. Dispensing a ‘C’ before or after any ‘T’ that is the result of
bisulfite conversion will therefore serve as a bisulfite control for pyrosequencing. When
the ‘sequence to analyze prior to bisulfite conversion’ is included in the assay design of
the Pyromark® software, it highlights in red the potential positions on the sequence where
bisulfite controls can be added by the user. Otherwise, the nucleotide dispensation can be
modified to include as many bisulfite controls or negative controls as desired or
depending on the time available to sequence each well, since more nucleotides dispensed
results in longer dispensations and more time needed for each well (155).
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The first time that pyrosequencing was used for body fluid identification for
forensics application was in 2012 and the results are displayed in the report of Madi et al.
(156). In their experimental setup, DNA extracted from several samples of body fluids
and methylation was quantified for 4 separate genome locations. The authors selected
which CpGs in each location show methylation differences between body fluids. When
multiple samples from different donors of each body fluid were ran with each primer
pair, the percent of methylation for each CpG of the 4 separate genome locations was
recorded. Thus each body fluid has an expected mean percent of methylation for each
genome location and a corresponding standard deviation.
The limitations of this method being implemented in forensic laboratories is the
fact that it requires new equipment and training of personnel, which may be a deterrent
for some laboratories. However the great advantage of pyrosequencing is its capacity for
high throughput and its ability to be automated (153). The forensic analyst can be
confident in which CpGs are methylated since the pyrogram reveals all issues associated
with the sequencing process. Furthermore, even though the method has not yet been
designed for multiplexing PCR, it may be possible to have multiple primers amplified in
a single PCR reaction and then sequenced separately depending on which sequencing
primer is added for each well.

B.4 High-Resolution Melt (HRM) Analysis
High-resolution melt (HRM) for DNA methylation analysis was first described in
1997 by Wojdacz and colleagues (157). After bisulfite conversion and PCR, an
unmethylated amplicon will be mainly composed of double hydrogen bonds between
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adenine and thymine thus having a lower melting temperature when compared to an
amplicon derived from a methylated template (158) (Figure 3.3). The melt analysis is
performed for the PCR products in a real-time instrument with melt analysis capacity, in
a closed tube, immediately after the end of PCR. Like many other real-time
amplifications, the mix contains an intercalating dye such as EvaGreen that emits
fluorescence when in the presence of double stranded DNA. With the completion of the
PCR reaction, the melting protocol begins by heating the PCR products in increments of
0.1-0.3 ºC and reading the decrease in fluorescence. The gradual heating results in a melt
of the double stranded DNA, which causes a release of the intercalating dye and a
decrease in fluorescence. As the temperature increases, the fluorescence decreases at a
steady pace, followed by a sudden decrease around the melting temperature (TM) of the
PCR product (Figure 3.4). The TM is defined as the temperature at which half of the
double stranded DNA has been melted, which roughly corresponds to half of the
fluorescence in a graph like the one on Figure 3.4. To facilitate the visualization of TM,
another graph depicting the first derivative in fluorescence per temperature, that is, the
observed change of slope (defined as ‘-dF/dT’) of Figure 3.4 is then plotted vs
temperature (T) and the peak observed corresponds to the TM of the amplicon (159, 160).
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Figure 3.3 – Schematic representation of
differences in melt curve analysis for one DNA
target with different methylation status. The melt
peaks will locate at different temperatures
depending on methylation. Adapted from (161)
The method is quick and nondestructive, allows the characterization of PCR products
(162) derived from bisulfite-modified DNA templates with different levels of
methylation. It uses an instrument available in most forensic laboratories, which
facilitates the adoption of this methodology by smaller forensic laboratories. HRM
analysis has some disadvantages when compared to pyrosequencing such as the fact that
it does not allow individual CpG quantification and that some amplicons may become
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difficult to analyze using melting properties because of potential secondary structures
formed after bisulfite modification (163).

Figure 3.4 – Schematic representation of the
decrease in fluorescence resulting from
intercalating dye release during the separation
of the double strands of a PCR product. The
slope resulting from the sudden drop in
fluorescence is plotted versus temperature to
better represent the TM of the PCR product.
Adapted from (160).
However, HRM analysis can also present several advantages when compared to
pyrosequencing. One advantage is the overall lower cost that results from a faster
turnaround because of the melt analysis after amplification being automatic. Moreover,
less expensive reagents and lower investment in a new instrument is necessary for those
cases where the laboratory needs to acquire a real-time instrument with melt analysis.
Another advantage of HRM is that the assay only needs a forward and reverse primers
and not a third sequencing primer. As a result of bisulfite modification, some templates
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become very rich in ‘A’ and ‘T’ and also become very similar amongst themselves which
may impair primer design. HRM analysis can be multiplexed if the amplicons display
different melting temperatures, which correspond to different peaks, or if the melt curves
can be distinguished by a fluorescent method .
Overall as a result of the quick turnaround, HRM analysis is a method that can
easily be optimized and is familiar to most forensic DNA analysts. For those reasons
there are many advantages in investing in HRM research and analysis for body fluid
identification.

B.5 Methylation-Sensitive Single Nucleotide Primer Extension
The analysis of methylation after bisulfite conversion can also be achieved using
capillary electrophoresis. The methylation-sensitive single nucleotide primer extension
(ms-SNuPE) method is similarly to SNaPshot, which has been widely used for SNP
analysis (164). Following bisulfite modification, the DNA is amplified with primers
specific for bisulfite-modified DNA and flanking the region of interest. The PCR product
is then purified to remove extra primers and dNTPs that were not used in the
amplification. The ms-SNuPE primers are designed to anneal to the bisulfite modified
DNA immediately upstream of the CpG of interest (164). During the single base
extension reaction, which is prepared similarly to a PCR, a dideoxy-modified nucleotide
is added to the nascent strand of DNA (165). Since the modified nucleotide does not
allow further amplification and because each dideoxy-nucleotide is labeled with a
specific fluorescence color, the fragments can be separated in a capillary electrophoresis
instrument. The capillary electrophoresis instrument determines the presence of a ‘T’ or a
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‘C’ on the template strand. The peak height provides the relative amount of each
nucleotide, which are labeled with different fluorophores. Even though this method
cannot provide information regarding the whole sequence, it does have single CpG
resolution and allows quantification (164). The instrumentation necessary for ms-SNuPE
is familiar to the forensic analyst which represents an advantage over pyrosquencing.
However, the procedure includes steps that are time consuming and not automatable,
such as enzyme incubation. Moreover, each sample requires two reactions to be set - the
initial amplification and the single-nucleotide extension reaction - which may limit
throughput. Ms-SNuPE has been explored in body fluid identification for forensic
sciences purposes with mixed results. For example, in the report by An and colleagues
(146) a set of 3 semen-specific markers (USP49, DACT1 and PRMT2) were analyzed by
ms-SNuPE (which is referred as SNaPshot by the authors). A fourth marker PFN3 which
has vaginal-specific methylation and was also included in the analysis. The authors were
able to achieve high sensitivity by obtaining results from samples with 500 pg of DNA.
However when semen samples of vasectomized and non-vasectomized men are analyzed,
the peaks are different amongst themselves at the DACT1 marker but more importantly
the peaks for all markers are different between the vasectomized males (n=5) and nonvasectomized males (n=35) when compared to the 29 semen samples (not labeled as
vasectomized or not). Even though the authors did not address the contradicting results,
the fact that the semen samples were pooled together may explain the disparity of results
and also the high sensitivity of 500 pg for this protocol. SNaPshot was used in two other
reports (166, 167) by the same team of researchers to validate results obtained from a
bead array study designed to identify new genome locations able to distinguish body
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fluids commonly found in forensic sciences. In both reports, the expected DNA
methylation values obtained by the bead array can differ when a PCR-based method, such
as SNaPshot, is used to analyze samples. However, on the second report (167) the
markers tested by SNaPshot showed higher specificity for each body fluid, probably due
to an increased number of samples analyzed in silico. Regarding the SNaPshot method,
only the 2015 report performed sensitivity studies. The results vary depending on how
much DNA was bisulfite modified even if the same amount was added to the PCR
reaction. Additionally, it is not clear how many samples were used for sensitivity studies
and even the authors agree that more work needs to be done (166).
One of the issues that can arise with SNaPshot results is the different sensitivity of
markers may mean that some will present high peaks whereas others may present peaks
so low in the electropherogram that they are not detected. If one PCR product amplifies
more efficiently than others in a multiplex PCR reaction, that peak may be so high that
smaller peaks will be undetected due to issues with dynamic range (99).

C. State of the Art
Even though the analysis of DNA methylation patterns in other fields begun
several years ago, their applications in forensic sciences is still at its infancy. The interest
in the use of DNA methylation for forensic science applications started only in 2010 with
a report from Frumkin and colleagues (168), which aimed to show that artificial DNA
amplified by PCR and left deliberately at a crime scene, can be distinguished from
authentic DNA from the victims and perpetrators based on methylation. Since amplified
DNA is all unmethylated, studying DNA regions naturally methylated would allow the
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distinction between the two types of DNA. During their work, Frumkin and colleagues
utilized methylation-specific restriction enzymes to observe that some of the loci used
presented different methylation levels for different body fluids examined. The difference
in methylation observed led to a second report specifically directed towards body fluid
identification using DNA methylation patterns (147). In the 7 years that have passed
since that first report, the number of loci described for body fluid identification analysis
has been limited. Research efforts have been made to identify more genome locations
capable of distinguishing body fluids for forensic purposes, particularlly using arraybased methods. However, each array can run a limited number of samples and is still
prohibitively expensive for most forensic research laboratories. Moreover, such arrays
cover mostly CpGs that provid specific methylation site for certain types of cancer or
pathologies and the CpGs are mostly located in CpGi, which are not necessarily colocalized with regions of the genome more relevant for body fluid identification.
Nonetheless in the past 7 years a balance between the validation of existing loci for body
fluid identification and the search for new loci has taken place. In the future, as this
technology becomes more reliable, it is expected that funding agencies will recognize the
value to invest in whole-genome studies aimed specifically for forensic samples which
have their own composition regarding the type of cells and the amount of DNA present.
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CHAPTER IV – FORENSIC DISCRIMINATION OF VAGINAL EPITHELIA BY
DNA METHYLATION ANALYSIS THROUGH PYROSEQUENCING

This is the pre-peer reviewed version of the following article: Antunes, J., Silva, D.
S.B.S., Balamurugan, K., Duncan, G., Alho, C. S. and McCord, B. (2016), Forensic
discrimination of vaginal epithelia by DNA methylation analysis through
pyrosequencing. Electrophoresis, 37: 2751–2758, which has been published in final form
at http://onlinelibrary.wiley.com/doi/10.1002/elps.201600037/full/.
® Copyright WileyVCH Verlag GmbH & Co. KGaA.
Reproduced with permission.
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A. Abstract
The accurate identification of body fluids from crime scenes can aid in the
discrimination between criminal and innocent intent. This research aims to determine if
the levels of DNA methylation in the locus PFN3A can be used to discriminate vaginal
epithelia from other body fluids. In this work we bisulfite-modified and amplified DNA
samples from blood, saliva, semen and vaginal epithelia using primers for PFN3A.
Through pyrosequencing we were able to show that vaginal epithelia presents distinct
methylation levels when compared to other body fluids. We also show that the sensitivity
of the method was determined to be 5 ng, that mixtures of different body fluids have
methylation values that correlate with single-body fluid samples, and that the primers for
PFN3A are specific for primates. We successfully demonstrated that analysis of
methylation in the PFN3A locus can be used for vaginal epithelia discrimination in
forensic samples.

B. Introduction
In forensic cases, determining the presence of vaginal secretions can aid in the
distinction between innocent and sexual contact. The current method used in forensic
laboratories to presumptively identify vaginal fluids depends on successful histological
staining of the glycogen-rich vaginal cells by the Schiff reagent. However, the method’s
sensitivity depends on the reproductive age and menstrual cycle of the female and it
easily gives false positives by unspecific staining of male buccal and urogenital cells
(169). More sensitive and reliable methods are those that rely on the quantification of
certain RNAs as a product of cell-specific gene expression. Gene expression can occur at
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the transcription level which is quantifiable by the levels of messenger RNA (mRNA)
present in a specific type of cells (133); or at the post-transcription level that occurs
through micro RNA (miRNA) presence in specific tissues (170). The most successful
reported methods that are able to quantify mRNA or miRNA are capillary electrophoresis
(171) and high-resolution melt analysis (172). Both methods show promising results
since they are automatable, easy to implement in a forensic laboratory and sensitive.
However, the use of RNA requires normalization of transcript levels with those of a
housekeeping gene in the same sample. Often that normalization has to be performed by
quantifying RNA levels prior to cDNA synthesis. Quantification methods available do
not discriminate between human and bacterial RNA, which is commonly present in most
vaginal samples (169). Since most transcripts are present at a basal level in body fluids,
the quantification of RNA for body fluid identification relies on levels of specific
transcripts being higher than a certain threshold in specific cells. Lack of an accurate
quantification of RNA in the sample can lead to false results since it influences the
threshold for the target transcript. Because of the aforementioned difficulties, we propose
the analysis of different DNA methylation levels as a way to discriminate body fluids.
DNA methylation is one of the epigenetic mechanisms for gene regulation in the human
body. Different levels of DNA methylation in certain loci are thought to control gene
expression by silencing or activating specific genes. The presence of a methyl group on
the 5’ carbon of a cytosine belonging to the dinucleotide CG (CpG) is believed to prevent
the binding of the transcription machinery in the promoter of genes (47). Some loci on
the genome called tissue-specific differentially methylated regions (tDMRs) can therefore
be used for body fluid discrimination (136, 147, 173) since they present different levels
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of DNA methylation depending on the cell studied (156, 174). To determine the pattern
of DNA methylation in a locus, the most commonly used methods include the bisulfite
modification of genomic DNA that chemically converts the unmethylated cytosines to
uracils but does not react with methylated cytosines. During the polymerase chain
reaction (PCR) uracils become copied as thymines and the resultant amplicons can then
be sequenced to determine the presence of a cytosine or a thymine at each specific CpG.
One of the most commonly used methods for DNA methylation analysis is
pyrosequencing because it allows individual quantification of CpG’s and a percent
methylation value is displayed on a pyrogram created by the instrument software (154).
In order to successfully use pyrosequencing in forensic laboratories, more loci capable of
discriminating several body fluids, including vaginal epithelia need to be identified. One
study that aimed to uncover more loci was the work of Lee et al. (2010) where samples of
blood, saliva, semen, menstrual blood and vaginal epithelia were collected from
volunteers. After extraction, the DNA from each body fluid was pooled so that the DNA
yield was sufficient for sequencing post bisulfite conversion. Sanger sequencing was
performed and the results compared to in silico converted sequence in order to obtain a
comparison of methylation levels. The methylation map revealed that the tDMR named
PFN3 presented an overall different DNA methylation level for vaginal fluid when
compared to the other body fluids (175). To determine if this tDMR can be used to
discriminate vaginal epithelia from crime scenes, we performed pyrosequencing on a subregion of PFN3 - PFN3A. Contrary to the method used by Lee et al. (2010),
pyrosequencing does not require DNA samples to be pooled. The region selected for this
study – PFN3A - includes only the CpGs that in the work of Lee et al. (2010) showed the
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highest methylation difference when compared to the other body fluids. The aim of this
work was to explore the potential of PFN3A to become a biomarker for vaginal fluid
discrimination in forensic laboratories.

C. Materials and Methods
Blood, buccal, vaginal swabs and semen samples were collected from volunteers
according to the approved IRB-13-0555 from Florida International University and
Pontifícia Universidade Católica do Rio Grande do Sul (CONEP #723.619/ CEP
#845.747). Swabs were air-dried and DNA extraction was performed using the EZ1®
DNA Investigator kit (Qiagen, CA) and the BioRobot® EZ1 automated purification
workstation (Qiagen, CA) according to the manufacturer’s specifications. Quantification
was performed using the PicoGreen® method (Life Technologies, CA). Fifty nanograms
of DNA were bisulfite modified using the EpiTect® Fast DNA Bisulfite Kit (Qiagen,
CA) according to manufacturer’s instructions. For the sensitivity studies, six vaginal
epithelia samples were serial diluted to obtain 10, 5 and 1 ng of input DNA to bisulfite
conversion. For the mixtures studies, DNA samples of blood, vaginal epithelia and semen
were quantified and mixed in different ratios of each two body fluids in order to have 100
ng total of DNA input to bisulfite modification. For the species-sensitivity studies, DNA
from cat, dog, chicken, cow, mice, bacterial pool (Escherichia coli, Staphylococcus
aureus, Enterococcus faecali and Pseudomonas aeruginosa), horse, gorilla, orangutan
and chimpanzee was collected and processed like described above. DNA from one
sample of human vaginal epithelia was used as positive control.
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DNA amplification reactions were performed using the PyroMark® PCR kit (Qiagen,
CA) by adding 2 µL of bisulfite-modified DNA to each reaction and following
manufacturer’s instructions. Primers for PFN3A were designed using the PyroMark®
Assay Design software version 2.0 (Qiagen, CA) and are displayed in Table 4.1. The
PCR products and a low molecular weight ladder (New England Biolabs, MA) were run
in 2% agarose gels, stained with ethidium bromide to confirm the presence and size of
amplicons.

Table 4.1 – Sequence of PFN3A primers used in this study.
Primers

Sequence

Forward
5’- GTG TAT AGT TTT GTT GAG GAT GTT TT - 3’
Reverse(a)
5’ - ACA AAC ACA CCT TCC TAC AA – 3’
Sequencing
5’ - GTT TTG TTG AGG ATG TTT TT – 3’
(a) shows the biotinylated primer
Pyrosequencing reactions were performed using a PyroMark® Q24 pyrosequencer
(Qiagen, CA) using 10 µL of PCR product and the protocol established by the
manufacturer. The percent methylation for each individual CpG was automatically
calculated by the PyroMark® Q24 software version 2.0.6 (Qiagen, CA).
Statistical analysis was performed using SPSS version 22. Methylation percent was
compared between body fluids for each CpG performing a one-way ANOVA followed by
Tukey-HSD post-hoc test. For the sensitivity studies, a dependent t-test was performed to
compare the percent methylation of each CpG from each dilution to the 50 ng group. A pvalue <0.05 represents that the difference observed is significant for all statistical tests
performed.
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D. Results and Discussion
We first aimed to determine if the DNA methylation levels in the PFN3A locus
are different for vaginal epithelia when compared to blood, saliva and semen. To address
this goal, we performed pyrosequencing of 8-12 DNA samples from each body fluid. The
results from each DNA sample from each body fluid are displayed by the Qiagen
software as a pyrogram that calculates percent of methylation for 10 individual CpGs
within the PFN3A region (data not shown). The percent methylation for each CpG from
each body fluid was recorded and the arithmetic average and standard deviations
calculated (Figure 4.1). Statistical analysis was performed and only the CpGs that had a
significant difference (p<0.05) between vaginal epithelia and all other body fluids were
reported. Our analysis showed that 9 out of 10 CpGs have an intermediate level of mean
percent methylation for vaginal epithelia that is significantly different when compared to
the other body fluids.
The only CpG (CpG9) that presented a p-value larger than 0.05 demonstrates that
methylation levels between blood and vaginal epithelia are very similar, therefore
differentiation between the two is not possible using this CpG. The similar methylation
percent on CpG9 demonstrate that for the locus PFN3A this particular CpG will not be
used for discrimination of vaginal epithelia, therefore it’s percent methylation value will
not be displayed in the following results.
Forensic evidence often contains low amounts of DNA that can severely hinder the
ability to obtain reliable values for percent of methylation. In order to determine the
sensitivity of our method, six DNA samples of vaginal epithelia were quantified and
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diluted to obtain inputs of 10, 5 and 1 ng to bisulfite conversion, followed by PCR
amplification and pyrosequencing.

Figure 4.1 - Graph showing mean percent of methylation for
samples of blood (n=8), saliva (n=11), semen (n=12) and vaginal
epithelia (n=10) with 50 ng input to bisulfite. * CpG where the
difference in methylation levels is not statistically significant
(p<0.05) between vaginal epithelia and blood.
The mean percent of methylation of the diluted samples were then compared with those
of samples with 50 ng input to bisulfite conversion. The results obtained (Figure 4.2)
show that for samples with 5 ng only one CpG (CpG6) showed levels of methylation
different when compared to the 50 ng samples. When samples of 1 ng of input DNA to
bisulfite were pyrosequenced, less reliable results were obtained. Both CpGs 2 and 3
show differences in methylation levels when compared to 50 ng input samples and all the
pyrograms generated for the 1 ng samples present warnings due to low peak height (as
example, Figure 4.3).
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Figure 4.2 - Graph showing mean percent of methylation for vaginal epithelia
samples (n=6) with different input of DNA. *CpGs and nanograms of DNA
that present methylation levels with statistically significant differences
(p<0.05) between groups.
Sensitivity studies show that some data can be obtained with as little as 1 ng of DNA
input to bisulfite since the methylation levels are the same as the ones presented by the 50
ng samples for 7 out of 9 CpGs. However the data showed that as the input of DNA
decreases so does the peak height in the pyrogram, which leads to warnings recorded by
the software. Such warnings are the result of a minimal peak height threshold set by the
manufacturer (20 relative light units). For that reason we suggest the use of at least 5 ng
of DNA input to bisulfite with this method.
Another common issue in forensic samples is that mixtures of body fluids are commonly
present in crime scenes samples. This work aimed to identify vaginal epithelia in samples
collected from specimens that are part of cases of suspected sexual assault. For that
reason we decided to ascertain how the methylation levels of the PFN3A locus change
when different ratios of blood, vaginal epithelia and semen are present in one sample.
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Figure 4.3 - Pyrogram showing a sample with 1 ng input to bisulfite. Peak height for
the majority of peaks corresponding to single nucleotide dispensations are lower
than 20 light units (y-axis) which creates a warning recorded by software.
Three randomly selected DNA samples, one from each body fluid, were quantified for
DNA methylation levels at the PFN3A locus and compared to the average percent
methylation for each body fluid observed in Figure 4.1. The same randomly selected
DNA samples were mixed with each other in ratios of 75:25, 50:50 and 25:75 and their
methylation levels assessed. Figure 4.4A shows that samples containing mixtures of
blood and vaginal epithelia have methylation values intermediate to those of samples
containing only blood or vaginal epithelia. Moreover there is a decrease in methylation
percent as the ratio of blood to vaginal epithelia decreases.
A similar correlation is also observed for the samples containing blood and semen
(Figure 4.4B) as well as samples where vaginal epithelia and semen are in the mixture
(Figure 4.4C).
The results displayed in Figures 4.4 are promising in the use of PFN3A as one of the
vaginal markers for forensic discrimination of body fluids. More genome locations
capable of discriminating vaginal epithelia based on DNA methylation have been
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reported (176). This research provides the first piece of data for methylation values using
PFN3A in mixtures of blood, semen and vaginal epithelia measured by pyrosequencing.

Figure 4.4 - Mean percent of methylation for samples containing different ratios of DNA
that was extracted from different body fluids. (A) shows the mixture of blood and vaginal
epithelia blood. As the DNA content of blood decreases compared to vaginal epithelia,
the percent of methylation also decreases. The average percent methylation for the blood
(n=8) and vaginal epithelia (n=11) samples are shown as control. The samples labeled
‘B’ and ‘VE’ are the DNA from blood and vaginal epithelia, respectively, used to make
the mixture. (B) shows the mixture of blood and semen. With the decrease in the content
of DNA from blood compared to semen, a decrease in the percent of methylation is also
observed. The average percent methylation for the blood (n=8) and semen (n=12)
samples are shown as control. The samples labeled ‘B’ and ‘S’ are the DNA from blood
and semen, respectively, used to make the mixture. (C) shows the mixture of vaginal
epithelia and semen. As the DNA content from vaginal epithelia decreases, so does the
methylation percent of the mixture.. The average percent of methylation for the vaginal
epithelia (n=11) and semen (n=12) samples are shown as control. The samples labeled
‘VE’ and ‘S’ are the DNA from vaginal epithelia and semen, respectively, used to make
the mixture.
To determine whether this method could also be hindered by the presence of non-human
DNA, we tested DNA from cat, dog, chicken, cow, mice, bacterial pool (Escherichia coli,
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Staphylococcus aureus, Enterococcus faecali and Pseudomonas aeruginosa), horse,
gorilla, orangutan and chimpanzee. One human DNA sample was used as a positive
control. Even though in the agarose gel only the samples from cat, cow, orangutan and
gorilla showed faint bands and only the human and chimpanzee showed bright bands
(data not shown), all PCR products were pyrosequenced to confirm the absence of peaks
on the pyrograms. We believe that the presence of bands in the agarose gel results from
non-specific amplification since 45 PCR cycles are necessary to amplify bisulfitemodified DNA. If that is the case, when pyrosequencing is performed, the sequence
should not correspond to the expected sequence and the software should display red
warnings.
The results showed that only the samples from human and chimpanzee present a
pyrogram without any warnings recorded by the software (Figure 4.5A and B). For the
samples of cat, cow, gorilla and orangutan the pyrogram showed peaks that do not
correspond to the expected DNA sequence (as example Figure 4.6A), which means that
the DNA sequenced was not the specific for the PFN3A locus. Pyrosequencing with
respect to DNA methylation analysis requires the user to input the target sequence to
analyze so that the software can automatically compare the peaks on the pyrogram with
the expected peaks from the sequence to analyze. Comparing Figures 4.5 and 4.6 one can
see that the observed peak height for the tested sample (Figure 4.6A) does not correspond
to the peak height of the expected sequence. This difference in peak height agrees with
the notion that the bands observed in the agarose gel are due to unspecific amplification
during PCR. All other samples provided negative results with no peaks present in the
pyrograms. One of those samples is the DNA from bacterial pool (Figure 4.6B). The
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absence of peaks is expected since no bands were observed in the agarose gel for these
samples.

Figure 4.5 – Pyrograms for the PFN3A locus showing DNA samples from (A)
chimpanzee and (B) human after pyrosequencing. Both samples show good peak
height and expected sequence therefore all CpGs analyzed passed the quality test
imposed by the software.
Contrary to methods that use RNA, body fluid discrimination using DNA methylation
methods do not depend on accurate quantification of human DNA present in the sample.
Through the use of specific primers for bisulfite-converted DNA, we can obtain
amplicons that correspond to a genome region that are primate-specific. Forensic samples
commonly contain DNA from other species, either due to exposure to the environment or
as a result of the presence of several bacterial species that are part of the human
microbiome. For that reason a method that uses nucleic acids for body fluid
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discrimination must be specific enough to tolerate the presence of non-human DNA or
RNA.

Figure 4.6 – (A) Pyrograms for the PFN3A locus showing a DNA sample from
cattle as an example of how red warnings are displayed by the software when the
sequence in the pyrogram does not correspond to the sequence expected.
(B)Pyrogram for the PFN3A locus showing the absence of peaks from a DNA
sample extracted from a bacterial pool containing the following species: Escherichia
coli, Staphylococcus aureus, Enterococcus faecali and Pseudomonas aeruginosa.
The DNA samples from dog, chicken, mouse and horse show similar pyrograms to
(B)
Our data showed that the locus PFN3A is specific for primates and does not provide
pyrosequencing data for bacterial DNA. The fact that the chimpanzee DNA provided a
pyrogram comparable to the human DNA is expected because of the high level of genetic
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similarity between the two species and does not constitute a major drawback in the
application of this method.

E. Concluding Remarks
This report demonstrates how the quantification of DNA methylation levels
measured by pyrosequencing on the PFN3A locus can successfully discriminate vaginal
epithelia from samples with as little as 5 ng of input DNA. Moreover we were able to
assess methylation levels when mixtures of body fluids were present and also performed
species-specific studies which showed that DNA from bacteria are not amplified using
the primers designed for PFN3A locus.
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CHAPTER V – VALIDATION OF FORENSIC MARKERS BY PYROSEQUENCING
AND SNAPSHOT
This chapter contains two validation studies performed with the purpose of
determining the feasibility of two methods and several loci to be used in forensic sciences
to determine body fluid of origin based on DNA methylation levels.
The first article focuses on the use of pyrosequencing to validate the loci
ZC3H12D, BCAS4 and cg06379435 for samples that represent mock crime scene
samples, according to the SWGDAM guidelines. I collaborated in this study by
evaluating the stability of methylation in samples stored for several years at room
temperature.
The second study uses SNaPshot methodology to determine methylation levels on
7 CpGs. The study was a collaboration exercise designed and led by Yonsei University
College of Medicine in South Korea to evaluate whether the same set of results would be
obtained when using SNaPshot in a set of samples prepared by the leading laboratory. I
collaborated in this study by preparing and running the samples sent by the leading
laboratory, followed by data analysis and reporting of results to be included in the
manuscript.
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A. Developmental Validation Studies of Epigenetic DNA Methylation markers for the
detection of Blood, Semen and Saliva samples
Elsevier® kindly provided copyright permission to use material contained in the
following publication as part of this portion of my dissertation: Silva DSBS, Antunes J,
Balamurugan K, Duncan G, Alho CS, McCord B. (2016) Developmental validation
studies of epigenetic DNA methylation markers for the detection of blood, semen and
saliva samples. Forensic Science International: Genetics, 23:55-63

A.1 Abstract
Determining the type and origin of body fluids in a forensic investigation can
provide important assistance in reconstructing crime scenes. A set of epigenetic markers,
ZC3H12D, BCAS4 and cg06379435, have been developed to produce unique and
specific patterns of DNA methylation that can be used to identify semen, saliva, and
blood, respectively. To ensure the efficacy of these markers, developmental validation
studies were performed to determine the conditions and limitations of this new tool for
forensic analysis. DNA was extracted from human samples and bisulfite modified using
commercial bisulfite modification kits. Specific primers were used to amplify the region
of interest and the methylation profile of the CpG sites were determined by
pyrosequencing. The percent methylation values at each CpG site were determined in
multiple samples and averaged for each tissue type. The versatility of these new markers
is presented by showing the results of validation studies on sensitivity, human specificity,
stability and mixture resolution. When testing the markers using different organisms, we
did obtain positive results for certain non-human primate samples, however, all other
tested species were negative. The lowest concentration consistently detected varied from
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0.1 to 10ng, depending on the locus, indicating the importance of primer design and
sequence in the assay. The method also proved to be effective when inhibitors were
present in the samples or when samples were degraded by heat. Simulated case- samples
were also tested. In the case of mixtures of different cell types, the overall methylation
values varied in a consistent and predictable manner when multiple cell types were
present in the same sample. Overall, the validation studies demonstrate the robustness
and effectiveness of this new tool for body fluid identification.

A.2 Introduction
Body fluids recovered from crime scenes are considered among the most
important types of evidence in forensic cases. They contain DNA evidence that may
identify a suspect or victim and exonerate an innocent person. Moreover, determining the
type and origin of a biological material can help reconstruct crime scenes (119, 175, 177).
Identifying body fluids can be a critical factor in criminal investigations as the presence
of skin cells may indicate innocent transfers of DNA while blood or other body fluids can
indicate that a criminal act has taken place. However, many times it can be difficult to
identify a forensic stain because of its similarities with other fluids or substances.
Additionally, when trace levels of body fluids are present, visualization may be
impossible and serological tests can fail to produce a result (119). Recent efforts in
researching new assays to identify body fluids have focused on epigenetic DNA based
markers. While RNA and protein markers may be used for body fluid identification,
DNA methylation presents the ideal methodology since it provides quantitative results, is
less prone to variations in expression, and has greater long term stability (140, 147). In
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addition, as the extracted DNA target is already present in the laboratory, only minor
sample processing is needed. This is important, since in many cases the forensic sample
available for analysis is limited. DNA methylation is an epigenetic modification that is
involved in transcriptional regulation. A typical mammalian genome has approximately 3
billion base pairs, with a G/C content of about 40%. Methylated cytosines typically occur
as CpG dinucleotides and the presence of a methyl group at the C-5 position of the
molecule tends to reduce gene expression. The CpG dinucleotide distribution is uneven,
with several short DNA elements having a much higher density of CpG dinucleotides
than other regions of the genome, forming so-called CpG islands. Most of these islands
are located near transcription start sites. The methylated form, 5-methylcytosine (5-mC)
correlates with cytosine in the same way that thymine correlates with uracil, with no
effect on the base pairing (147, 178, 179). Although much is still to be understood about
the mechanisms by which methylation affects gene expression, it is known that
methylation is important in cell differentiation, and genomic loci are differentially
methylated between tissues. Because of this, differentiation of methylation patterns can
provide the basis of an assay for body fluid identification.
The most common body fluids found at crime scenes are blood, semen and saliva. A set
of epigenetic markers have been developed, ZC3H12D, BCAS4, and cg06379435, which
produce unique and specific patterns of DNA methylation that can be used to identify
semen, saliva and blood, respectively (156, 176). The process involves bisulfite
modification, followed by amplification by the polymerase chain reaction (PCR), and
pyrosequencing. The results permit quantitative determination of methylation patterns at
each locus for each body fluid type. The data demonstrate the applicability of epigenetic
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markers as an assay for trace body fluid identification. However, to ensure the efficiency
of these epigenetic markers, developmental validation studies need to be performed to
determine the conditions and limitations of this new tool for forensic analysis.

A.3 Materials and Methods
Sample collection
Biological samples (semen, blood and saliva) were obtained from volunteer
donors. Buccal cells were collected using cotton swabs. Blood was obtained by finger
pricking and blood cells were collected using cotton swabs. Male volunteers were given a
specimen jar and requested to donate a semen sample. All participants signed informed
consent statements prior to sample collection. All samples were collected after obtaining
appropriate Institutional Review Board approvals from Florida International University
(IRB-13-0555), The University of Southern Mississippi (protocol #12010303) and
Pontifícia Universidade Católica do Rio Grande do Sul (CONEP #723.619/CEP
#845.747).

DNA extraction and modification
DNA extraction was performed using the BioRobot1 EZ1 automated purification
workstation (Qiagen, CA) and the EZ1 DNA Investigator kit according to manufacturer’s
protocol. DNA was recovered in a final volume of 50 ml and quantified using
PicoGreen1 fluorescence (Life Technologies, CA) (156). Because standard PCR
amplification does not preserve DNA methylation sites, genomic DNA extracts were
treated with sodium bisulfite in order to convert unmethylated cytosines to uracil using
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the EpiTect® Fast DNA Bisulfite Kit (Qiagen Inc, CA). For all tests conducted in this
research, except for the sensitivity test, the standard manufacturer’s protocol for the
conversion of around 400 ng DNA in a maximum volume of 40 ml was used. In this
method the converted uracils are then replaced by thymine during the PCR amplification
process. The bisulfite modified DNA was amplified by site-specific PCR primers
designed to amplify the bisulfite modified target region.

Markers
As previously described, a set of epigenetic markers, ZC3H12D, BCAS4, and
cg06379435 have been developed to produce unique and specific patterns of DNA
methylation that can be used to identify semen, saliva, and blood, respectively. Markers
ZC3H12D and BCAS4 were described by Madi et al. (156) and both targeted 5CpG sites
in the sequence to be analyzed. Marker cg06379435 was described by Park et al. (176)
and targeted only one CpG site. We have investigated this locus and added 4 additional
CpG sites around the cg06379435 site. BCAS4 and cg06379435 PyroMark® CpG assays
were custom designed in house using the Pyromark® assay design software (Qiagen). A
predesigned ZC3H12D PyroMark® CpG assay was available from the Qiagen
GeneGlobe Web Portal (Table 5.1). The reverse primers were biotin labeled allowing for
the production of biotinylated PCR products necessary for the pyrosequencing reaction
(156).
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PCR and pyrosequencing reactions
Singleplex PCR reactions were performed using the PyroMark® PCR Kit
(Qiagen) in a GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA). For
all samples, 1.2 ml of modified DNA template was added to the PCR mixture in a total
reaction volume of 15 ml. The complete PCR protocol outlined by the manufacturer was
followed (Qiagen). Pyrosequencing was performed following completion of the PCR
reactions using a Pyromark® Q24 pyrosequencer (Qiagen) following the protocols
recommended by the manufacturer. Once the pyrosequencing was complete, the percent
methylation was calculated automatically by the Pyromark® Q24 software and was
displayed as a pyrogram (156).

Validation studies
We tested 15 samples of each cell type (blood, saliva and semen) to be used in
these studies. The pyrosequencing data generated for each marker was analyzed and
compared to other samples in the validation studies performed to ensure they do not
differ statistically.

Body fluid specificity
The specificity of the markers was previously tested against blood, semen and
saliva (156, 176). In this study we tested the performance of the markers against 3
samples of each: menstrual blood vaginal epithelia and nasal epithelia/secretion.
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Table 5.1. Panel of markers used in this study.
Marker

BCAS4

cg06379435a

PCR and sequencing primers
Forward primerAGTGGGTGAGGTTGTGAAATGT
Reverse primerCCCATCCTACTAAAACATCTAA
TT
Sequencing primerAGTTTTTTGGTGAAGTTTAT
Forward primerAGTAGAGGTGGGGGTTAATAAT
T
Reverse primerACCACACAACAAAACAACTATC
TC
Sequencing primerGTTAGGAAAGAAAAATGTAATT
TA
Proprietaryb

CpG sites to be analyzed
in the nucleotide
dispensation order
(underlined)
TATCGTATCGAGAGAG
ATCGAGATCGTATATC
GTATAGATCGTCGAT

TCGGGATAATCGGTGG
AATTTTAGGCGTGGGA
CGGTTGTCGGA

TCGTCGAGTATCGTCG
TCG
a
TargetID is a unique ID in the Illumina Human Methylation 450K bead array; 4th CpG
site in the sequence provided is the target in Park et al (176).
b
Primer sequences are proprietary (Qiagen Inc.) and not available.
ZC3H12D

Species specificity
Species specificity studies were performed with non-human DNA samples of dog,
cat, mouse, chicken, bovine, equine, pig, mouse, chimpanzee, orangutan, gorilla and a
microbial pool (Escherichia coli, Staphylococcus aureus, Enterococcus faecali and
Pseudomonas aeruginosa). A human blood sample was used as positive control.
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Sensitivity studies
According to the SWGDAM guidelines (108) it is important to evaluate the limits
of DNA quantities to be used in the reaction in order to obtain reliable results. Madi et al.
(156) processed a saliva sample five separate times and, for each replicate, the amount of
DNA subjected to bisulfite modification was varied (385, 100, 50, 10 and 5 ng). The
samples were amplified with the ZC3H12D PyroMark® CpG Assay. All replicates
showed no significant differences in the methylation levels observed at each CpG site.
Park et al. (176) tested marker cg06379435 and were able to obtain successful
pyrosequencing results when using 500–10 ng of premodified DNA. However, when
working with forensic samples, it is important to test the assay for its sensitivity limits
and to examine the lowest levels of DNA possible while maintaining reliability in the
results. For this validation study we therefore decided to test the following DNA
quantities: 10, 5 and 1 ng. Three distinct samples for each body fluid were processed for
each DNA amount tested.

Stability studies and case-type samples
Forensic samples are often exposed to environmental and chemical insults, and
may contain impurities, which can act as PCR inhibitors. In this study, we simulated
casework samples to evaluate the robustness and stability of the markers. To assess the
effect of the inhibitors on PCR, we tested 2 different solutions: hematin (100 mM in 0.1
N sodium hydroxide) and humic acid (1 mg/ml in water). From these stock solutions, we
prepared subsequent dilutions in water in a final concentration of 0.08 mM (hematin) and
0.24 mg/ml (humic acid) (180). Aliquots of 2 ml of the inhibitors were added before or
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after bisulfite conversion. For this study, we tested three distinct samples for each body
fluid. To test the stability of the markers under degraded conditions, samples with
genomic DNA extracts were heated in deionized water at 95 ºC for 10, 15, 20, and 25
min to simulate natural DNA fragmentation (180). For this study, we tested three distinct
samples for each body fluid. Also, DNA from the following simulated case-type samples
was extracted and evaluated for all tested markers:
i)

200 ml of blood in 100% cotton fabric

ii)

200 ml of semen in 100% cotton fabric

iii)

Saliva swab of lid of a coffee drink

Mixture studies
DNA mixtures were prepared in order to determine if there are differences in
methylation values when multiple cell types were present in the same sample. DNA from
blood, saliva and semen were tested in different ratios of mixtures:
i)

Blood + saliva: ratios of 75% blood: 25% saliva—50% blood: 50% saliva—
25% blood: 75% saliva

ii)

Blood + semen: ratios of 75% blood: 25% semen—50% blood: 50% semen—
25% blood: 75% semen

iii)

Saliva + semen: ratios of 75% saliva: 25% semen—50% saliva: 50% semen—
25% saliva: 75% semen

iv)

Blood + saliva + semen: ratios of 75% blood: 12.5% saliva: 12.5% semen—
50% blood: 25% saliva: 25% semen—75% saliva: 12.5% blood: 12.5%
semen—50% saliva: 25% blood: 25% semen—75% semen: 12.5% blood:
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12.5% saliva—50% semen: 25% blood: 25% saliva In addition to these
mixtures, each sample was analyzed individually as a positive control.

Reproducibility
This study was performed by testing 24 samples (saliva n = 8, blood n = 8, semen
n = 8). The pyrosequencing data generated by our laboratory (Florida International
University) and an independent laboratory (University of Southern Mississippi) was
analyzed and compared to assess the reliability and the production of concordant results
between different laboratories (181).

Data analysis
The CpG sites were examined and, for each marker, the methylation values were
averaged and listed for each cell type along with standard deviations. Using a one-way
ANOVA, the methylation values were compared across CpG sites of each marker
between controls and other samples to determine if they differed significantly. A t-test
was used to compare results obtained by the two different laboratories in the
reproducibility study. A p-value of <0.05 was assumed as significant for all tests
conducted.
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A.4 Results and Discussion
Control samples
A set of 15 samples of each cell type (blood, saliva and semen) were analyzed and
methylation profiles of each locus were obtained to be used as controls. Table 5.2
presents the pyrosequencing data generated for each marker.

Table 5.2. Methylation profiles of the three loci investigated in this study.
Body
Marker
Fluid
CpG (Mean % Methylation ± SD)
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
Semen
5.4±4.0
5.3±3.9
6.7±4.3
6.3±4.0
5.1±3.7
ZC3H12D
14
13
15
14
13
Specific for *Threshold
semen
Blood
94±1.6
94±2.7
100±0.0
97±7.9
86±3.5
Saliva
81±4.1
78±4.5
99±2.1
79±4.9
82±3.4
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
Blood
24±7.8
22±6.7
33±7.4
30±8.2
49 ±12
cg06379435
*Threshold
8.2
8.4
18
14
25
Specific for
3.13±1.
blood
Semen
3.4±1.7
2.4±1.8
2.7±1.1
1.8±1.3
2
Saliva
8.7±7.0
2.6±1.4
6.0±3.9
3.5±2.6 7.7±4.7
CpG1
CpG4
CpG5
CpG6
CpG7
Saliva
64±7.1
27±5.6
16±4.5
45±6.7
11±2.7
BCAS4
49
16
7.2
31
6.1
Specific for *Threshold
saliva
Blood
6.1±1.4
3.2±2.8
2.7±1.3
6.4±1.9 2.4±1.6
Semen
3.9±1.6
2.5±1.1
3.0±1.1
5.6±1.6 2.3±0.9
*Each CpG site from each marker is given a specific threshold value due to the fact that
each CpG has its unique level of methylation. A threshold value is assigned as the
average methylation level ± 2 S.D depending on whether hypo or hyper methylation is
present (182).
Body fluid specificity
Besides previously testing the performance of the markers against blood, semen and
saliva, we also tested the markers against menstrual blood, vaginal epithelia and nasal
epithelia/secretion (Table 5.3). Most of the CpG sites presented significant differences in
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the methylation levels when compared with the different types of fluids. For marker
BCAS4, the methylation level of CpG5 did not significantly differ when saliva samples
were compared to vaginal epithelia samples (p > 0.05). For marker cg06379435, the
methylation level of CpG2 did not significantly differ when blood samples were
compared to menstrual blood samples (p > 0.05). However, all CpGs within each marker
must be evaluated to obtain an indication of the body fluid present. Our results show that
the majority of CpGs within each marker presents different mean methylation levels
between the target body fluid and all other body fluids tested (Table 5.3).
In this study, we calculated the threshold as ±2 SD from the average methylation
percent for each CpG, according to what has been published in terms of DNA
methylation and threshold calculation (182). However, in our study multiple CpG sites
are available at each locus for each body fluid; therefore we suggest that the user can
adjust the threshold levels to ±1 SD, making the test more discriminatory.
At present, in order to have a conclusive result for the identification of a body fluid, all
CpG sites of a marker should reach the threshold value; otherwise the test should be
indicated as inconclusive.
This study represents the first validation for the use of DNA methylation patterns in
specific genome locations for body fluid discrimination. In order to achieve a higher
discriminatory power for a wider range of body fluids, additional genome locations need
to be determined using array technology and NGS and validated using pyrosequencing.
With the advancements in next-generation sequencing we estimate that the number of
research studies addressing this issue for forensic purposes will increase.
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Table 5.3. Methylation profiles of the three investigated loci when testing menstrual
blood, vaginal epithelia and nasal epithelia/secretion samples. Comparison with
methylation levels of the three main fluids investigated in this study.
Marker
Body Fluid
CpG (Mean % Methylation ± SD)
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
Semen
5.4±4.0
5.3±3.9
6.7±4.3
6.3±4.0
5.1±3.7
Blood
94±1.6
94±2.7
100±0.0
97±7.9
86±3.5
ZC3H12D
Saliva
81±4.1
78±4.5
99±2.1
79±4.9
82±3.4
Specific for
Menstrual
80±4.7
79±6.2
98±2.9
77±12
74.3±3.5
semen
Blood
Nasal Epithelia 83±6.4
83±6.8
99±1.2
78±11
77.0±6.9
Vaginal
77±9.7
77±10.0
97±2.5
73±10
80.0±4.0
Epithelia
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
Semen
3.4±1.7
2.4±1.8
2.7±1.1
1.8±1.3 3.13±1.2
Blood
24±7.8
22±6.7
33±7.4
30±8.2
49±12.2
cg06379435
Saliva
8.7±7.0
2.6±1.4
6.0±3.9
3.5±2.6
7.7±4.7
Specific for
Menstrual
10±12
12±19a
12±18
8.0±12
23±30
blood
Blood
Nasal Epithelia 5.7±5.5
5±6.9
9.7±11
7.7±11
18±22
Vaginal
2.3±0.6
1.3±0.6
3.0±1.0
2.0±1.0
8.3±7.8
Epithelia
CpG1
CpG4
CpG5
CpG6
CpG7
Semen
3.9±1.6
2.5±1.1
3.0±1.1
5.6±1.6
2.3±0.9
Blood
6.1±1.4
3.2±2.8
2.7±1.3
6.4±1.9
2.4±1.6
BCAS4
Saliva
64±7.1
27±5.6
16±4.5
44±6.7
11±2.7
Specific for
Menstrual
35±8.5
15±4.6
11±3.1
27±5.5
8.0±1.0
saliva
Blood
Nasal Epithelia 39±20.5
12±8.0
9±3.6
33±20
6.7±3.5
Vaginal
36±16.7
13±7.5
11±4.9b
30±11
6.7±3.2
Epithelia
a
The methylation level of CpG2 did not significantly differ when menstrual blood
samples were compared to blood samples (p>0.05).
b
The methylation level of CpG5 did not significantly differ when vaginal epithelia
samples were compared to saliva samples (p>0.05).
Species specificity
Several non-human DNA samples were tested to assess the specificity of the
markers. Non-human primate samples amplified the target regions but not all showed
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pyrosequencing results. For marker cg0679435, an error occurred as the surrounding
reference sequence was not recognized in all primate samples tested. Also, the orangutan
sample did not sequence for marker ZC3H12D. All other primate samples presented
pyrograms similar to those obtained when testing a human sample. These results are
expected since there is a close evolutionary relationship between these animals and
humans (181). In contrast, the other species used in this validation study, which are more
evolutionarily distant to humans, failed to show any results. The specificity results
obtained here are sufficient to enable the application of these markers in forensic
casework.

Sensitivity studies
The sensitivity was assessed to determine the minimum quantity of DNA with
which accurate and reliable results could be obtained. For markers BCAS4 and
cg06379435, we were able to obtain successful pyrosequencing results when using 10 ng
of pre-bisulfate modified DNA. When the samples were amplified for the ZC3H12D
marker, good results were obtained using 1 ng of pre-modified DNA. When the input premodified DNA was lowered to 0.1 ng, good quality methylation profiles were obtained
(Table 5.4). All low template samples for the three markers were compared with the
control samples and no significant differences were found. For most of the samples
tested, the amplification with the markers BCAS4 and cg06379435 was a success, and we
were able to see bands with the correct size on a 2% agarose gel. However, after
pyrosequencing, the percent methylation of samples with DNA inputs lower than 10 ng
differed from the values presented by the control samples. When working with bisulfite-
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treated DNA, this so-called PCR-bias is often observed in the amplification step. When
using low amounts of DNA, a more efficient amplification can occur with unmethylated
alleles when compared to those which are methylated.

Table 5.4. Methylation profiles of the three investigated loci when using low amounts of
pre-modified DNA.
Marker
Samples
CpG (Mean % Methylation + SD)
ZC3H12D
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
marker for Semen control
5.4±4.0 5.3±3.9 6.7±4.3 6.3±4.0 5.1±3.7
semen
samplesa
Semen samples
4.7±4.0 4.7±3.8 4.3±3.5 3.7±2.1 3.0±4.4
(DNA input=0.1ng)
cg06379435
CpG 1
CpG 2
CpG 3
CpG 4
CpG 5
marker for Blood control
23.8±7.8 21.8±6.7 33.2±7.4 30.4±8.2 49 ±12
blood
samplesa
Blood samples
23±8.7
22±10 26.3±8.3 23±9.5 36.3±7.5
(DNA input=10ng)
BCAS4
CpG1
CpG4
CpG5
CpG6
CpG7
marker for Saliva control
63.6±7.1 27.5±5.6 16.3±4.5 44.5±6.7 11.5±2.7
saliva
samplesa
Saliva samples
65.7±6.0 29.3±4.9 16.0±1.0 44.0±9.5 10.3±6.5
(DNA input=10ng)
a
DNA input of control samples ranged from 100 to 500 ng.

Alternatively, in some cases, an inverse bias can occur with a deviation toward the
methylated alleles (183). With regard to the samples amplified with the ZC3H12D
marker, it was possible to keep the consistency in the results even when using low DNA
templates. According to Moskalev et al. (183) the primer design of some markers may
lead to a more unbiased amplification of bisulfite-treated DNA. However we cannot
prove this assumption for the ZC3H12D PyroMark® CpG assay, since its sequence is
proprietary and not provided by the manufacturer of the assay (Qiagen, CA).
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Stability study and case-type samples

Figure 5.1. Mean methylation levels of samples in which PCR inhibitors were added
before bisulfite modification. There were no significant differences between the
control and the tested samples. A) Marker ZC3H12D: saliva samples. B) Marker
ZC3H12D: blood samples. C) Marker ZC3H12D: semen samples. D) Marker
cg06379435: saliva samples. E) Marker cg06379435: blood samples. F) Marker
cg06379435: semen samples. G) Marker BCAS4: saliva samples. H) Marker BCAS4:
blood samples. I) Marker BCAS4: semen samples.
When dealing with forensic casework samples, it is common to encounter
degraded and contaminated samples. Therefore, we have investigated the effects of PCR
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inhibitors on the methylation levels. The final inhibitor concentrations tested were:
hematin (0.08 mM) and humic acid (0.24 mg/ml).
We could observe that when these inhibitors were added prior to bisulfite
modification, all samples were amplified and there was no significant difference between
the methylation values of the control and the other tested samples (Figure 5.1). However,
when inhibitors were added after bisulfite modification, the amplification process failed
and the pyrosequencing results were similar to those obtained when testing a no template
control (water).
According to the data provided by the manufacturer (Qiagen, CA), the bisulfite
modification kit provides bisulfite conversion as well as cleanup of the modified DNA
for subsequent methylation analysis. The cleanup step is likely the reason that PCR
inhibitors had no discernable effect on the PCR amplification that followed bisulfite
modification. When testing the stability of the markers under degraded conditions, we
noticed that all primers were still able to amplify the target sequence. There were no
significant differences in the methylation values for the degraded samples versus intact
DNA (positive control) (Figure 5.2). Also, all three simulated case-type samples were
successfully modified, amplified and pyrosequenced. Table 5.5 presents the
pyrosequencing data obtained for each tested sample.
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Figure 5.2. Mean methylation levels of samples degraded by heat with different time
points. There were no significant differences between the control and the degraded
samples. A) Marker ZC3H12D: saliva samples. B) Marker ZC3H12D: blood samples. C)
Marker ZC3H12D: semen samples. D) Marker cg06379435: saliva samples. E) Marker
cg06379435: blood samples. F) Marker cg06379435: semen samples. G) Marker
BCAS4: saliva samples. H) Marker BCAS4: blood samples. I) Marker BCAS4: semen
samples.
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Table 5.5. Methylation levels of simulated case-type samples.
Marker
Samples
CpG (% Methylation)
CpG1 CpG2 CpG3 CpG4 CpG5
200 µl of semen in 100%
15
10
16
14
13
ZC3H12D cotton fabric
marker for 200 ul of blood in 100%
93
96
100
99
85
semen
cotton fabric
Saliva swab of lid of a coffee
72
73
100
79
85
drink
CpG1 CpG2 CpG3 CpG4 CpG5
200 µl of semen in 100%
10
7
9
5
15
cg06379435 cotton fabric
marker for 200 µl of blood in 100%
23
20
36
33
49
blood
cotton fabric
Saliva swab of lid of a coffee
5
6
10
7
17
drink
CpG1 CpG4 CpG5 CpG6 CpG7
200
µl
of
semen
in
100%
BCAS4
5
5
5
11
3
marker for cotton fabric
200 µl of blood in 100%
semen
6
7
6
7
6
cotton fabric
Saliva swab of lid of a coffee
50
19
17
70
24
drink

Mixtures
Determining the presence of a mixture is considered a difficult task, even in a
case of human identification using short tandem repeats. To determine which body fluids
are present in a mixture containing multiple tissue sources is even more arduous. In this
study, we prepared different ratios of DNA mixtures to analyze if there were differences
in the methylation values when multiple cell types are present in the same sample. For all
markers, regardless of whether a mix of two or three body fluids are present (semen,
blood and saliva) in one sample, it is possible to recognize that a mixture is present. The
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methylation levels for mixtures show intermediate percentages when com-pared to pure
samples (Figure 5.3).
In this study, with the analysis of a single specific marker for a particular body
fluid, we were not able to perform complete mixture deconvolution. Additional genome
locations will need to be identified and analyzed in order to fully deconvolute this data,
however our results demonstrate that mixtures can be detected for sample discrimination.
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Figure 5.3. Mean methylation levels of different ratios of DNA mixtures. A) Marker
ZC3H12D: semen + blood+ saliva. B) Marker ZC3H12D: semen + blood. C) Marker
ZC3H12D: semen + saliva. D) Marker cg06379435: blood + saliva+ semen. E) Marker
cg06379435: blood + saliva. F) Marker cg06379435: blood + semen. G) Marker BCAS4:
saliva + blood+ semen. H) Marker BCAS4: saliva + blood. I) Marker BCAS4: saliva +
semen.
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Reproducibility
A concordance study was performed in two independent laboratories by operators
with different experience levels. No significant difference was found when we compared
the methylation values for each CpG site obtained by both laboratories (t test, p > 0.05)
(Figure 5.4).

Figure 5.4. Comparison between pyrosequencing data generated by two independent
laboratories: Laboratory 1 (Florida International University) and Laboratory 2
(University of Southern Mississippi). A) Methylation data of marker BCAS4 (saliva
samples n=8). B) Methylation data of marker cg06379435 (blood samples n=8). C)
Methylation data of marker ZC3H12D (semen samples n=8).
A.5 Conclusion
Body fluids recovered from crime scenes can provide crucial information for an
investigation, particularly in situations where the presence of a suspects DNA may not in
dispute, such as sexual assault and other types of violent crime. Epigenetic markers
permit the identification of these biological fluids from trace levels of extracted DNA
making them a powerful investigative tool. The validation studies presented here
demonstrate robustness and reliability of the tested markers. We present results
demonstrating, sensitivity, species specificity, resistance to degradation and the effect of
mixtures. Our results demonstrate the capability of these new epigenetic markers in the
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determination of trace levels of body fluids. They provide the community with specific
and sensitive epigenetic methods that can add important information to the trier of fact in
forensic analysis.

B. A Collaborative Exercise on DNA Methylation-based Body Fluid Typing
This is the pre-peer reviewed version of the following article:
Jung, S.-E., Cho, S., Antunes, J., Gomes, I., Uchimoto, M. L., Oh, Y. N., Di Giacomo, L.,
Schneider, P. M., Park, M. S., van der Meer, D., Williams, G., McCord, B., Ahn, H.-J.,
Choi, D. H., Lee, Y. H., Lee, S. D. and Lee, H. Y. (2016), A collaborative exercise on
DNA methylation based body fluid typing. Electrophoresis, 37: 2759–2766, which has
been published in final form at
http://onlinelibrary.wiley.com/doi/10.1002/elps.201600256/full/.
®Copyright WileyVCH Verlag GmbH & Co. KGaA.
Reproduced with permission.
B.1 Abstract
A collaborative exercise on DNA methylation-based body fluid identification was
conducted by 7 laboratories. For this project, a multiplex methylation SNaPshot reaction
composed of 7 CpG markers was used for the identification of blood, saliva, semen,
menstrual blood and vaginal fluid. A total of 30 specimens were prepared and distributed
to participating laboratories after thorough testing. Required experiments included tasks
divided into 4 parts of increasing complexity ranging from capillary electrophoresis of
purified single-base extension reaction product, multiplex PCR of bisulfite-modified
DNA, bisulfite conversion of genomic DNA and extraction of genomic DNA from body
fluid samples. In steps dealing with bisulfite converted DNA, genomic DNA and body
fluid samples, one or more mixtures were included, and specimens of indicated or
unnamed body fluid sources were used. All of the laboratories, except one that failed to
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set up appropriate condition for the capillary analysis of reference single-base extension
products, generated consistent body fluid typing results for specimens of bisulfite
converted DNA and genomic DNA. This result supports the successful incorporation of
DNA methylation-based body fluid identification method to forensic laboratory
workflow. Variation in the values obtained for DNA methylation between laboratories
increases with the complexity of the required experiments, but all laboratories coincided
in the interpretation of produced DNA methylation profiles. Although a test for overall
sensitivity and the establishment of interpretational guidelines on DNA methylationbased body fluid identification remain to be performed, this study adds to the support for
the possibility of successful application of DNA methylation profiling to forensic body
fluid typing.

B.2 Introduction
Body fluid identification can be of significant importance in solving crimes by
assisting the triers of fact in the determination of potential scenarios that may have led to
the deposition of evidentiary material (119). Recently, molecular approaches that permit
the detection of specific messenger RNA (mRNA) and micro RNA (miRNA) expression
as well as differential DNA methylation patterns have been intensively investigated
(184). Among these, the mRNA-based detection methods have been the most scrutinized,
and performance in terms of reproducibility and sensitivity has been well evaluated
through a series of large collaborative exercises (127, 184-189).
DNA methylation-based body fluid identification has many advantages when
compared to mRNA-based methods, such as higher specificity, the ability to be
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incorporated into current forensic DNA-based testing protocols, and the applicability to
old cases where only DNA extracts are available (136). Many CpG markers have been
identified which produce differential DNA methylation patterns when extracted DNA
from body fluids are compared using genome-wide profiling and gene-specific analysis
(147, 156, 166, 175, 176, 190). Three recent publications (166, 176, 190)are particularly
notable for reporting a set of CpG markers that show a methylation signal only in the
target body fluids, which can be beneficial to mixed sample analysis. In particular, two
earlier studies (166, 176) reported two markers in common; cg17610929, suggested to
distinguish semen and cg06379435, for blood. Moreover, further analysis of array data
from the two studies revealed that they reported a third blood-specific marker in both
studies, cg08792630. Because the identification and use of semen-specific CpG markers
is not a problem because of the significant difference in DNA methylation between
somatic cells and germ cells, further validation studies of CpGs specific to other body
fluids, such as vaginal fluid, menstrual blood, saliva etc., would be needed for better
application of DNA methylation analysis in forensic caseworks. To detect DNA
methylation levels at multiple CpG sites simultaneously, methylation-sensitive restriction
enzyme-PCR (MSRE-PCR) and the methylation-sensitive single nucleotide primer
extension (SNuPE)-based approach, generally called methylation SNaPshot, have been
utilized (166, 175, 190). In comparison to MSRE-PCR, methylation SNaPshot reactions
provide better resolution, and have been adopted in more recent studies (146, 166, 190).
The present collaborative exercise was organized by Yonsei University College of
Medicine in order to evaluate the robustness and reproducibility of DNA methylation
profiling for body fluid identification in seven forensic laboratories using kits and

129

chemistries of their own choice and using their own instrumentation. The multiplex
methylation SNaPshot reaction used by the collaborative laboratories described in (166)
was modified to include seven CpG markers that show a methylation signal only in the
target body fluids. Since the participating laboratories had varying levels of experience,
especially with DNA methylation profiling using bisulfite conversion and with the
SNaPshot reaction, the goal was to implement the method and compare the
interpretational results of DNA methylation profiling from the various laboratories.

B.3 Materials and Methods
Samples and materials provided
The exercise was divided into four parts such that participants could easily check
the success of experiments performed after each step of the consecutive procedures
(Table 5.6). Parts 1 involved the capillary electrophoresis of purified single-base
extension (SBE) reaction products, part 2 involved multiplex PCR of bisulfite converted
DNA, part 3 involved the bisulfite conversion of genomic DNA and part 4 involved the
DNA extraction of body fluid samples.
As such, the complexity of the required experiments increased as the participants
proceeded through each part. Specimens, including blood, saliva, semen, vaginal fluid,
and menstrual blood, were collected from seven healthy volunteers using procedures
approved by the Institutional Review Board of Severance Hospital, Yonsei University in
Seoul, Korea.
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Table 5.6 - Overview of the samples and experiments required in each part of
collaborative exercise
Part
Samples
Required experiments
a
Purified SBE(single-base extension
reaction) productb
1
Capillary electrophoresis
6 samples : for each cell typec, single
source samples, cell type indicated
Bisulfite converted DNAd
5 samples : for each cell typec, single
source samples, cell type indicated
Multiplex PCR, Multiplex
2
2 samples : single source samples,
SBE,
unspecified cell type
Capillary electrophoresis
1 sample : mixture of two body fluids,
unspecified cell type
Genomic DNAe
5 samples : for each cell typec, single
Bisulfite conversion,
source samples, cell type indicated
Multiplex PCR, Multiplex
3
2 samples : single source samples,
SBE, Capillary
unspecified cell type
electrophoresis
1 sample : mixture of two body fluids,
unspecified cell type
Body fluid swabs
4 samples : for each cell typef, single
DNA extraction, DNA
source samples, cell type indicated
quantification,
1 sample : mixture of two body fluids,
Bisulfite conversion,
4
cell type indicated
Multiplex PCR, Multiplex
2 samples : single source samples,
SBE, Capillary
unspecified cell type
electrophoresis
1 sample : mixture of body fluids,
unspecified cell type
a
Purified with SAP-Recombinant enzyme
b
Multiplex SBE reaction product
c
Semen, blood, vaginal fluid, menstrual blood and saliva
d
Bisulfite converted DNA using the Sigma’s Imprint® DNA modification kit
e
Genomic DNA extracted using the Qiagen’s QIAamp DNA Mini kit and
quantified using the ABI’s Quantifiler® Duo DNA Quantification kit
f
Semen, blood, vaginal fluid and saliva
Blood was collected by venipuncture with a syringe, and 200 µL aliquots from EDTA
containing tubes were stored frozen at -20˚C. Saliva samples were collected with the
Oragene™ DNA self-collection kit (DNA Genotek Inc., Ottawa, Canada), and stored at
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ambient temperature. Freshly ejaculated semen was collected in plastic cups, and 200 µL
aliquots were frozen at -20˚C for storage. Vaginal fluid and menstrual blood were
collected using sterile cotton swabs and allowed to dry at room temperature. The eight
body fluid specimens used in part 4 included four single source samples and one mixture
of indicated origin, and two single source samples and one mixture of unspecified origin.
One hundred and twenty microliter of freshly ejaculated semen and blood were prepared
separately in an eppendorf microfuge tube with indicated origin. A 200 µL of saliva
sample was prepared in the Oragene™ DNA self-collection kit buffer with indicated
origin. Two vaginal swabs and a menstrual blood swab were obtained from a volunteer.
From the two vaginal swabs obtained from a volunteer, one was spiked with 70 µL of
semen and both were provided to the collaborative laboratories with an indication of their
origin. The menstrual blood swab was sent to the collaborative laboratories with
unspecified origin. A semen swab was prepared by dropping 100 µL of semen on a sterile
cotton swab, and was provided to the collaborative laboratories with unspecified origin.
A body fluid mixture swab was prepared by adding 100 µL solution of blood, saliva and
semen mixed in a ratio of 2:1:1.5 on a sterile cotton swab and was provided to the
collaborative laboratories with unspecified origin. Treated swabs were allowed to dry at
room temperature and stored at -80˚C until sent to participating laboratories.
For parts 2 and 3, 100 ng of bisulfite converted DNA and 200 ng of genomic DNA
were prepared for five single source samples with an indicated source of origin, two
single source samples of unspecified origin, and one mixture of unspecified origin. To
prepare mixtures in parts 2 and 3, the same concentration of each bisulfite converted
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DNA (from blood and saliva) or genomic DNA (from semen and vaginal fluid) were
mixed in a ratio of 1:1.
For part 1, the final products from the methylation SNaPshot reaction obtained from
one sample each of semen, blood, vaginal fluid and saliva, and two samples from
menstrual bloods were prepared as reference materials.
All samples and PCR primer mixtures were thoroughly tested prior to shipment and
sent to participating laboratories on dry ice taking from one to four days. When
requested, additional reagents such as SNaPshot kit (Applied Biosystems, Foster City,
CA, USA) or enzymes necessary for PCR product purification, SBE reaction and
purification were sent together on dry ice, and the Imprint™ DNA Modification kit
(Sigma-Aldrich, St. Louis, MO, USA) for bisulfite conversion was sent at room
temperature.

DNA extraction, DNA quantification and bisulfite conversion
In the organizing laboratory, samples were subjected to DNA extraction,
quantification and sodium bisulfite treatment. DNA was extracted from each aliquot of
blood, saliva, and semen or from each swab of vaginal fluid and menstrual blood using a
QIAamp® DNA Mini kit (Qiagen, Hilden, Germany) following the manufacturer’s
instructions. Extracted DNA was quantified using a Quantifiler® Duo DNA
Quantification kit (Applied Biosystems), and 200 ng of genomic DNA was bisulfite
converted using the Imprint™ DNA Modification kit and eluted with 20 µL of distilled
water. For preparation of specimens to send to collaborative laboratories, an appropriate
number of genomic DNA and bisulfite converted DNA batches were pooled and
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redistributed into 10 µL aliquots, which contained 20 ng/µL of genomic DNA or
approximately 10 ng/µL of bisulfite converted DNA. The specified genomic DNA input
in bisulfite conversion of part 3 was 100 ng of genomic DNA, but in part 4, the input
amount was not suggested. Example protocols were provided to participating laboratories
as a reference, but the chemistries and instrumentation to be used were left for each
laboratory to decide.

Multiplex methylation SNaPshot
The multiplex methylation SNaPshot reaction described in (166) was modified to
include seven CpG markers that show a methylation signal only in the target body fluids.
For this study, a blood marker, cg01543184, with cross reactivity to semen was replaced
with blood marker cg08792630 (176), and a semen marker cg17621389 with that
produced semen-specific non-methylation was removed. The resultant multiplex included
two CpGs (SE1 and SE2) for semen, two CpGs (BL1 and BL3) for blood, two CpGs
(VF1 and VF2) for vaginal fluid and one CpG (SA1) for saliva; SE1, SE2, BL1, BL3,
VF1, VF2, and SA1 represent cg17610929, cg26763284, cg06379435, cg08792630,
cg09765089-231d, cg26079753-7d, and cg09652652-2d, respectively. The multiplex
PCR was performed in 20 µL reactions containing 1 µL of bisulfite-converted DNA (10
ng), 3 U of AmpliTaq Gold® DNA polymerase, 2 µL of Gold ST*R 10× buffer (Promega,
Madison, WI, USA), and PCR primers (Figure 5.5).
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Figure 5.5 – List of PCR primers used in this study.

PCR cycling was conducted using a Veriti™ Thermal Cycler (Applied Biosystems)
under the following conditions: 95˚C for 11 min; 34 cycles of 94˚C for 20 s, 56˚C for 60
s, and 72˚C for 30 s; and a final extension at 72˚C for 7 min. Then, 5 µL of PCR products
were purified with 1 µL of ExoSAP-IT (USB, Cleveland, OH, USA) by incubation at
37˚C for 45 min followed by heat inactivation at 80˚C for 15 min. Multiplex SBE
reaction was performed using 1 µL of purified PCR products, SBE primers (Figure 5.6)
and a SNaPshotTM kit according to the manufacturer’s instructions.
The final extension products were purified with SAP-Recombinant (USB) enzyme. Large
batch of 5× PCR primer and 10× SBE primer stocks were prepared and aliquoted to
provide all laboratories with the same primer mixtures.
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Figure 5.6 – List of SBE primers used in this study
The specified bisulfite converted DNA input for the multiplex PCR of parts 2 and 3 was
10 ng; in part 4, the input amount was not suggested. Example protocols were provided to
participating laboratories, but a choice was given regarding which PCR buffers and
amplicon purification methods were to be used.

Capillary electrophoresis and analysis of DNA methylation profiles
In the organizing laboratory, the extension products were analyzed using the ABI PRISM
3130xl Genetic Analyzer and GeneScan software 3.1 (Applied Biosystems). In
participating laboratories, samples were injected and run according to conditions of
choice on various types of standard genetic analyzers (Tables 5.7 and 5.8).
For the analysis of DNA methylation profiles, participating laboratories were requested to
report peak heights observed from the electropherograms and to calculate percentage
methylation values (0–100%) at each CpG site by dividing nucleotide G intensity
(detection of unconverted methylated cytosine on the reverse strand) by nucleotide G plus
nucleotide A intensity (detection of converted unmethylated cytosine on the reverse
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strand). Then, body fluid typing results were reported in reference to the electrophoretic
results of SBE products in part 1.

Table 5.7 - Summary of the kits, chemicals and instrumentation used in 7 participating
laboratories
DNA extraction
Lab no.
QIAamp DNA Mini kit
1, 2, 5
DNA extraction QIAamp DNA Investigator kit
3
kit
Qiagen Micro kit
4
Qiagen EZ1 DNA Investigator kit
6, 7
Quantifiler® Duo DNA Quantification kit
1, 2, 5
Nanodrop
3
Quantification
Qiagen Human Duo kit
4
method
Qubit 2.0
6
Picogreen
7
Bisulfite conversion
Imprint™ DNA Modification kit
1, 2, 3, 4, 7
Conversion kit
Epitect Fast Bisulfite Conversion kit
5, 6
Multiplex PCR
ABI VERITI
1, 5
®
Thermocycler
GeneAmp PCR System 9700
2, 3, 4, 7
ABI 2720
6
Gold ST*R 10x buffer
1, 2, 3, 4, 7
PCR buffer
AmpliTaq Gold Buffer
5, 6
Taq polymerase
Total PCR
volume
Post-PCR
purification
SBE reaction
Thermocycler
SBE kit
Post-extension
purification

3U of AmpliTaq Gold DNA Polymerase

1, 2, 3, 4, 5, 6, 7

20 ul

1, 2, 3, 4, 5, 6, 7

2 ul/rxn of USB ExoSAP-IT
2-4 ul/rxn of USB ExoSAP-IT
ABI VERITI
GeneAmp® PCR System 9700
ABI 2720
SNaPshot™ kit
1 ul/rxn of USB SAP-Recombinant
2 ul/rxn of USB SAP-Recombinant
1 ul/rxn of USB Fast AP
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1, 3, 4, 5, 6, 7
2
1, 5
2, 3, 4, 7
6
1, 2, 3, 4, 5, 6, 7
1, 2, 3, 5, 7
4
6

Table 5.8 - Summary of settings and instruments used to analyze the SBE products in
the 7 participating laboratories
GeneScan settings
Lab. No
ABI 3130xl
1, 4
Instrument
ABI 3130
2, 3, 6
platform
ABI PRISM 310
5, 7
Genemapper ID v3.2
1, 4, 5, 7
GeneScan
GeneMapper ID-X
2, 6
software
Genemapper ID v3.2.1
3
Size standard
GeneScan 120 LIZ
1, 2, 3, 4, 5, 6, 7
1 ul SBE product in 10 ul Hi-Di
1, 2, 3, 4, 6, 7
formamide
SBE product
1.5 ul SBE product in 9 ul Hi-Di
5
formamide
3 sec
1, 2, 7
5 sec
5
Injection time
10 sec
6
15 sec
3
22 sec
4
480 sec
1
1000 sec
2, 4, 6
Collection time
1200 sec
5
1300 sec
3
1440 sec
7

B.4 Results and Discussion
Participating laboratories
Seven laboratories including the organizing laboratory participated in this
exercise. The participating laboratories varied in experience with regard to DNA
methylation analyses. Two laboratories indicated they were beginners at DNA
methylation testing; two other laboratories, advanced beginners; one laboratory, an
experienced researcher; and two other laboratories, experts. The participating laboratories
were also asked to complete a questionnaire describing the kits, chemicals, quantities and
instrumentation they used (Tables 5.7 and 5.8). The seven laboratories used four different
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kits for DNA extraction, five different quantification methods, two different kits for
bisulfite conversion, two different PCR buffers for multiplex PCR, three different
thermocyclers, three different genetic analyzers and three different analytical software
and five different analytical settings. The diversity of instrumentation and respective
analysis tools emphasizes the importance of such collaborative exercises in order to
evaluate the robustness of implementation of methods in different laboratories.

Exercise tasks: parts 1 to 4
The collaborative exercise started with part 1, where purified SBE products are
analyzed with capillary electrophoresis. Analysis of the final multiplex methylation
SNaPshot products from various body fluid samples provided references to the following
data interpretation and enabled adjustment of the genetic analyzer setting if necessary.
Six of the seven laboratories reported very similar results in part 1 (Figure 5.7).
One laboratory (laboratory 4) had, on average, 4-fold higher peaks than the
organizing laboratory with low non-specific peaks that seemed to be due to the use of
higher injection settings. Because of failure in adjusting the genetic analyzer setting and
unsuccessful enzyme treatment to purify PCR products in the subsequent parts 2–4 at
laboratory 4, the results discussed in this report will only include data from the remaining
six laboratories.
The methylation percentages at each CpG site were similar among the laboratories,
but two laboratories using an ABI PRISM 310 genetic analyzer showed somewhat lower
methylation percentages. In addition, it seems that because two types of menstrual blood
of which one had the same profile as vaginal fluid (menstrual blood type 1) were
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provided as references in part 1, participating laboratories had difficulty in inferring the
sample origin with the profile of vaginal fluid. In this case, some laboratories reported the
origin of the sample to be either vaginal fluid or menstrual blood, while others reported it
to be vaginal fluid or menstrual blood. As such, a distinction between vaginal fluid and
menstrual blood could not be provided for the reports regarding parts 2–4.

Figure 5.7 - DNA methylation profiling results of part 1 conducted with the final
SBE products of the multiplex methylation SNaPshot reaction. DNA methylation was
recorded as a percentage value by dividing nucleotide G intensity by nucleotide G
plus nucleotide A.
In part 2, bisulfite converted genomic DNA of semen, blood, vaginal fluid, menstrual
blood and saliva with known body fluid origin, and three other samples with unspecified
origin of which two were single source and one was a mixture, allowed us to test the
proficiency of the participating laboratories in performing the SNaPshot reaction. Four of
the six laboratories reported methylation signals only at target body fluid-specific CpG
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markers with correct body fluid typing results (Figure 5.8).

Figure 5.8. DNA methylation profiling results of part 2 conducted with bisulfite
converted DNA. Part 2 results show the proficiency of each laboratory in SBE reaction.
(Un) indicates samples provided with unspecified body fluid origin.
Two laboratories reported additional low level methylation signals at SE1, BL1 and
SA1 markers, but these results did not affect correct interpretation of the body fluid
typing results. These signals had low methylation percentages, mostly less than 15%. For
example, the two lowest methylation signals from laboratory 6 were 100 rfu and 94 rfu
corresponding to 6.7% and 8.1% methylation percentages at BL1 and SA1 CpG sites,
respectively. Therefore, all six laboratories properly performed and implemented the
multiplex SNaPshot reactions with 10 ng of bisulfite converted DNA.
For part 3, genomic DNA from semen, blood, vaginal fluid, menstrual blood and
saliva and three genomic DNA samples of unspecified origin were provided to test each
laboratory’s proficiency in bisulfite conversion. The participating laboratories were asked
to treat 100 ng of genomic DNA with a bisulfite conversion kit of choice and to perform
multiplex methylation SNaPshot reactions with a 1/10 portion of the eluted bisulfite
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converted DNA. Two kits were used in bisulfite conversion (Table 5.7), but no
significant difference was observed between the results. As in part 2, the same four
laboratories reported methylation signals only at target body fluid-specific CpG markers
with correct body fluid typing results (Figure 5.9).

Figure 5.9. DNA methylation profiling results of part 3 conducted with genomic DNA.
Part 3 results show the proficiency of each laboratory in bisulfite conversion. (Un)
indicates samples provided with unspecified body fluid origin.
Two laboratories (laboratories 5 and 6) reported sporadic methylation signals at the
BL1 or BL3 markers in semen, menstrual blood and in the mixture of semen and vaginal
fluid. These peaks were generally low in methylation percentage, i.e. less than 15%, and
did not affect the correct interpretation of body fluid typing results. However, the
methylation percentages at each target CpG site showed higher variation among
laboratories in part 3 when comparing to parts 1 and 2. Laboratory 3 reported no signal at
the BL3 marker that was most likely a result of PCR failure at this site; however, it did
not affect the identification of body fluid type. In addition, laboratory 6 reported a high
methylation percentage (35.6%) at the BL1 site in the mixture of semen and vaginal fluid,
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leading to a body fluid typing result of a mixture of semen and menstrual blood. In most
cases, laboratories concurred on the expected interpretation of the results reported among
them with genomic DNA and bisulfite converted DNA. This result suggests that DNA
methylation-based body fluid identification using multiplex methylation SNaPshot and
bisulfite conversion of genomic DNA could be successfully incorporated into forensic
laboratory workflow.
In part 4, various body fluid samples with and without specified origin were
provided. Specimens were subjected to DNA extraction, quantification, bisulfite
conversion and multiplex methylation SNaPshot reaction using various methodologies
according to each laboratory’s preference. Three DNA extraction kits and four
quantification methods were used by the six different laboratories. Sufficient amounts of
DNA were obtained from most of the laboratories, but relatively small yields of DNA
were obtained in one of the laboratories using an automatic DNA extraction system
(laboratory 6). Various amounts of DNA were subjected to bisulfite conversion and 1/10
or 1/20 of the volume of eluted bisulfite converted DNA was amplified in a subsequent
multiplex methylation SNaPshot reaction. The resultant amplified bisulfite converted
DNA varied in amount from 0.8 ng to 20 ng. Of the six laboratories being evaluated, five
laboratories produced acceptable results with the correct body fluid identification. The
sixth laboratory (laboratory 5) failed to obtain electrophoretic results from a few
specimens but produced correct results from the others. The five laboratories reported
methylation signals only at target body fluid-specific CpG markers except for a menstrual
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blood swab with unspecified origin (Figure 5.10).

Figure 5.10. DNA methylation profiling results of part 4 with body fluid samples. Part 4
results show the proficiency of each laboratory in the whole procedure of DNA
methylation-based body fluid typing raging from DNA extraction to capillary
electrophoresis. Methylation percentages in a menstrual blood swab and a mixture swab
of semen, blood and saliva with unspecified origin were presented in consideration of the
possibility of sample switch in laboratory 5. (Un) indicates samples provided with
unspecified body fluid origin.
For this sample, laboratory 6 produced unexpected methylation signals at SE1 and
BL1 CpG markers, and laboratory 7 showed methylation signals at BL1 and BL3 CpG
markers. However, these methylation signals were all less than 10%, and had no adverse
effect on data interpretation since both laboratories reported the specimens to be either
vaginal fluid or menstrual blood. Laboratory 5 did not get body fluid typing results from
three samples with indicated origin. Since certain amounts of DNA were extracted and
quantified from these three samples, failure seems to have occurred in the recovery of
bisulfite converted DNA or in PCR amplification. This laboratory also reported
“inconclusive” for a mixture swab with a methylation signal only at SE1, BL3 and SA1.
However, additional low methylation signals at SE2 and BL1 (~50 rfu) (data not shown)
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suggested the presence of semen, blood and saliva in this sample. In this exercise, the
most experienced laboratories produced better DNA methylation profiles and
interpretation results. However, even the laboratories that varied from less experienced to
beginners in DNA methylation analysis produced successful body fluid typing results,
providing strong evidence for the potential application of DNA methylation profiling for
use in forensic body fluid typing.

B.5 Conclusion
This collaborative exercise aimed to examine the possibility of incorporating
DNA methylation-based body fluid identification methods into forensic workflow. Most
of the participating laboratories reported consistent results for mixtures as well as for
single source samples with the use of their own laboratory equipment and different kits
and chemicals of choice, which demonstrate the usefulness of this application of DNA
methylation profiling in forensic body fluid typing. In this study, we found that certain
laboratories reported low but detectable methylation signals at unexpected CpG sites, and
there were variations in DNA methylation percentages among laboratories. Because these
unexpected methylation signals were frequently at less than 10% methylation and
sometimes lower than 100 rfu, we recommend that in the future an appropriate detection
threshold in terms of rfu and percent of methylation, e.g., more than 100 rfu and 10%
methylation, should be applied. As for the methylation variation, this is not an
unexpected result given that the participating laboratories used a variety of methods and
instrumentation. It is important to note that the seven CpGs used in this multiplex provide
on-off signal variations in results that can alleviate the effect of methylation variation
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among laboratories. Because it is not possible to differentiate vaginal fluid and menstrual
blood with the present multiplex methylation SNaPshot system, the addition of new
menstrual blood-specific CpG markers to the multiplex system is needed for better
identification of body fluids. In addition, with the use of two or more CpG markers for
each target body fluid being preferred, it is evident that there is also a need to identify
more CpGs that are specific to saliva. If possible, the multiplex system should be
supplemented in the future with more CpG markers to have two or more CpGs for each
body fluid and consequently increase the accuracy of the identification of body fluids.
While routine use of DNA methylation-based body fluid typing and identification assays
may yet require further tests for sensitivity and specificity, this study demonstrates that
methylation profiling can be successfully implemented in forensic laboratories once clear
guidelines are set for data interpretation.
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A. Abstract
The goal of this paper was to develop a method for the detection of semen in biological
stains using high resolution melt analysis and DNA methylation. To perform this task we
have utilized an epigenetic locus, which targets a tissue-specific differentially methylated
region for semen (tDMR). This specific locus, ZC3H12D contains methylated CpG sites
that are hypo methylated in semen and hyper methylated in blood and saliva. Using this
procedure, DNA from forensic stains can be isolated, processed using bisulfite modified
PCR and detected by real time PCR with HRM capability. The method described in this
report is robust as we were able to obtain results from samples with as little as 1 ng of
genomic DNA. Samples inhibited by humic acid still produced reliable results.
Furthermore, the procedure is specific and will not amplify non-bisulfite modified DNA.
Because this process can be performed using real time PCR and is quantitative, it fits
nicely within the workflow of current forensic DNA laboratories. As a result it should
prove to be a useful technique for processing trace evidence samples for serological
analysis.

B. Introduction
In cases where the presence of a suspect is expected, determining the type of body
fluid present can make the distinction between innocent and criminal contact and
therefore be a valuable addition to DNA genotyping. The tissue source of a DNA sample
(156, 191)can be determined by analyzing DNA methylation patterns. Several reports
demonstrate the existence of tDMRs (37, 58, 192) and how they can be used as a
powerful tool for body fluid identification (136, 147, 173). Common methodologies for
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DNA methylation analysis include DNA digestion by methylation-sensitive
endonucleases followed by PCR amplification (147) and bisulfite conversion of genomic
DNA that causes the unmethylated cytosines to be chemically converted to uracil while
the methylated cytosines are protected. After bisulfite modification, the DNA is amplified
by PCR using specific primers (193) and the amplicons can be analyzed by
pyrosequencing, which provides quantitative methylation values for each CpG site
present in the target sequence (152).
High-Resolution melt analysis (HRM) can detect DNA sequence variants based on their
different melting temperatures (158, 162, 172). PCR products can be differentiated even
if they only diverge in a single nucleotide (159) making this an optimal method to
analyze single nucleotide polymorphisms (162, 194, 195). HRM involves the
amplification of a DNA template by real-time PCR in the presence of a double strand
DNA (dsDNA) intercalating dye such as Eva Green™. The fluorescence is maximized at
the end of amplification when the largest quantity of dsDNA is present.
HRM can also be used to explore the melting differences between unmethylated and
methylated DNA after bisulfite conversion. During bisulfite conversion the unmethylated
cytosines but not the methylated ones are converted to uracils and subsequently thymine
during PCR. The amplicon resulting from amplifying unmethylated DNA has a lower GC
content when compared with the amplicon resulting from methylated DNA, thus having
lower melting temperature. If the bisulfite conversion fails, the GC content of the
amplicon is similar to methylated DNA and an overestimation of methylation occurs
(196, 197). Even though the available commercial kits for bisulfite conversion modify
99% of the DNA, appropriate controls should be in place to confirm that there is no
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amplification of unmodified DNA. One way of tackling this is to design primers that
anneal only with bisulfite converted DNA.
Several reports (54, 158, 197-199) have explored differences in melting temperatures
making use of HRM analysis of differentially methylated DNA with success. Even
though DNA methylation analysis by HRM cannot quantify individual CpGs, it provides
a robust and inexpensive method to differentiate DNA with different degrees of
methylation.
One challenge faced in PCR based methods is the decrease of amplification efficiency
due to inhibition. DNA is often co-extracted with substances that can hinder PCR. There
are two main mechanisms of PCR inhibition. One mechanism occurs when the inhibitor
binds the DNA and the other mechanism is when the inhibitor hinders the catalytic
activity of Taq polymerase. When the inhibitor binds to the DNA it can diminish the
processivity of the DNA polymerase or prevent primers to anneal to the template DNA,
thus decreasing PCR efficiency. Moreover for inhibitors binding to the DNA, a simple
cleanup step may not be sufficient to remove the decrease in PCR efficiency. Humic acid
is one substance known to inhibit PCR because it binds to the template DNA (86, 88).
In this work we investigated whether the methylation differences between blood, saliva
and semen for the locus ZC3H12D can be identified using HRM. When pyrosequencing
analysis is performed in the locus ZC3H12D, blood and saliva show hypermethylation
when compared to semen (156). The successful analysis of this locus using HRM would
be extremely useful in the identification of the source of DNA samples in forensic
investigations.
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C. Methods
DNA collection, extraction and bisulfite conversion
Ten Blood, 9 buccal swabs and 7 semen samples were collected from volunteers
according to the approved IRB-13-0555 from Florida International University. Swabs
were air-dried and DNA extraction was performed using the EZ1® DNA Investigator kit
(Qiagen, CA) and the BioRobot® EZ1 automated purification workstation (Qiagen, CA)
according to the manufacturer’s specifications. Quantification was performed using the
PicoGreen® method (Life Technologies, CA). One and fifty nanograms of DNA were
bisulfite modified using the EpiTect® Fast DNA Bisulfite Kit (Qiagen, CA) according to
manufacturer’s instructions. For the sensitivity studies, samples were serial diluted to
obtain 0.5 and 0.25 ng of input DNA to bisulfite conversion. In parallel the DNA samples
that were modified using 1 ng input to bisulfite modification were serially diluted after
modification to determine the lowest amount amplifiable by HRM. Samples that were not
bisulfite modified were diluted to 0.5 ng/µL in order to obtain a 1 ng input to the HRM
reaction.

DNA amplification
Amplification reactions were performed using the Epitect® HRM kit (Qiagen,
CA) on a Rotor Gene 6000 real time instrument (Qiagen, CA). The kit is composed of an
HRM buffer that contains Eva Green®, HotStarTaq® Plus and a dNTP mix all with
unknown concentrations. Two microliters of DNA were added to the master mix
composed of HRM buffer and 0.75 µM of each forward and reverse primers. Primers
were designed using the online tool MethPrimer (200). The primers sequence is provided
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on Table 6.1. Amplification was made by initially holding the temperature for 95 ºC for 5
minutes followed by 45-50 cycles of 95 ºC for 10 seconds, 55 ºC for 30 seconds and 72
ºC for 10 seconds. Melt analysis was performed by increasing the temperature from 65 to
85 ºC in 0.3 °C increments and detecting fluorescence in the HRM channel. Melt curve
analysis was made using the Rotor-Gene 6000 Series Software version 1.7.

Table 6.1 – Sequence of the primers used in this study.
Primers
Sequence
ZC3H12D Forward
GGG TGA GGG TTT AAG GGT
ZC3H12D Reverse
CTC CCC TCA AAA CCT CAT
Humic Acid inhibition
Humic acid was added to each DNA sample at a final concentration of 1.92x10-3
ng/µL prior to bisulfite conversion. Both samples without (control samples) and with
humic acid were bisulfite converted and amplified as described above. A master mix
containing humic acid with a final concentration of 1.92x10-3 ng/µL was made and
samples were amplified using this master mix as described above.

Statistical analysis
One-way ANOVA with a Tukey post-hoc was performed using SPSS® (Version
22, IBM) to compare the melting temperatures between the 7 semen samples, 10 blood
samples and 9 saliva samples and determine if the difference observed is statistically
significant. For p-values inferior to 0.05 the melting temperature was considered to be
significantly different.
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D. Results and Discussion
High-resolution melt can be used to discriminate between fragments of DNA that
present varying degrees of methylation. HRM has the advantage of being cost effective,
besides being a useful alternative/additional method to pyrosequencing protocols, since it
permits the fast analysis of amplicons with sizes larger than 70 base-pairs. From the work
of Madi et al. 2012, we note that for locus ZC3H12D, semen presents low percent of
methylation (around 10%) whereas other body fluids have levels of methylation around
100%. The hypo-methylation of semen is expected to result in a melt curve with a lower
melting temperature when compared to blood and saliva cells. Figures 6.1 and 6.2
illustrate that DNA from semen presents a melting temperature of 75.5 ºC with a standard
deviation of 0.2 ºC, which is lower than for other body fluids (78.2 ºC and 78.1 ºC for
blood and saliva, respectively). Our primers amplify a specific genomic region that is
hypermethylated in saliva and blood resulting in amplicons with high GC content.
Methylated cytosines are protected from bisulfite conversion and remain as cytosines.
Amplification will result in amplicons with a high GC content, which results in higher TM
as higher temperatures have to be reached to break the triple hydrogen bonds that bind
guanine to cytosine. In semen, the same region amplified by our primers is
hypomethylated. The lack of methyl groups in the cytosines from semen DNA causes
them to convert to uracil through the bisulfite reaction. Those uracils are amplified as
thymines and result in an amplicon with low GC content, resulting in curves with lower
TM. The differences in TM are visible in Figures 6.1 and 6.2. To determine the sensitivity
of this method we performed serial dilutions of extracted DNA from blood, saliva and
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semen to obtain inputs of DNA to bisulfite conversion of 1, 0.5 and 0.25 ng. Those
samples were amplified and the TM was determined by HRM analysis.

Figure 6.1 – Negative of the first derivative calculated from the change in slope
resulting from a decrease in fluorescence with temperature (-dF/dT) for highresolution melt curves, showing 7 semen samples (blue), 10 blood samples (red) and 9
saliva samples (green). A no template control (NTC, no DNA) was also included and
is seen at the baseline in pink color. Body fluid samples were donated from individual
volunteers. Samples were amplified from 50 ng of genomic DNA added to bisulfite
conversion.
Figure 6.3 shows that for inputs of DNA lower than 1 ng, some samples fail to amplify,
even when the amplification is extended for 50 cycles. One nanogram of genomic DNA
seems to be the minimum amount to input to bisulfite conversion to guarantee
amplification using this protocol for HRM analysis.
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Figure 6.2 – Chart showing the mean values for melting
temperatures (ºC) determined by HRM for 10 blood samples,
9 saliva samples and 7 semen samples. Analysis of variance
was performed showing that the melting temperature is
significantly different for semen when compared to blood and
saliva (* signifies p<0.05).

To further explore whether amplification for low content samples fails due to low
template added to PCR or as a higher loss on the bisulfite conversion, we performed
serial dilutions from the samples that were bisulfite-modified with 1 ng input to bisulfite,
posterior to the conversion.

Four serial dilutions of 1:2 were performed from the

bisulfite-modified samples with 1 ng of input to bisulfite conversion. Figure 6.4 shows
that a dilution of 1:2 is enough to impair amplification for 2 out of a total of 9 samples.
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Figure 6.3 – Chart showing the melting temperatures (ºC) for
3 individual samples from 3 different volunteers of each body
fluid, Blood (red), Saliva (green) and Semen (blue). The xaxis shows the different amounts of input DNA added to
bisulfite modification. Each body fluid should have 3
individual bars for individual amplifications. The absence of a
bar indicates that amplification failed.
As the bisulfite-modified samples get further diluted, fewer samples amplify properly as
it can be seen for the 1:16 dilution only having 5 successful amplifications out of a total
of 9 samples. Figure 6.4 also shows that for the dilutions of 1:2 and 1:4, when
amplification is successful the expected TM is observed for the body fluid tested. The
saliva samples at 1:8 dilution show a higher standard deviation (77.50 ± 0.72) when
compared to the 1:2 (78.50 ± 0.15) and 1:4 (78.25 ± 0.00) possibly due to stochastic
effects on amplification and melt analysis when low amounts of DNA are used.
The results displayed in Figures 6.3 and 6.4 show that below 1 ng of input to bisulfite
conversion, amplification may be impaired due to low amounts of DNA added to PCR.
However, in the cases where amplification occurs below 1 ng, distinction between semen
and blood and saliva may still be possible using the melting analysis. The fact that the
melting temperatures do not change when low amounts of DNA are successfully
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amplified shows that this method is unlikely to give false results that would otherwise
lead to a misclassification of a body fluid. Additional samples including replicates for
each dilution can further establish the sensitivity for this method.

Figure 6.4 –Chart showing the melting temperatures (ºC) for 3 individual samples
from 3 different volunteers of each body fluid, Blood (red), Saliva (green) and
Semen (blue). The x-axis shows the dilution factor from samples that were bisulfitemodified with 1 ng of DNA. For comparison the non-diluted samples (1ng) are
displayed. Each body fluid should have 3 individual bars for individual
amplifications. The absence of a bar indicates that amplification failed.
To further test the robustness of the method we explored whether the designed
primers can amplify non-bisulfite modified DNA. Differences in methylation can only
accurately be explored if the DNA is completely bisulfite modified prior to amplification
and HRM. Incomplete bisulfite modification can result in overestimation of methylation
in DNA due to lack of conversion of unmethylated cytosines to uracils. As a result, a
PCR product resulting from an unmodified template will keep all cytosines regardless of
their methylation status and will have a TM similar to a PCR product that results from a
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modified, fully methylated template (196). To determine if our primers are specific for
bisulfite-converted DNA we performed HRM for the same extracted samples of semen,
blood and saliva before (genomic DNA, gDNA) and after bisulfite conversion (bisulfitemodified DNA, bDNA).

Figure 6.5 – Graphs showing samples before and after bisulfite modification. bDNA
from semen samples are blue, from blood samples are in orange and from saliva
samples are in green. gDNA samples are shown in pink. (A) shows the increase in
fluorescence as a result of incorporation of the green fluorescent dye Eva Green® as
the cycle number increases. DNA samples that were not bisulfite modified (gDNA) do
not amplify and are in pink color at the baseline. The bDNA samples amplify showing
an increase in fluorescence. (B) Melt curve analysis shows that the bDNA samples
amplified show a melt profile consistent with Figures 6.1 and 6.2. Semen samples are
blue, blood samples are in orange and saliva samples are in green.
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Figure 6.5A demonstrates that gDNA samples did not amplify (pink lines) even after 50
cycles. The bDNA amplified properly (blue, orange and green lines on Figure 6.5A) and
presented the expected melt curves, with a lower TM for semen when compared to blood
and saliva (Figure 6.5B).
In some circumstances samples collected from crime scenes contain substances
that when co-extracted with DNA can cause inhibition of the amplification. To determine
if the cleanup steps in the bisulfite conversion reaction is sufficient to remove such
inhibitors, we incorporated humic acid before and after bisulfite modification. Humic
acid is an inhibitor known to decrease amplification efficiency by binding to the template
DNA (86). PCR efficiency is evaluated by the number of copies of DNA synthesized per
cycle (or unit of time). On a graph displaying the amplification curve, such as Figure
6.5A a steeper slope on the exponential curve will represent a more efficient
amplification. Efficiency is 100% when E=2 (E=10slope) and it means that the PCR
product doubles at each cycle.
Humic acid was added before bisulfite conversion to simulate co-extraction with
DNA. Figure 6.5A shows that samples without humic acid (control, thin lines) and
samples where the humic acid was added before bisulfite conversion (dashed lines)
amplify with similar efficiency. The fact that the steepness of the curves for the control
samples and those where humic acid was added before bisulfite treatment are similar
allows us to conclude that the cleanup steps performed as part of the bisulfite kit seem
sufficient to remove humic acid co-extracted with DNA at the concentration tested.
To determine whether the same concentration of humic acid causes changes in
PCR efficiency we performed another reaction where the humic acid was added to the
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PCR mix. All the samples amplified in the presence of humic acid (thick lines) show a
decrease in PCR efficiency which is seen by a decrease in slope steepness on Figure
6.6A.

Figure 6.6 – Graphs showing amplification curves for samples without humic acid
(control, thin lines), samples where humic acid was added prior to bisulfite conversion
(dashed lines) and samples where humic acid was added to the PCR master mix (thick
lines). DNA from blood is in red, saliva cells in green and semen in blue. (A) The
presence of the inhibitor during amplification (thick lines) causes a decrease in the
steepness of the slope of the curve when compared to samples without humic acid
(thin lines) or when humic acid was added prior to bisulfite conversion (dashed lines).
(B) The presence of humic acid does not affect melt curve since all samples have a
similar TM even when amplified in the presence of humic acid.
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Even though the presence of inhibitor in the amplification seemed to decrease the
PCR efficiency as seen by a less steep slope in Figure 6.6A, it did not cause a shift on the
melting curve (Figure 6.6B). The TM of DNA extracted from semen samples (blue in
Figure 6.6B) still shows a lower TM when compared to blood (red in Figure 6.6B) and
saliva (green in Figure 6.6B), regardless of the presence of humic acid (thick lines). The
results observed are likely due to the fact that even though amplification efficiency
decreased, the number of cycles was sufficient to reach completion of PCR. Since melt
analysis is done to the PCR products, as long as there is a sufficient number of amplicons
at the end of amplification, the melt results will be similar. Previous studies by Thompson
and colleagues (86) speculated that changes in the melt curve due to the presence of
inhibitors that can bind to the PCR product can depend on the size and GC content of the
amplicon. Our amplicon has a size of 91 base-pairs and a GC content of 21% for
complete methylated (blood and saliva cells) and 14% for unmethylated (semen) DNA
strands. Pionzio and colleagues (88) concluded that long amplicons with low GC content
are more prone to display effects of inhibition. Our amplicon is considered to be short
and with low GC content but shows robustness in melt curve analysis even when the
concentration of inhibitor is sufficient to reduce PCR efficiency.

E. Conclusion
The HRM analysis here described allows the amplification and identification of
DNA from semen even when only 1 ng of input DNA is bisulfite-converted. When tested
with DNA that is not bisulfite converted, our primers failed to amplify the DNA, which
proves that incomplete conversions will not result in false results which would possibly
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lead to mis-identification of a body fluid. The results presented here also show that when
inhibitors like humic acid are co-extracted with the DNA, the cleanup step performed as
part of the bisulfite conversion process is capable of cleaning the DNA from such
inhibitors, since no decrease in the amplification efficiency was observed. Furthermore
when humic acid was added to the amplification step, the HRM method provided reliable
results since the TM values observed are similar to those obtained in the absence of
inhibitor. HRM analysis is a promising technology to identify the tissue source of a given
DNA sample in forensic laboratories.
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CHAPTER VII – IDENTIFICATION OF NEW CpGs ABLE TO DISCRIMINATE
BODY FLUIDS FROM CRIME SCENES

A. Introduction
DNA typing methodologies have been developed a short time ago but nonetheless
have evolved in sensitivity and accuracy. Since January 1, 2017 the CODIS (Combined
DNA Index System), which was started in 1990 with a specific team at the FBI, has
expanded the number of STRs from 13 to 20 to increase the power of discrimination on
DNA typing (https://www.fbi.gov/services/laboratory/
biometric-analysis/codis, Sept 29).
Similarly, in the analysis of DNA methylation patterns for body fluid
discrimination, having a greater number of markers per body fluid will also increase the
ability to discriminate between body fluids, especially when a sample contains a mixture
of tissues. Currently, the majority of markers for a body fluid present intermediate levels
of methylation. For example, the marker BCAS4, which is specific for saliva, includes 4
CpGs. CpG1, which is the one presenting higher differences in methylation between
saliva and other body fluids, shows 64.0 ± 7.1 % methylation in saliva and 3.9 ± 1.6 %
(semen) to 39 ± 21% (nasal epithelia), with the percent for other body fluids in between
those of semen and nasal epithelia (Table 5.3 and (201)). When the same marker is tested
with a mixture of body fluids, the percent of DNA methylation is similar for the sample
composed of 75%saliva+12.5% blood+12.5% semen and the sample composed of 75%
saliva+25% blood (201) which indicates that semen could go undetected and be confused
with blood.
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Similarly, other research groups (167, 176) have found the need to identify new loci able
to discriminate body fluids using DNA methylation patterns. The simplified way to
identify potential new CpGs able to discriminate body fluids is the use of a DNA
methylation bead array that interrogates 450,000 individual CpGs in the human genome.
The Infinium HumanMethylation450 (Illumina, CA) quantifies DNA methylation based
on two types of assays and on bisulfite-modified template. The Infinium I assay uses two
probes with different colors, one that anneals to methylated DNA and another to
unmethylated DNA. The Infinium II assay has one single probe that anneals to the DNA
regardless of its methylation state, however the extension product will emit a color
depending on whether the DNA is methylated or unmethylated.
There are an estimated 30 million CpGs in the human genome (202, 203), therefore those
arrays only cover a small portion of CpGs. Additionally, the results obtained by a bead
array methodology do not always correlate with PCR-based methods, due to several
factors including the samples used, technical limitations of the array, and the power of
statistical analysis performed (204). For example, Park and colleagues (176) identified
several CpGs with potential to identify blood, saliva, semen and vaginal epithelia,
according to the statistical analysis of the array data. However, looking at the
pyrosequencing data for 8 CpGs selected and obtained by sequencing 20 samples of each
body fluid, the results show such a high variability in the percent values of DNA
methylation between samples of the same body fluid, that some samples of one body
fluid could be mistaken by another body fluid. Additionally, from the 2986 CpGs
identified as statistically significant to discriminate body fluids, the 8 validated by
pyrosequencing were selected by the authors based on the following criteria: “1. the rank
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of the p value in each body fluid, 2. hypermethylation in one body fluid, 3. a high
methylation difference, and 4. practicality with regard to pyrosequencing.” Despite of
criteria number 3 being a high methylation difference between body fluids, all 4 CpGs
selected for saliva and blood show a predicted percent of methylation of about 50-59%,
which corresponds to an intermediate level. The 2 CpGs selected as potential markers for
vaginal epithelia present an estimated percent of methylation somewhat higher 65-72%
but with standard deviations of 13-22%. In summary, even if only considering the
statistical analysis of the results obtained from the array, the selected CpGs do not seem
able to show large differences in methylation for the target body fluid when compared to
other body fluid. For that reason, additional studies using either arrays or whole genome
methods must be performed in order to increase the number of body fluids tested for
forensic purposes.
Regarding the statistical analysis performed in the same report, it was made based on the
beta-value, which is the default output value given by the software that accompanies the
Infinium HumanMethylation450 bead array. The beta-value is defined as the ratio of the
methylated signal versus the total signal (methylated+unmethylated signals). However,
the beta-value is known to be highly heteroscedastic, that is, the variance across samples
with beta values close to 0 or 1 is artificially reduced. In practical terms, this means that
when performing a statistical analysis based on the beta-value, the CpGs that present
beta-values close to 0 or 1 can show low variability from sample to sample. To tackle this
limitation, the M-value, which is defined as the log of the ratio of the methylated signal
versus the unmethylated signal, is preferable since it displays an approximately constant
variation across the methylation range of values (204, 205).
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Park and colleagues adopted a statistical analysis of the array data by performing
Student’s t-test “to evaluate the significance of differences in DNA methylation levels
between any one type of body fluid and the other types of body fluids.” This use of the
Student t-test implies that the average methylation of all 4-6 samples of one body fluid
for one CpG on the array will be compared to the average methylation of all other
samples from all other body fluids in the same CpG. This approach may allow the sorting
of those CpGs that present bigger differences between body fluids since to show
significance, the methylation on the target body fluid, for that specific CpG, must be
quite different from all others, regardless of which body fluid is in the other group.
However, DNA methylation for three groups of body fluids was measured separately,
which would make the analysis of variance (ANOVA) more appropriate as a statistical
test. Additionally, ANOVA also provides an output considering the variance between the
methylation values within each group, which may result in loci with true differences in
mean methylation values (206).
Finally the use of a PCR-based method to confirm the results obtained by the
array should allow for an easy and quick distinction between body fluids, even if it
cannot quantify methylation at individual CpGs. Due to its easy use, fast turnaround and
inexpensive properties, HRM has the potential to provide the confirmation needed for
array-based methods.
Taking this into account, the goal of this work was to perform a statistical analysis
of the array data reported by Park et al. (2014) and screen the results obtained using
HRM to identify new potential CpG able to discriminate blood, saliva and vaginal
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epithelia. Additionally it is also the goal of this work to select a set of primers able to be
amplified in a multiplex PCR reaction for body fluid identification.
This project was submitted to the National Institute of Justice on the form of a
Graduate Research Fellowship grant proposal which was awarded in 2015 (2015-R2-CX0012).

B. Materials and Methods
Samples
Blood, saliva, vaginal epithelia and semen samples were collected from
volunteers according to the approved IRB (IRB-16-0021) from Florida International
University. Blood samples were collected by finger prick and soaking the blood onto
sterile cotton swabs. Saliva samples were collected by asking volunteers to rub the inside
of their cheek with a sterile swab and vaginal epithelia and semen samples were collected
by volunteers on their own time and later returned to the laboratory. All swabs were dried
and stored at room temperature until DNA extraction was performed. Aliquots of semen
samples were created and frozen at -20 ºC until DNA extraction was performed. DNA
control samples were purchased and consisted of human fully methylated and
unmethylated DNA, not bisulfite modified (Zymo Research, Irvine, CA) or already
bisulfite modified (Qiagen, Valencia, CA).

DNA extraction, quantification and bisulfite modification
Each swab or liquid semen sample was placed in a 2 mL tube containing lysing
buffer G2 (Qiagen, Valencia, CA) and proteinase K, according to the manufacturer’s
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instructions for the EZ1 DNA Investigator kit (Qiagen, Valencia, CA). After 3 hours of
incubation at 56 ºC, the tubes were dried, quickly spun and the swabs transferred to spin
baskets in order to remove the liquid absorbed by them. After centrifugation, all the
lysate was transferred to a 2 mL tube and Buffer MTL (Qiagen, Valencia, CA) was
added. The extraction procedure was performed automatically by the Biorobot EZ1
Automated purification system (Qiagen, Valencia, CA), according to the manufacturer’s
specifications. DNA quantification was performed either by the PicoGreen method (90,
91) for blood samples or by real-time quantification using Alu primers (79) for all other
body fluids, due to the likelihood of containing non-human DNA derived from naturally
occurring microflora.
Two hundred microliters of DNA from samples or controls (Zymo Research, Irvine, CA)
were bisulfite modified using the Epitect® Fast DNA Bisulfite kit (Qiagen, Valencia, CA)
which converts unmethylated cytosines but not methylated ones to uracil. The bisulfitemodified DNA was eluted by adding 20 µL of elution buffer to the silica column from the
kit.

Bioinformatic Analysis
The raw data for the array study reported by Park et al. (2014) was retrieved from
Gene Expression Omnibus (GEO) accession number GSE55734. Using Microsoft Excel
the M-value was calculated by performing the log of the ratio of the methylated signal
versus the unmethylated signal for all 6 blood, 6 vaginal, and 4 saliva samples of over
450,000 CpGs. Statistical analysis was performed using R software and in collaboration
with Dr. Vanessa-Aguiar Pulido from the BioRG group at Florida International
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University. The analysis consisted in performing ANOVA and Kruskal-Wallis tests
followed by post-hoc Tukey HSD and Dunn’s tests, respectively. The CpG locations that
showed a p-value<0.05 on both tests were selected. To further filter the results, CpGs
were selected based on the ratio of methylated and unmethylated signals. The sorting of
CpGs was performed in a two-step fashion; first by filtering locations with ratios above 2
for the target body fluid and below 0.5 for the other two body fluids; and secondly by
filtering those locations with a ratio below 0.5 for the target body fluid and above 2 for
the other two body fluids. If too many locations were still returned, the values of 2 and
0.5 were increased and lowered, respectively. This type of sorting returns CpGs that
present more than double of signal intensity for the methylated probes when compared to
the unmethylated probes (ratio ≥ 2) of one body fluid, while the two remaining body
fluids present more than double the signal for the unmethylated probe when compared to
the methylated one (ratio ≤ 0.5).

Primer design
The raw array data provides the identification of each CpGs with a ‘cg’ code
attributed by Illumina (San Diego, CA) and deposited in genome browsers. For this
study, the genome browser from University of California at Santa Cruz
(http://genome.ucsc.edu/), assembly GRCh37/hg19 was used to search for each ‘cg’ code
sorted from the bioinformatics analysis, to which corresponds to a specific CpG in the
human genome (207). A DNA sequence consisting of 300 bp upstream and 300 bp
downstream of the CpG was downloaded and used to design primers. Three different
tools were used to design primers, the online tools Methprimer (200) and Bisearch (208,
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209) and the PyroMark Assay Design SW version 2.0 (Qiagen, Valencia, CA). The tools
work by initially assuming that all cytosines not followed by guanine are unmethylated
and therefore are considered thymines by the algorithm. Then, the primers are designed
based on those sequences and some user-defined parameters. Following the guidelines by
Wojdacz and colleagues (210, 211), the parameters where set to allow only 1 ºC
difference on the melting temperature (TM) of forward and reverse primers, an optimal
TM of primers near 65 ºC, allowing one CpG within the primer sequence and setting 100
bp as the preferred amplicon length. Due to the fact that bisulfite modified DNA is almost
a 3-letter genome sequence, the difficulty to design primers specific for one region is
increased. Furthermore, some of the CpGs selected were located in areas with high
density in either CpGs or thymines. Thus, the parameters for primer design were
modified whenever none of the primer design tools could design any oligo sequences.
The parameters for primer design were altered consecutively by first changing the
preferred length of amplicon size from 100 bp to 150 bp and a maximum 300 bp. If no
primer sequences were returned, a second change was made which consisted on altering
the preference of having one CpG on the primer sequence to having none or more than
one. If still no primer was designed, the stringency on having a specific primer TM was
lowered which allows more dissimilar TM between forward and reverse oligos and TM
outside the vicinity of 60 ºC. Fifty different regions were tested for blood and vaginal
epithelia, and 31 tested for saliva.
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PCR amplification and melt curve analysis
Initially the amplification of bisulfite-modified DNA was performed using the
Epitect® HRM kit (Qiagen, CA). Two microliters of bisulfite modified DNA (samples or
controls) were added to the master mix according to manufacturer’s instructions, with
0.5-0.75 µM of each forward and reverse primers. Ultimately a custom made master mix
was optimized (‘My Mix’) which consists of 1X PCR buffer (Qiagen, CA), 0.125U of
Hot Star Taq Plus (Qiagen, CA), 0.2 mM of each dNTP (Denville Scientific, MA), 0.50.75 µM of each forward and reverse primers, 1X of EvaGreen (in water, Biotium Inc.,
CA), 0.2 mg/mL of Bovine Serum Albumin (BSA, Sigma Aldrich, MO) and 2.5% of
Dimethyl sulfoxide (Sigma Aldrich, MO) in a total volume of 20 µL in the PCR reaction
which also contained 2 µL of bisulfite-modified DNA. Optimization was performed by
combining different concentrations of master mix constituents and additives and
determining which provided a CT and TM similar to those obtained by amplifying the
ZC3H12D primer with the Epitect® HRM kit (Qiagen, CA). The concentrations to be
analyzed were determined by the Design Expert® (version 10, Stat-Ease, Inc.).
The singleplex PCR reactions were introduced in the real-time instrument which was set
to an initial hold at 95 ºC for 5 min, followed by 45-55 cycles of 95 ºC for 10 seconds,
40-60 ºC (depending on TM for the primers being amplified) for 30 seconds and 72 ºC for
10 seconds. The multiplex reactions were amplified with similar settings except the
annealing step was performed at 54 ºC for 40 seconds and the extension step was
modified to 20 seconds. Melt analysis for singleplex and multiplex reactions were
performed by increasing the temperature from 65 to 85 ºC in 0.3 °C increments and

171

detecting fluorescence in the HRM channel. Melt curve analysis was made using the
Rotor-Gene 6000 Series Software version 1.7.

C. Results
Bioinformatic analysis
From the initial comparison between body fluids 30,075 individual CpGs were
returned for blood, 5,667 for saliva and 9,469 for vaginal epithelia by using both
statistical tests (ANOVA and Kruskal-Wallis), and defining the p-value<0.05. A filter
was applied to that initial list so that the ratio of methylated signal versus the
unmethylated signal for the target body fluid would be very low or very high whereas for
the other two body fluids it would be of opposite magnitude. There were several rounds
of filtering as each CpG got experimentally tested. The actual values used and the
number of CpGs filtered per set of values are shown on Table 7.1. The total number of
newly identified CpGs to be tested was aimed at 50, which was not possible for saliva
since only 31 new CpGs showed methylation differences considered relevant between
saliva and other body fluids, according to our defined parameters. Thus, 50 CpGs were
tested for blood and vaginal epithelia and 31 CpGs tested for saliva.

Experimental Results using HRM
The selected CpGs and the surrounding DNA sequence was retrieved from the
UCSC genome browser online platform (207) in order to allow for primer design. Several
of the CpGs selected (Table 7.1) had to have several sets of primers designed because the
initial set did not amplify properly or showed very inefficient amplification. For blood,
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only one CpG had 2 primers designed, saliva had 6 primers designed twice and 1 primer
designed three times and vaginal epithelia had 5 primers designed twice.
In the initial screen for all primers, 1 sample of each body fluid and both
methylated and unmethylated controls were amplified.

Table 7.1 – Summary of parameters used to filter CpGs by ratio of methylated versus
unmethylated probes for each target body fluid. The number of CpGs displayed
correspond to those obtained from each parameter only.
# CpGs
Target
Methylated/unmethylated Methylated/unmethylated
per
Body
Target body fluid
Other two body fluids
filtering
Fluid
criteria
<0.1
>1
5
<0.5
>1
24
Blood
<0.5
>2
3
≥2
≤0.5
17
<0.6
>1
10
<1
>1
1
Saliva
<0.5
>0.8
11
<0.6
>0.8
4
≥2
≤0.5
5
<0.2
>0.5
16
<0.1
>0.5
15
Vaginal
<0.4
>1
3
Epithelia
<0.5
>1
15
<0.6
>1.9
3
≥2
≤0.5
3
The primer sets that showed a different TM between the target body fluid and the other
three body fluids were selected to test with additional samples. A total of 12 blood, 3
saliva and 6 vaginal epithelia CpGs were tested with multiple samples, from which 3
locations for blood, 1 for vaginal epithelia and 1 for saliva (Table 7.2) provided
consistently different TM for 10 samples of the target body fluid when compared to 10
samples of each one of the other body fluids (Table 7.3).
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Table 7.2 – List of primer sequences for the 5 markers identified in this study. Fw stands
for forward primer and Rv stands for reverse primer
Marker
‘cg’ code
Sequence 5’-3’
Name
Fw AAGGAGAGGGTTGGTAAGAGAGT
INPP5D200_
cg00438740
CAATAAAAAAAAAAAAACTAAACTACRAA
TM60
Rv
AAAC
Fw TTATGTTTTTTTAGAAGTGGT
INPP5D1500 cg02935132
Rv TCTCCTTCCTAACAACTAAT
INPP5D200_
Fw TTTTTTGTTTGGTTTTTGTAATGAGGAAGT
cg22029587
2
Rv AAACACCCCCAAAACCCACAC
Fw TTAAATTAGGGTGTGGGTAGA
VE_8
cg08751438
Rv AAACATACCAAAAAAACAAAAC
Fw GTGAAAGGAAAGAGAGAATAAATATT
VE_15
cg25975690
Rv CAAAAACAAACAAAAAACCTTTC
Table 7.3 – Summary of the TM values for the loci identified in this study as potential
markers for blood and vaginal epithelia (VE). TM ± SD for each body fluid represents
an average melting temperature value and standard deviation calculated for 10 samples
analyzed per body fluid, 3-4 samples analyzed for the unmethylated (UnM) and
methylated control (M).
Target
Body
Fluid

Blood

VE

TM (ºC) ± S.D.

Marker Name
Blood

Saliva

Semen

VE

UnM

M

INPPD200_TM60

80.0
±0.1

83.0
±0.2

82.7
±0.3

82.6
±0.4

80.0
±0.2

83.0
±0.2

INPPD1500

74.3
±0.1

75.8
±0.1

75.5
±0.5

75.3
±0.8

74.1
±0.1

75.6
±0.1

INPPD20_2

80.0
±0.1

81.6
±0.7

81.6
±1.1

80.2
±0.5

80.0
±0.1

82.1
±0.1

VE_8

78.1
±0.1

78.1
±0.1

78.1
±0.1

76.6
±0.2

76.5
±0.1

78.1
±0.1

The CpGs able to distinguish saliva (cg25975690) was discovered from the list of
potential CpGs for vaginal epithelia by showing an intermediate genotype for saliva (10
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samples) when compared to the methylated control and all other body fluids (10 samples
of each body fluid) and the unmethylated controls.
The genotype discrimination function on the Rotor Gene software consists of a
curve showing the decrease in fluorescence as a result of the melting of DNA and release
of intercalating dye molecules with the increase in temperature. Each line depicting each
sample is the fluorescent signal resulting from a set of molecules of DNA melting at the
same time.

Figure 7.1 – Genotype differences between saliva (n=10), in green color and thick lines,
when compared to blood (n=10) in red color, vaginal epithelia (n=10) in orange and
semen (n=10) in blue. Controls used are depicted in black.
Considering the area near the TM, a steeper drop in fluorescence indicates that all DNA
molecules in each sample have the same amplicon sequence, a less steeper drop in
fluorescence may indicate that the DNA molecules vary in the levels of methylation with
the result that each molecule melts at slightly different rate around the same TM (Figure
7.1).
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Optimization of a PCR master mix to amplify bisulfite-modified DNA
A commercial kit, Epitect® HRM (Qiagen, CA), consisting of a pre-made master
mix that contains dNTPs, magnesium, Eva Green as intercalating dye and Hot Star Taq
Plus (Qiagen, CA) in a buffer solution that contains other additives was initially used. In
order to design our own master mix, the Material Safety Data Sheet (MSDS) for the
Epitect® HRM kit is available online and was consulted (212). The MSDS showed that
the master mix on the kit contains glycerol and DMSO each with concentrations between
1 and 10%. The information regarding concentrations of magnesium, dNTPs, polymerase
and eva green dye used were not available on the MSDS. The polymerase in the kit (Hot
Star Taq Plus DNA polymerase, Qiagen, CA) is available for purchase as individual
reagent and therefore it was also used on a newly developed master mix named ‘My
Mix’. The purchased polymerase includes a handbook that served as a guideline for the
optimization of ‘My Mix’ (213). Additionally, the presence of additives was also
investigated.
The software Design Expert (Stat-Ease, MN) provided a list of concentrations
tested for each additive to be added to the mixture, namely BSA, betaine, DMSO and
glycerol, and also provided guidelines for the concentration of dNTPs and magnesium.
Each concentration was tested using control unmethylated and methylated DNA and the
primer pair for ZC3H12D. The amplification efficiency and melt curve resulting from
‘My Mix’ and the Epitect® HRM kit were compared. The comparison allowed to
determine a concentration of additives, dNTPs and magnesium for My Mix that presented
similar results to those observed when the Epitect® HRM kit was used. As an example,
Figure 7.2 displays the melt curves for the methylated (red) and unmethylated (green)
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controls when amplified in the presence of 0.2 mg/mL of BSA and either 2.5% glycerol
(light green and dark red) or 2.5% DMSO (dark green and light red). The TM for the
peaks in the figure were compared with the dashed lines that represent the TM for the
unmethylated control (green line) and the methylated control (red line) when amplified
with the Epitect® HRM kit.

Figure 7.2 - Melt curve obtained in the presence of 2.5% DMSO or Glycerol in ‘My
Mix’ which includes BSA (0.2 µg/µL). The dashed lines represent the melt temperature
for the DNA controls amplified with the Epitect® HRM kit (Qiagen, CA) used as
reference for ‘My Mix', where green is the unmethylated control and red is the
methylated control.
The optimized mixture consisted of 1X PCR buffer (Qiagen, CA), 0.125U of Hot
Star Taq Plus (Qiagen, CA), 0.2 mM of each dNTP, 0.5-0.75 µM of each forward and
reverse primers, 1X of EvaGreen (in water) 0.2 mg/mL of BSA and 2.5% of DMSO in a
total volume of 20 µL in the PCR reaction.

Multiplex for markers showing specific amplification of blood, semen and vaginal
epithelia
From Table 7.3, one marker per target body fluid was selected for amplification in
the same PCR reaction as the marker ZC3H12D, previously described as being
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unmethylated for semen, but not blood or saliva. Thus, the primer set INPD200_TM60
and VE_8 were added to a master mix containing ZC3H12D. After optimization, the final
concentrations of each primer set were determined as 0.75 µM for ZC3H12D, 0.75 µM
for each INDP200_TM60 and VE_8. The average TM of 3 samples per body fluid for
each primer when amplified with 54 ºC annealing temperature and extended times for the
annealing and extension steps of the PCR cycle is displayed in Table 7.4.

Table 7.4 – Average TM of amplified samples with the markers INPPD200_TM60,
VE_8 and ZC3H12D at 54 ºC annealing. Values displayed are of 3 samples of blood,
saliva, semen and vaginal epithelia (VE) and 2 samples of each unmethylated (UnM)
and methylated (M) control.
Target
TM (ºC)
Marker
Body
‘cg’ code
Un
Name
Blood Saliva Semen VE
M
Fluid
M
Blood

INPPD200_
TM60

cg00438740

79.5

82.5

82.4

82.2

79.5 82.4

VE

VE_8

cg08751438

77.7

77.5

78

76.2

76.2 77.7

Semen

ZC3H12D

N/A

78.7

78.9

75.6

78.8

75.8 78.8

Figure 7.3 shows the melt curves for the multiplex amplification of all 3 primer sets in
the same PCR conditions. The TM for ZC3H12D and VE_8 are too similar and are
therefore displayed as one single peak, making them indistinguishable.
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Figure 7.3 – Melt curve for an unmethylated control (red) and a methylated
control (blue) amplified in a multiplex PCR reaction with INPP5D200_TM60,
VE_8 and ZC3H12D, at an anneling temperature of 54 ºC.
D. Discussion
There have been continuous efforts to develop loci capable of discriminating body
fluids at crime scenes using tissue-specific DNA methylation (167, 176). In an attempt to
increase the number of DNA methylation markers, we have re-analyzed array data from
the study of Park and colleagues from 2014. A new M-value was used to calculate the
ratio between the methylated and unmethylated signal with the goal of improving the
statistical analysis. Initially we obtained a higher number of potential CpGs for each
target body fluid when compared to Park et al. (2014). We were able to obtain 30,075
CpGs for blood, 5,667 for saliva and 9,469 for vaginal epithelia, whereas Park and
colleagues selected 618 for blood, 37 for saliva and 176 for vaginal epithelia.
Interestingly, the number of new locations follows a similar trend when comparing body
fluids. In both studies, a higher number of CpGs were selected for blood, followed by
vaginal epithelia and lastly saliva.
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Since we were targeting a simple method of analysis –HRM – we were able to
screen 50 new CpGs for blood and vaginal epithelia and 31 for saliva. On the initial
screening, it was easy to identify new CpGs for blood, however the same was not true for
vaginal epithelia or saliva. The blood samples collected for this study and for the array
study consisted of whole blood, since that is what is commonly left at crime scenes.
Whole blood is composed of several cell types but only the nucleated cells provide
genomic DNA (214). In comparison, saliva and vaginal epithelia are composed of more
than one type of cells, including epithelial cells and immune cells (215, 216). Moreover,
research has shown that DNA methylation differences are observed between the different
cell types present in saliva (217). Additionally, we speculate that the immune cells
existing in saliva and vaginal secretions may present higher variability in terms of DNA
methylation due to its induced tolerance resulting from the presence of commensal
bacteria (218). Taken together, the observed variability in cells present in saliva and
vaginal epithelia may account for a more variable DNA methylation signature when
compared to blood. Such variability could therefore explain why markers for blood seem
to be easier to find when compared to saliva and vaginal epithelia. Additionally, the same
differences in DNA methylation can also explain why a CpG initially selected as a
potential marker for vaginal epithelia, showed in fact, superior results for saliva when
compared to the methylation values for other body fluids. After the initial screening with
one sample from each body fluid and one from each control, several markers were
determined as potential vaginal secretion markers but ended up not showing consistent
results when an additional 9 samples from each body fluid were analyzed.
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The CpGs that showed a different TM in blood when compared to other body fluids were
cg00438740, cg02935132 and cg22029587, which were all located on a CpG island
upstream of the RefSeq gene INPP5D. The gene INPP5D is expressed exclusively in
hematopoietic cells, which are the precursors of blood cells (207). The marker found for
vaginal cells was cg08751438, which is located on the q24.1 band of chromosome 16. It
is not associated with any RefSeq gene (Table 7.3).
The CpG which showed specific methylation for saliva when compared to the
other body fluids was cg25975690, located on a CpG island located upstream of the
RefSeq gene HOXA9, which is a homeobox A9 coding for transcription factors that may
be involved in gene expression (207). This CpG was initially selected as a vaginal
epithelia-specific CpG from the statistical analysis of the bead array. However when the
location was amplified with blood, saliva, semen and vaginal epithelia, this location
showed differences in melting characteristics of DNA from saliva. It was interesting to
notice that the difference in melting temperature for saliva samples results from a steady
loss of fluorescence as the DNA molecules melt. In samples that have all their DNA
strands fully methylated or fully unmethylated, the TM should be displayed as a sharp
peak on the graph of the first derivative of fluorescence over the temperature. The first
derivative represents a graphical illustration of how the fluorescence decreases for each
increase in temperature. If the DNA molecules present in a given sample contain different
levels of methylation, with some being methylated, and others unmethylated, the decrease
in fluorescence will be gradual since each group of strands will melt at a different
temperature (Figure 7.1). This seems to be the case for the cg25975690 for saliva, but not
for the other body fluids tested, allowing its discrimination by melt characteristics.
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Regarding the optimization of a master mix to use with bisulfite-modified DNA,
the initial mix was tested according to the handbook specific for the Hot Star Taq Plus
DNA polymerase (Qiagen, CA). However since the polymerase was not specifically
developed for application to amplify bisulfite-modified DNA, the booklet does not take
into account the complexity of such DNA templates. Several additives were tested to
improve the amplification and melt curve analysis step. Bovine serum albumin (BSA) is
commonly used to prevent the master mix components, specifically the polymerase from
adhering to the tube walls, thus increasing their availability for template amplification.
Betaine and DMSO act by altering the melt characteristics of DNA either by equilibrating
the TM between GC and AT pairs, or by disrupting inter- and intra-strand re-annealing
avoiding the formation of DNA secondary structures such as hairpins and others (219).
According to the MSDS for the Epitect HRM® kit, which was the kit used to amplify
bisulfite-modified DNA, the master mix available in the kit contains 1-10% DMSO and
glycerol. Results from Farell and Alexandre, has shown that the combination of BSA and
DMSO can enhance the amplification of GC-rich DNA templates (220). During
experiments on the effects of DMSO and glycerol in My Mix, it was discovered that the
melt peak for both the unmethylated and methylated controls show similar TM for DMSO
and glycerol, however the overall shape of the methylated peak was sharper with DMSO
than with glycerol, which is why that compound was picked as an additive to be included
in My Mix (Figure 7.2).
In the development of a multiplex capable of amplifying the CpGs that show
specific DNA methylation patterns for blood, semen and vaginal epithelia, we obtained
mixed results. On one hand, the amplification was successful since all 3 primer sets
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amplify properly. However since two of the melt curves show peaks at similar TM, they
overlap, making analysis very difficult (Figure 7.3). The initial goal was to develop a
system similar to Plexor™ (Promega), which would allow the monitoring of
amplification and melt curve for each primer set individually through the use of different
fluorophores for each primer set (Figure 2.3, Chapter II). The elegance of that method
makes it quite attractive to use in the DNA methylation analysis of multiplex reactions.
However, the Plexor™ technology is no longer available as a product that can be
customized.
Other strategies were analyzed, however few offer the ability to monitor both
amplification and melt curve analysis in a single step. One option was the use of a
Snapback primer, which consists of a regular primer with a tail that is complementary to
the target region on the amplicon, folding over the original primer and forming an hairpin
(194). The melt temperature for that hairpin is smaller than the regular amplicon. One of
the primers (either the one specific for vaginal epithelia or the one specific for semen)
would have the extra sequence allowing the hairpin to form, thus distinguishing the melt
curves based on the TM of the hairpin and not of the major amplicon peak. Several
snapback primers were designed and tested but the melting peak for the hairpin was not
observed. Further experiments are continuing with the assistance of Drs. Luming Zhou
and Zachary Dwight from University of Utah (221).

E. Conclusion
With the advance in technology regarding the match of a suspect with a crime
scene using DNA, in certain cases, the identification of a body fluid can confirm or acquit
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the suspect. The confirmatory power that DNA methylation patterns can have in such
cases relies on the identification of several CpGs able to display a unique pattern of DNA
methylation in one body fluid and a different pattern for all other body fluids. Thus,
identifying new CpGs of interest can greatly aid the forensic discrimination of body
fluids. Using a new bioinformatic analysis, we were able to screen potentially new CpGs
and identify 5 new CpGs with a specific DNA methylation pattern for blood, saliva and
vaginal epithelia. Moreover we were also able to show the possibility of amplifying
simultaneously 3 markers which may represent an important step on the use of DNA
methylation markers in forensic laboratories in a near future.
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CHAPTER VIII – CONCLUDING REMARKS
The description of the chemical structure of DNA and the sequence of the human
genome represented major events in the recent past of mankind. In addition, the
optimization of methods like the polymerase chain reaction (PCR) made it possible to
study and use the information stored in DNA for several applications. One of those
applications is law enforcement. The ability to match the DNA of a suspect to the DNA
found at a crime scene represents one of the most powerful piece of evidence on
convictions or exonerations. However, information stored in DNA can be further used in
other forensic applications. For example, patterns of DNA methylation allow the
discrimination between body fluids. DNA methylation represents one type of epigenetic
modification that allows differential gene expression in different tissues. The ability to
identify such differential gene expression in forensic laboratories has the potential to
overcome issues with current presumptive methods for body fluid identification and to
promote investigative leads such as age prediction.
To successfully use DNA methylation in forensic laboratories, several parameters
must be satisfied. One of those parameters has to do with the methodology and its
reproducibility. DNA methylation consists of the presence of a methyl group on the 5carbon of specific cytosines spread throughout the human genome. The extracted
genomic DNA must undergo a chemical modification that uses sodium bisulfite and
causes DNA fragmentation. Such bisulfite modification allows the conversion of
unmethylated cytosines to uracils which can be detected with downstream analysis
methods. Since methylated cytosines are protected from this modification, it is important
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to demonstrate complete conversion during analysis. Additionally, the conversion process
can result in severe fragmentation on the extracted DNA, thus careful primer design and
use of controls is important for optimal results. In fact, several reports have been
published in the last years showing promising results regarding the usability and
validation of these methods in forensic sciences. The use of methods capable to
distinguish DNA methylation for body fluid identification is preferential to those that
analyze proteins or mRNA since the same extracted DNA sample used for STR analysis
can be used for DNA methylation analysis, without the need to use additional evidence.
In this work we demonstrate that HRM analysis can be used to distinguish body fluids
that present different levels of DNA methylation in specific loci. The results here
described represent our contribution to the field of forensic epigenetics.
We were able to demonstrate the reproducibility and usability of some markers
discovered by our team. Namely we showed that ZC3H12D, BCAS4 and cg06379435
show differential methylation analyzed by pyrosequencing, are primate-specific, have
sensitivity in a low nanogram quantity, can detect mixtures of body fluids, can withstand
degradation by UV light and high temperatures and allow the discrimination of semen,
saliva and blood, respectively. Moreover, we were also able to show that the ZC3H12D
locus is an excellent marker for semen since it is hypomethylated when compared to
saliva and blood. The marker ZC3H12D represents the ideal DNA methylation markers
to be used in forensic sciences since all the CpGs amplified in the loci show levels of
methylation below to 10% for semen, whereas other body fluids are highly methylated on
the same CpGs. Due to the high difference in methylation when comparing body fluids
and also the consistency of methylation in all of the CpGs included in the loci, this
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marker can provide usable results even when using a non-quantitative method such as
DNA melt analysis. The use of high-resolution melt (HRM) analysis has benefits due to
the high throughput and low cost, when compared to other analysis methods.
The current number of markers available for each body fluid is low considering
that mixtures of body fluids will provide intermediate values of methylation. For that
reason, it is needed to identify new loci able to discriminate body fluids from crime
scenes and the usability of ZC3H12D with HRM inspired us to pursue a project focused
on performing bioinformatics analysis of published array data and then screen the
potential CpGs using HRM. Those CpGs that showed consistent and differential
methylation between the target and other body fluids on the array should also show
different melting temperatures on HRM analysis. In this dissertation, results from
screening work of newly identified CpGs provided new blood, saliva and vaginal
epithelia markers capable of discriminating between those body fluids. Additionally some
of those markers can be amplified in a multiplex PCR which is ideal for its use with
crime scene samples as it permits multiple results from the same aliquot of DNA.
There is a specific need to identify markers for vaginal epithelia, since no
presumptive test is commonly used in serological analysis in forensic laboratorie. To
tackle that task, we examined published literature that used DNA methylation or mRNA
transcripts for body fluid identification. One locus near the PFN3 gene showed mixed
results in different reports. For that reason, we investigated specific CpGs on that locus to
determine if they were able to distinguish vaginal epithelia from other body fluids.
Through the use of pyrosequencing we established that vaginal epithelial cells show
intermediate levels of methylation between the high methylation of blood and saliva and
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the low methylation levels of semen. Moreover we also established the primatespecificity of that marker and the ability of providing results even with 1 ng of DNA.
Even though it has been known for several years that DNA methylation is the
mechanism causing differential gene expression in mammals, research applying this
knowledge to forensic sciences is only 7 years old. The results here presented are an
important contribution to that body of knowledge and represent important progress in the
development of DNA methylation differences for use in forensic sciences.
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CHAPTER IX – FUTURE DIRECTIONS
The combined information on gene expression due to differential methylation
established before birth, such is the case for tDMRs, or established during the lifespan of
one individual, such is the case of loci that are modified with age, provide a powerful tool
for forensic sciences. At this point, age prediction can only be achieved with the
information of which body fluid originated the DNA sample. For that reason, it is
extremely important to establish a set of several loci able to discriminate body fluid and
predict age. Those loci can be amplified by multiplex PCR and analyzed in a massively
parallel sequencing platform such as the MiSeq FGx (Illumina, CA), which is currently
specific for forensic analysis of DNA and is the new alternative to capillary
electrophoresis analysis; or on less established, but simpler platforms such as the MinIon
(Oxford Nanopore, UK). The MinIon technology does not require DNA amplification,
which represents a major advantage for forensics, especially for the analysis of DNA
methylation patterns, since the bisulfite modification step may become unnecessary,
depending on sensitivity requirments. Theoretically the MinIon has the ability to directly
detect methylated cytosines, however it is such a recent technology has described the
process (222).
Regardless of which technology will be used for analysis, the identification of more loci
for body fluid discrimination will provide more reliable results, which is essential in
forensic sciences. To solve that need, the whole human methylome, and not only a subset
of it, must be analyzed using several samples from each type of body fluid commonly
found in crime scenes. The large quantity of data resulting from such studies, requires
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optimized bioinformatics analysis able to better identify CpGs of interest in silico prior to
experimental screening, thus saving time and cost of analysis.
Ultimately, the use of DNA methylation patterns for body fluid identification and
age prediction will have to be compatible with whatever platform is adopted in STR
typing. Despite of the technology used, the findings of this study will further benefit from
additional optimization to increase sensitivity as well as an increase of number of
samples of each body analzyed to determine its robustness.
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APPENDICES

Appendix 1
DNA extraction using biorobot EZ1 Advanced (Qiagen, CA)
Materials:
EZ1 DNA Investigator kit Qiagen Cat#952034
Buffer MTL Qiagen Cat#19112
Protocol:
1. With sterile scissors cut the swab into an appropriate tube. For liquid samples
(semen) use 150 µL semen per extraction
2. Add 490 µL buffer G2 and 10 µL of Proteinase K
3. Vortex and incubate for more than 2 hours at 56 ºC. During incubation vortex
the tube occasionally to improve cell lysis (every 30-45 min)
4. Using a spin basket remove the liquid from the swab
5. All the 500 µL of lysate should be in the 2 mL sample tubes provided with the
DNA Investigator kit (Qiagen, CA)
6. Add 400 µL of Buffer MTL to each sample tube with lysate. Vortex
7. Load the sample tubes in the proper location of the EZ1 Advanced BioRobot
(follow instructions manual)
8. Load all tubes and tips to the machine as well as the reagent cartridges
9. Run the Large Volume protocol with 50 µL final volume elution with TE
buffer
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10. Run the program. Remove the samples and freeze at -20 ºC for large periods
of time or at 4 ºC if quantification is performed on the same day

DNA Quantification using PicoGreen dye (Blood samples only)
Materials:
PicoGreenDNA reagent Life Technologies Cat#P7581
OR
SybrGreen 10,000X in DMSO Invitrogen Cat# S7563
Protocol:
1. Prepare DNA standards from 50 ng/µL down to 0.5 ng/µL concentration by
serial dilutions of the stock.
2. Add 30 µL of molecular grade Millipore water to enough 0.5 mL tubes for all
standards, No Template Control and the samples
3. Add 2 µL of each standard or sample to the appropriate tubes and 2 µL water
to the control. Make a 1:10 and/or 1:2 dilution of each unknown sample to
make sure the calculated value is within the range for the standard curve.
4. In the dark add 32 µL of a 1:200 dilution of PicoGreen solution in DMSO to
each tube
5. Vortex, quick spin to remove drops from the inside of lids and incubate for at
least 5 minutes in the dark
6. Transfer 20 µL aliquots of each tube to 3 different 0.2 mL (PCR) tubes
7. Load tubes in the real-time PCR machine with the standard of highest
concentration on position 1 (per manual instruction)
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8. Run the protocol with the settings for 20 µL of sample and hold for 2 min. at
50 ºC followed by 10 cycles of 15 seconds at 50 ºC with fluorescence reading
after each cycle on FAM (470 nm source and 510 nm detector at gain 5)
9. Determine concentration of the sample based on the standard curve
ALTERNATIVELY: If PicoGreen is not available, SybrGreen can be used if diluted in
the following manner:
Working stock is 1:200 dilution in DMSO:
2 µL SybrGreen + 398 µL DMSO
Quantification stock:
2 µL working stock SybrGreen + 48 µL TE buffer 1X

DNA Quantification using Alu markers (samples from all body fluids)
Materials:
Buffer 10X with 15 mM MgCl2 Applied Biosystems
MgCl2 25 mM Applied Biosystems
Alu primers at 100 uM
BSA Sigma tube at 20 mg/mL concentration
dNTPs mix at 2.5 mM each
Triton X cat# T9284-100 from Sigma, 10% dilution
Sybr Green Life Technologies 10,000. Dilute 1:200 in DMSO
RampTaq Denville 5U/uL
Protocol:
1. make the following master mix for the number of reactions you will run, plus 1:
Water
Buffer 10X
dNTPs
MgCl2
Alu Forward primer
Alu Reverse primer
Triton X
BSA
Sybr Green
Ramp Taq

15.1 µL
2.3 µL
1.9 µL
1.4 µL
0.2 µL
0.2 µL
0.2 µL
0.2 µL
0.2 µL
0.4 µL
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2. Take out 18 uL and add 2 uL of your DNA/ standards/ water (for NTC)
Bisulfite Conversion
Materials:
Epitect® Fast Bisulfite kit (200) Qiagen Cat#59826
Protocol:
1. Samples and all reagents need to be at room temperature
2. According to each sample’s concentration pipette enough volume to have 400
ng of DNA to a 0.2 mL (PCR) tube
3. Add molecular grade water up to 40 µL of volume
4. Add 85 µL of bisulfite solution
5. Add 15 µL of DNA protect buffer
6. Vortex and quick spin on the centrifuge to remove drops from inside lid
7. Place tubes in a thermal cycler and run the program 5 min at 95 ºC, 20 min at
60 ºC, 5 min at 95 ºC, 20 min at 60 ºC and hold indefinite at 20 ºC
8. Briefly centrifuge the tubes and transfer the solution to 1.5 mL tubes
9. Mix carrier RNA solution with buffer BL at the ratio of 3.5 µL carrier RNA to
350 µL Buffer BL. Multiply each volume for the number of samples
10. Add 310 µL of the mixture buffer BL with carrier RNA to each tube. Vortex
and quick spin in the centrifuge
11. Add 250 µL of ethanol (96-100%) to each sample. Vortex for 15 seconds and
quick spin in the centrifuge
12. Transfer the content of each tube to labeled MinElute® DNA spin columns
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13. Centrifuge the columns for 1 minute at 12000 x g or maximum speed. Discard
the liquid on bottom of tubes (flow through) and place the columns back on
the collection tubes
14. Invert Buffer BW several times before use and add 500 µL of Buffer BW to
each spin column. Centrifuge for 1 minute at 12000 x g or maximum speed,
discard the flow through and place the columns back on the collection tubes
15. Add 500 µL of Buffer BD to each tube; close the tubes and incubate for 15
minutes at room temperature; make sure Buffer BD is not open for longer than
required
16. Centrifuge the columns for 1 minute at 12000 x g or maximum speed. Discard
the flow through and place the spin columns back in the collection tubes
17. Add 500 µL of Buffer BW to each spin column and centrifuge for 1 minute at
12000 x g or maximum speed. Remove flow through and place spin columns
back in the collection tubes
18. Repeat step 17
19. Add 250 µL of ethanol (96-100%) to each spin column and centrifuge for 1
minute at 12000 x g or maximum speed
20. Place the spin columns in new 2 mL collection tubes. Centrifuge for 1 minute
at 12000 x g or maximum speed to remove any remaining liquid.
21. Incubate the spin columns for 5 minutes at 60 ºC with the lids open to
evaporate any residual ethanol
22. Place the spin columns into clean labeled 1.5 mL tubes (not provided with the
kit)
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23. Add 20 µL of Buffer EB into the center of the membrane on the spin column.
Incubate for 1 minute at room temperature and centrifuge for 1 minute at
12000 x g or maximum speed.
24. Repeat step 23
25. Store the converted DNA at -20 ºC
NOTE: the concentration of DNA on step 2 and the volume of elution buffer on step 23
were the ones used to screen new genome locations.
Polymerase Chain Reaction for Pyrosequencing
Materials:
PyroMark® PCR Kit (200) Qiagen Cat#978703
QiagenPyroMark®CpG Assays Qiagen
BCAS4: Cat#PMC0002408
FGF7: Cat#PMC0004067
ZC3H12D: Cat#PM00124145
PFN3A: Cat# PMC0084567
Protocol:
1. Thaw the Pyromark PCR Master Mix, the Coral Load Concentrate, Molecular
grade water aliquot, the aliquot of the Pyromark assay primers and the
bisulfite-modified DNA to be amplified
2. To determine the number of reactions, add the number of DNA samples with
2 for No Template Controls (NTC, no DNA is added, just water) plus one (to
account for pipetting loss)
3. Prepare a master mix by adding 12.5 µL of Pyromark® PCR Master Mix, 2.5
µL of Coral Load Concentrate, 2.5 µL of Pyromark assay primers, 5.5 µL of
water per reaction. To determine the volumes to add, multiply each volume
given per the number of reactions determined in step 2
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4. Aliquot 23 µL of the mix prepared in step 3 to the appropriate number of 0.2
mL (PCR) tubes
5. Add 2 µL of molecular grade water to the NTC tubes and 2 µL of DNA to the
remaining tubes.
6.

Centrifuge the tubes and load them in a thermal cycler. Program the thermal
cycler for an initial step of 15 minutes at 95 ºC followed by 45 cycles of 30
seconds at 94 ºC, 30 seconds at 55 ºC and 30 seconds at 72 ºC, with a 10
minutes final extension at 72 ºC and a last hold at 4 ºC for infinite time. For
custom primers the annealing temperature is usually set to Tm - 5ºC.

7.

When the PCR is complete, remove the tubes and store at – 20 ºC

Confirmation of PCR products by running an Agarose gel
Material:
Agarose molecular biology grade
TBE buffer 1X containing 10.8 g Tris base, 5.5g Boric acid, 0.93g disodium
ethylenediaminetetraacetate (Na2C10H14O8N2.H2O) all dissolved in 1 liter of
deionized water.
Ethidium bromide
Low molecular weight DNA ladder (New England Biolabs, cat#N3233S)
Protocol:
1. Prepare a 2% agarose gel in 1X Tris-Borate-EDTA buffer
2. Cool the gel and add ethidium bromide before pouring the gel in the tray
3. Let the gel solidify for at least 20 minutes
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4. Take the comb out and place the tray with the gel on the electrophoresis
apparatus
5. Load the ladder with the loading buffer and 2-5 µL each PCR product to the
appropriate wells on the gel. The PCR product doesn’t need loading buffer
since the Coral Load Concentrate has that function
6. Turn the electrophoresis power ON at a proper current for the size of the gel
7. Take a picture of the gel under an ultraviolet light and check for the bands
around 200 bp size and no bands for the NTC
Pyrosequencing on the Q24 Advanced system
Materials:
PyroMark Q24 Advanced System Qiagen Cat#9002270
PyroMark Q24 Advanced Software Qiagen Cat#9022779
PyroMark Q24 Advanced CpG Reagents (4 X 24) Qiagen Cat#970922
PyroMark Denaturation Solution (500 mL) Qiagen Cat#979007
PyroMark Wash Buffer (concentrated, 200 mL) Qiagen Cat# 979008
PyroMark Q24 Cartridge (3) Qiagen Cat#979202
PyroMark Q24 Plate (100) Qiagen Cat#979201
PyroMark Q24 Plate Holder Qiagen Cat#979205
PryoMark Q24 Vacuum Prep Troughs Qiagen Cat#979206
PyroMark Q24 Vacuum Workstation (110V) Qiagen Cat#9001516
PyroMark Vacuum Prep Filter Probe (100) Qiagen Cat#979010
Streptavidin Sepharose High Performance Beads (5 mL) GE Healthcare Cat#175113-01
Protocol:
1. Turn the Pyrosequencer ON at least 30 minutes before using
2. Thaw the PCR products,an aliquot of biotinylated PCR primers (this aliquot is
only used for pyrosequencing and should never be used to amplify to avoid
contamination from PCR products to pre-amplification DNA) and the
sequencing primer. Equilibrate at room temperature the diluted washing
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buffer, the denaturation buffer, the annealing solution, the binding solution,
the streptavidin-coated beads and the Pyromark Gold reagents. Place the metal
tray for the Q24 plate on a heating plate set at 80ºC
3. Prepare the beads mixture by adding 40µL of binding buffer, 29µL of
molecular grade water, and 1 µL of beads per reaction. Multiply each volume
per the number of samples plus one for pipetting loss. Add 70 µL of this
mixture to 22 wells of a 24-well PCR plate. Leave the last two wells empty for
negative controls and do not put beads mixture in these wells.
4. Add 10 µL of PCR product in the corresponding well of the 24-well PCR
plate. Close the wells with a strip cap and mix at 1400 rpm for at least 15
minutes. Remove from mixing only when ready to use the vacuum station
5. Add 20 µL of 1x sequencing primer in annealing buffer to 22 wells on the
Pyromark® Q24- sequencing plate. The last two wells are reserved for the
primer controls. Add the sequencing primer in one well, and add a mixture of
biotinylated PCR primer (2 µL) and sequencing primer (20 µL) to the other
well
6. Place the Pyromark® Q-24 plate on the vacuum station and fill all the trays of
the station with the corresponding solutions
7. Prepare the template for the plate on the Pyrosequencing software. Check the
volumes to add to the cartridge for each nucleotide, enzyme mix and substrate
mix. Add the volumes to the cartridge and place it on the Q24 pyrosequencer
8. Turn the vacuum switch in the suction probe to ‘ON’ and place it on the prime
tray with distilled water aspirating approximately 70 mL
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9. Remove the 24-well PCR plate from agitation, take the lids off and place in
the vacuum station. Place the suction probe into the PCR plate wells with the
vacuum position ‘ON’ carefully capturing all the solution from the wells for
about 15 seconds
10. Wash the beads/samples with 70% Ethanol for 5 seconds
11. Continue to the tray with Denaturing solution, flush for 5 seconds.
12. Aspirate for 10 seconds on the Washing Buffer tray and tilt the suction probe
to beyond vertical 90º for a few seconds
13. Place the vacuum suction probe on top of the Pyromark® Q24 plate without
touching the liquid. Turn off vacuum and then lower the handle on the
Pyromark® Q24- sequencing plate. Shake the suction probes gently from side
to side for 30 seconds to 1 minute to release the beads on the sequencing plate
containing sequencing primers
14. Rinse the vacuum suction probe on the rinse tray containing distilled water by
agitating for 10 seconds
15. Aspirate distilled water on the prime tray with aspirating 70 mL of water
16. Move the suction probe beyond 90º vertical for a few seconds and disconnect
the vaccum
17. Place the sequencing plate on the metal tray and heat at 80 ºC for 5 minutes
18. Within a 30 seconds interval place the sequencing plate on the Q24
Pyrosequencer, close the lid and start the run
19. When the run is complete discard the Q24 plate, and the unused contents of
the cartridge by inverting it and rinse the cartridge with deionized water. Fill
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up each well of the cartridge with water and by applying pressure on the top
with your fingers force the water to pass the small needles on the bottom.
Repeat this for at least 3 times each well. Let it dry at room temperature
20. Remove and rinse all trays with deionized water from the vacuum station and
dry at room temperature

Data analysis on the Q24 Software
1. The Pyromark Q24 software will perform the methylation percent analysis at
each variable CpG sites and the data is displayed as a pyrogram
2. If any yellow or red warning is displayed due to a height variation on a
homopolymer, deselect that peak as a reference peak
3. Get the percent methylation value for each variable position and make an
excel spreadsheet with values for all tissues tested for each primer set

High-Resolution Melt Amplification and Analysis
NOTE: The DNA is extracted and bisulfite modified as described above. This step is
performed instead of the Pyromark® PCR amplification and pyrosequencing
Reagents:
-

Hot Star Taq Plus (Qiagen, CA) containing Hot Start Polymerase and 10X Buffer
(without Coral Load)
Solution of 5 mM each dNTP
Primers forward and reverse at 10 µM concentration
Eva Green 20X dye solution in water (Biotium, CA)
BSA solution at 10 mg/mL (1:2 dilution from Sigma Aldrich stock)
DMSO 100%
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-

Water, molecular grade

Procedure:
1) Thaw all reagents at room temperature, except for the polymerase
2) Prepare a master mix for the number of samples, plus one to account for pipetting.
The master mix for one reaction is as follows:
a. 2 µL of 10X buffer (Qiagen, CA)
b. 0.8 µL dNTP (5 mM)
c. 1.5 µL forward primer (10 µM)*
d. 1.5 µL reverse primer (10 µM)*
e. 1 µL Eva Green dye (20X)
f. 0.4 µL of BSA (10 m/mL)
g. 0.5 µL DMSO (100%)
h. 0.5 µL Hot StartTaq Plus polymerase
i. 9.8 µL water
* primer ZC3H12D is amplified with only 1µL of each forward and reverse.
In that case the amount of water is adjusted to 10.8 µL
3) Pipette 18 µL of the master mix prepared to each individual 0.2 mL tube
4) Add 2 µL of bisulfite-modified DNA
5) Close the tubes, insert in the RotorGene and start the protocol

RotorGene protocol:
PCR cycle:
- Set a Hold step that runs for 5 minutes at 95 ºC (this step will activate the HotStart
Polymerase)
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-

Set the instrument to run 45 cycles. If needed more cycles can be added to make
sure that all the amplification curves reach a plateau.
o 10 seconds at 95 ºC
o 30 seconds at <<annealing temperature of the primer¥>>
o 10 seconds at 72 ºC, acquiring on green and HRM channels
¥ - Table with the list of annealing temperatures for the
primers ran with 10 samples each for this report
Annealing
Marker
Temperature (ºC)
INPP5D200_TM60
55
ZC3H12D
55
VE_8
50
VE_15 (saliva marker)
50
INPP5D1500
45
INPP5D200_2
55

-

Set a Melt step according to the settings:
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